1
|
Xie Z, Qin Y, Chen X, Yang S, Yang J, Gui L, Liu P, He X, Zhou S, Zhang C, Tang L, Shi Y. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes. Target Oncol 2024:10.1007/s11523-024-01057-w. [PMID: 38643457 DOI: 10.1007/s11523-024-01057-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/15/2024] [Indexed: 04/22/2024]
Abstract
BACKGROUND The clinical and genetic characteristics, as well as treatment outcomes, of diffuse large B-cell lymphoma (DLBCL) patients with different MYD88 and CD79B mutation status merit further investigation. OBJECTIVE This study aims to investigate the distinctions in clinical manifestations, genetic characteristics, and treatment outcomes among MYD88-CD79Bco-mut, MYD88/CD79Bsingle-mut, and MYD88-CD79Bco-wt DLBCL patients. PATIENTS AND METHODS Clinical and genetic characteristics, along with treatment outcomes among 2696 DLBCL patients bearing MYD88-CD79Bco-mut, MYD88/CD79Bsingle-mut, and MYD88-CD79Bco-wt treated with R-CHOP/R-CHOP-like regimens from the Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and six external cohorts were analyzed. Potential molecular mechanisms were investigated through Gene Set Enrichment Analysis and xCell methodology. RESULTS In the MCD subtype, patients with MYD88-CD79Bco-mut showed comparable progression-free survival (PFS) and overall survival (OS) compared to MYD88/CD79Bsingle-mut or MYD88-CD79Bco-wt. However, in the non-MCD subtype, patients with MYD88-CD79Bco-mut exhibited significantly inferior OS than MYD88/CD79Bsingle-mut or MYD88-CD79Bco-wt, while there was no significant OS difference between MYD88/CD79Bsingle-mut and MYD88-CD79Bco-wt (median OS: 68.8 [95% CI 22-NA] vs NA [95% CI 112-NA] vs 177.7 [95% CI 159-NA] months; MYD88-CD79Bco-mut vs MYD88/CD79Bsingle-mut: p = 0.02; MYD88-CD79Bco-mut vs MYD88-CD79Bco-wt: p = 0.03; MYD88/CD79Bsingle-mut vs MYD88-CD79Bco-wt: p = 0.33). Regarding patients with MYD88-CD79Bco-mut, there was no significant difference in PFS and OS between the MCD and non-MCD subtypes. Within the MYD88-CD79Bco-mut group, patients with PIM1mut had better PFS than PIM1wt (median PFS: 8.34 [95% CI 5.56-NA] vs 43.8 [95% CI 26.4-NA] months; p = 0.02). Possible mechanisms contributing to the superior PFS of PIM1mut patients may include activated lymphocyte-mediated immunity and interferon response, a higher proportion of natural killer T cells and plasmacytoid dendritic cells, as well as suppressed angiogenesis and epithelial-mesenchymal transition, along with lower fibroblast and stromal score. CONCLUSIONS In the MCD subtype, patients with MYD88-CD79Bco-mut showed comparable PFS and OS compared to MYD88/CD79Bsingle-mut or MYD88-CD79Bco-wt, while in the non-MCD subtype, they exhibited significantly inferior OS. There was no significant disparity in PFS and OS of MYD88-CD79Bco-mut between the MCD and non-MCD subtypes. The presence of PIM1mut within the MYD88-CD79Bco-mut group correlated with better PFS, which may result from an intricate interplay of immune processes and tumor microenvironment alterations.
Collapse
Affiliation(s)
- Zucheng Xie
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
| | - Yan Qin
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China
| | - Xinrui Chen
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
| | - Sheng Yang
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
| | - Jianliang Yang
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
| | - Lin Gui
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
| | - Peng Liu
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
| | - Xiaohui He
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
| | - Shengyu Zhou
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
| | - Changgong Zhang
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
| | - Le Tang
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
| | - Yuankai Shi
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
| |
Collapse
|
2
|
Dai L, Chen H, Tan Q, Wang Y, Li L, Lou N, Fan G, Xie T, Luo R, Wang S, Zhou Y, Zhong Q, Yao J, Zhang Z, Tang L, Shi Y, Han X. Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray. Cancer 2024; 130:1257-1269. [PMID: 38133926 DOI: 10.1002/cncr.35158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 10/18/2023] [Accepted: 11/20/2023] [Indexed: 12/24/2023]
Abstract
BACKGROUND R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is a standard first-line treatment for diffuse large B-cell lymphoma (DLBCL). However, 20%-40% of patients survive less than 5 years. Novel prognostic biomarkers remain in demand. METHODS Baseline plasma autoantibodies (AAbs) were assessed in 336 DLBCLs. In the discovery phase (n = 20), a high-density antigen microarray (∼21,000 proteins) was used to expound AAb profiles. In the verification phase (n = 181), with a DLBCL-focused microarray, comparative results based on event-free survival at 24 months (EFS24) and lasso Cox regression models of progression-free survival (PFS) and overall survival (OS) were integrated to identify potential biomarkers. They were further validated by enzyme-linked immunosorbent assay in validation phase 1 (n = 135) and a dynamic cohort (n = 12). In validation phase 2, a two-AAb-based risk score was established. They were further validated in an immunohistochemistry cohort (n = 55) and four independent Gene Expression Omnibus datasets (n = 1598). RESULTS Four AAbs (CREB1, N4BP1, UBAP2, and DEAF1) were identified that showed associations with EFS24 status (p < .05) and superior PFS and OS (p < .05). A novel risk score model based on CREB1 and N4BP1 AAbs was developed to predict PFS with areas under the curve of 0.72, 0.71, 0.76, and 0.82 at 1, 3, 5, and 7 years, respectively, in DLBCL treated with R-CHOP independent of the International Prognostic Index (IPI) and provided significant additional recurrence risk discrimination (p < .05) for the IPI. CREB1 and N4BP1 proteins and messenger RNAs were also associated with better PFS and OS (p < .05). CONCLUSIONS This study identified a novel prognostic panel of CREB1, N4BP1, DEAF1, and UBAP2 AAbs that is independent of the IPI in DLBCL.
Collapse
Affiliation(s)
- Liyuan Dai
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Haizhu Chen
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Qiaoyun Tan
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Yanrong Wang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Lin Li
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Ning Lou
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Guangyu Fan
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Tongji Xie
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Rongrong Luo
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Shasha Wang
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Yu Zhou
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Qiaofeng Zhong
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Jiarui Yao
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Zhishang Zhang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Le Tang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Yuankai Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Xiaohong Han
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| |
Collapse
|
3
|
Hao L, Bakkes THGF, van Diepen A, Chennakeshava N, Bouwman RA, De Bie Dekker AJR, Woerlee PH, Mojoli F, Mischi M, Shi Y, Turco S. An adversarial learning approach to generate pressure support ventilation waveforms for asynchrony detection. Comput Methods Programs Biomed 2024; 250:108175. [PMID: 38640840 DOI: 10.1016/j.cmpb.2024.108175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Revised: 04/11/2024] [Accepted: 04/11/2024] [Indexed: 04/21/2024]
Abstract
BACKGROUND AND OBJECTIVE Mechanical ventilation is a life-saving treatment for critically-ill patients. During treatment, patient-ventilator asynchrony (PVA) can occur, which can lead to pulmonary damage, complications, and higher mortality. While traditional detection methods for PVAs rely on visual inspection by clinicians, in recent years, machine learning models are being developed to detect PVAs automatically. However, training these models requires large labeled datasets, which are difficult to obtain, as labeling is a labour-intensive and time-consuming task, requiring clinical expertise. Simulating the lung-ventilator interactions has been proposed to obtain large labeled datasets to train machine learning classifiers. However, the obtained data lacks the influence of different hardware, of servo-controlled algorithms, and different sources of noise. Here, we propose VentGAN, an adversarial learning approach to improve simulated data by learning the ventilator fingerprints from unlabeled clinical data. METHODS In VentGAN, the loss functions are designed to add characteristics of clinical waveforms to the generated results, while preserving the labels of the simulated waveforms. To validate VentGAN, we compare the performance for detection and classification of PVAs when training a previously developed machine learning algorithm with the original simulated data and with the data generated by VentGAN. Testing is performed on independent clinical data labeled by experts. The McNemar test is applied to evaluate statistical differences in the obtained classification accuracy. RESULTS VentGAN significantly improves the classification accuracy for late cycling, early cycling and normal breaths (p< 0.01); no significant difference in accuracy was observed for delayed inspirations (p = 0.2), while the accuracy decreased for ineffective efforts (p< 0.01). CONCLUSIONS Generation of realistic synthetic data with labels by the proposed framework is feasible and represents a promising avenue for improving training of machine learning models.
Collapse
Affiliation(s)
- L Hao
- Electrical Engineering, Eindhoven University of Technology, Eindhoven University of Technology, Den Dolech 12, Eindhoven 5612AZ, the Netherlands
| | - T H G F Bakkes
- Electrical Engineering, Eindhoven University of Technology, Eindhoven University of Technology, Den Dolech 12, Eindhoven 5612AZ, the Netherlands
| | - A van Diepen
- Electrical Engineering, Eindhoven University of Technology, Eindhoven University of Technology, Den Dolech 12, Eindhoven 5612AZ, the Netherlands
| | - N Chennakeshava
- Electrical Engineering, Eindhoven University of Technology, Eindhoven University of Technology, Den Dolech 12, Eindhoven 5612AZ, the Netherlands
| | - R A Bouwman
- Catharina Hospital, Michelangelolaan 2, Eindhoven, Noord-Brabant, EJ 5623, the Netherlands
| | - A J R De Bie Dekker
- Catharina Hospital, Michelangelolaan 2, Eindhoven, Noord-Brabant, EJ 5623, the Netherlands
| | - P H Woerlee
- Catharina Hospital, Michelangelolaan 2, Eindhoven, Noord-Brabant, EJ 5623, the Netherlands
| | - F Mojoli
- Fondazione I.R.C.C.S. Policlinico San Matteo and the University of Pavia, S.da Nuova, 65, Pavia 27100, Italy
| | - M Mischi
- Electrical Engineering, Eindhoven University of Technology, Eindhoven University of Technology, Den Dolech 12, Eindhoven 5612AZ, the Netherlands
| | - Y Shi
- School of Automation Science and Electrical Engineering, Beihang University, Beijing 100191, China
| | - S Turco
- Electrical Engineering, Eindhoven University of Technology, Eindhoven University of Technology, Den Dolech 12, Eindhoven 5612AZ, the Netherlands.
| |
Collapse
|
4
|
Li GS, Peng C, Shi Y, Wang Y, Chen BY. [Techniques for quantifying endotypes of obstructive sleep apnea]. Zhonghua Jie He He Hu Xi Za Zhi 2024; 47:383-388. [PMID: 38599817 DOI: 10.3760/cma.j.cn112147-20231027-00274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/12/2024]
Abstract
Obstructive sleep apnea (OSA) is the frequent occurrence of apnea and/or hypopnea during sleep, leading to intermittent hypoxia, hypercapnia, and disruption of sleep architecture, further resulting in multisystem damage. The pathophysiological mechanisms include abnormal anatomical structure, low arousal threshold, high loop gain, and poor muscle reactivity, etc. As there are individual differences in the underlying mechanisms of OSA (i.e. endotypes), the effectiveness of treatment and prognosis may also vary according to these characteristics. Understanding the endotype of OSA is critical to understanding which patients are most likely to benefit from non-invasive ventilation therapy. Quantification of endotypes is central to the precision treatment of OSA and may provide the basis for accurate clinical treatment of OSA based on endotypes.
Collapse
Affiliation(s)
- G S Li
- Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China
| | - C Peng
- Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China
| | - Y Shi
- Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China
| | - Y Wang
- Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China
| | - B Y Chen
- Department of Respiratory and Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China
| |
Collapse
|
5
|
Gong HL, Tian S, Ding H, Tao L, Wang L, Wang J, Wang T, Zhang M, Shi Y, Xu CZ, Wu CP, Wang SZ, Zhou L. [Clinical efficacy of induction chemoimmunotherapy for locally advanced hypopharyngeal carcinoma: a prospective phase Ⅱ study]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2024; 59:350-356. [PMID: 38599645 DOI: 10.3760/cma.j.cn115330-20240129-00056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/12/2024]
Abstract
Objective: To evaluate the objective response rate (ORR) of induction chemoimmunotherapy with camrelizumab plus TPF (docetaxel, cisplatin, and capecitabine) for locally advanced hypopharyngeal squamous cell carcinoma (LA HSCC) and potential predictive factors for ORR. Methods: A single-center, prospective, phase 2 and single-arm trial was conducted for evaluating antitumor activity of camrelizumab+TPF(docetaxel+cisplatin+capecitabine) for LA HSCC between May 21, 2021 and April 15, 2023, patients admitted to the Eye & ENT Hospital affiliated with Fudan University. The primary endpoint was ORR, and enrolled patients with LA HSCC at T3-4N0-3M0 received induction chemoimmunotherapy for three cycles: camrelizumab 200 mg day 1, docetaxel 75 mg/m2 day 1, cisplatin 25 mg/m2 days 1-3, and capecitabine 800 mg/m2 days 1-14. Patients were assigned to radioimmunotherapy when they had complete response or partial response (PR)>70% (Group A), or assigned to surgery plus adjuvant radiotherapy/chemoradiotherapy when they had PR≤70% (Group B), and the responses were defined by using tumor volume evaluation system. Tumor diameter was also used to assess the treatment responses by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Use SPSS 23.0 software was used to analyze the data. Results: A total of 51 patients were enrolled who underwent the induced chemoimmunotherapy for three cycles, and all were males, aged 35-69 years old. After three cycles of induction immunochemotherapy, 42 (82.4%) patients existed in Group A (complete response or PR>70%) and 9 patients (17.6%) in Group B (PR≤70%), the ORR was 82.4%. The primary endpoint achieved expected main research objectives. Compared to the patients of Group A, the patients of Group B showed the higher T stage and the larger volume of primary tumor before induced immunochemotherapy, and also had the less regression of tumor volume after induced immunochemotherapy (all P<0.05). The optimal cutoff value of pre-treatment tumor volume for predicting ORR was 39 cm3. The T stage (OR=12.71, 95%CI: 1.4-112.5, P=0.022) and the volume (OR=7.1, 95%CI: 1.4-36.8, P=0.018) of primary tumor were the two main factors affecting ORR rate of induction chemoimmunotherapy. Conclusion: The induction chemoimmunotherapy with camrelizumab plus TPF shows an encouraging antitumor efficacy in LA HSCC.
Collapse
Affiliation(s)
- H L Gong
- Department of Otorhinolaryngology Head and Neck Surgery, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
| | - S Tian
- Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
| | - H Ding
- Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
| | - L Tao
- Department of Otorhinolaryngology Head and Neck Surgery, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
| | - L Wang
- Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
| | - J Wang
- Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
| | - T Wang
- Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
| | - M Zhang
- Department of Otorhinolaryngology Head and Neck Surgery, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
| | - Y Shi
- Department of Otorhinolaryngology Head and Neck Surgery, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
| | - C Z Xu
- Department of Otorhinolaryngology Head and Neck Surgery, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
| | - C P Wu
- Department of Otorhinolaryngology Head and Neck Surgery, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
| | - S Z Wang
- Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
| | - L Zhou
- Department of Otorhinolaryngology Head and Neck Surgery, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
| |
Collapse
|
6
|
Shi Y, Chen G, Zhao Y, Zhao J, Lin L. Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801). Cancer Pathog Ther 2024; 2:103-111. [PMID: 38601485 PMCID: PMC11002752 DOI: 10.1016/j.cpt.2023.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Revised: 10/15/2023] [Accepted: 10/25/2023] [Indexed: 04/12/2024]
Abstract
Background Chemotherapy remains the standard-of-care for many patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC), but acquired resistance presents challenges. The aim of this open-label, multicenter phase 2 clinical trial was to determine the efficacy and safety of utidelone, a novel genetically engineered epothilone analog and microtubule-stabilizing agent, as a third- or later-line treatment for locally advanced or metastatic NSCLC. Methods Patients who had failed standard second-line treatment (including platinum-containing chemotherapy or targeted therapy) received utidelone (40 mg/m2 via intravenous injection daily, day 1-5) every 21 days. The primary endpoint was the objective response rate (ORR). Secondary endpoints were the duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Results From March 12, 2019 to January 18, 2021, 26 pretreated patients with locally advanced or metastatic NSCLC (100% of patients had received prior platinum and 65.4% patients had received prior taxane treatment) were enrolled (80.8% of patients had adenocarcinoma). At baseline, nine (34.6%) patients had received second-line treatment, 10 (38.5%) patients had received third-line treatment, and seven (26.9%) patients had received fourth- or later-line treatment. By the data cut-off date of August 10, 2021, the median follow-up was 7.49 months (range, 1.4-26.7 months). The ORR was 15.4% (95% confidence interval [CI], 4.4%-34.9%) in the intention-to-treat (ITT) cohort (N = 26) and 19.0% (95% CI, 5.4%-41.9%) in the per-protocol (PP) cohort (N = 21). The disease control rate was 69.2% (95% CI, 48.2%-85.7%) and 81.0% (95% CI, 58.1%-94.6%) in the ITT and PP cohorts, respectively. The median DoR was 4.1 months (95% CI, 3.1-5.1 months) in the ITT cohort. The median PFS was 4.37 months (95% CI, 2.50-5.29 months) in the ITT cohort and 4.37 months (95% CI, 2.50-9.76 months) in the PP cohort. The median OS was not reached, and the 12-month OS rate was 69% (95% CI, 45.1%-84.1%). Grade 3/4 treatment-emergent adverse events occurred in 38.5% of patients, and the most common was peripheral neuropathy (23.1%, all Grade 3), which was manageable with dose modifications. Conclusions In this clinical trial, utidelone showed promising efficacy and had a manageable safety profile. Further clinical studies are warranted to confirm its role in NSCLC treatment. Trial registration No.NCT03693547; https://classic.clinicaltrials.gov.
Collapse
Affiliation(s)
- Yuankai Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing 100021, China
| | - Gongyan Chen
- Department of Respiration, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, China
| | - Yanqiu Zhao
- Respiratory Department of Internal Medicine, Henan Provincial Cancer Hospital, Zhengzhou, Henan 450003, China
| | - Jing Zhao
- Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China
| | - Lin Lin
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing 100021, China
| |
Collapse
|
7
|
Sun K, Li M, Shi Y, He H, Li Y, Sun L, Wang H, Jin C, Chen M, Li L. Convolutional neural network for identifying common bile duct stones based on magnetic resonance cholangiopancreatography. Clin Radiol 2024:S0009-9260(24)00164-8. [PMID: 38616474 DOI: 10.1016/j.crad.2024.02.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Revised: 01/31/2024] [Accepted: 02/27/2024] [Indexed: 04/16/2024]
Abstract
AIMS To develop an auto-categorization system based on machine learning for three-dimensional magnetic resonance cholangiopancreatography (3D MRCP) to detect choledocholithiasis from healthy and symptomatic individuals. MATERIALS AND METHODS 3D MRCP sequences from 254 cases with common bile duct (CBD) stones and 251 cases with normal CBD were enrolled to train the 3D Convolutional Neural Network (3D-CNN) model. Then 184 patients from three different hospitals (91 with positive CBD stone and 93 with normal CBD) were prospectively included to test the performance of 3D-CNN. RESULTS With a cutoff value of 0.2754, 3D-CNN achieved the sensitivity, specificity, and accuracy of 94.51%, 92.47%, and 93.48%, respectively. In the receiver operating characteristic curve analysis, the area under the curve (AUC) for the presence or absence of CBD stones was 0.974 (95% CI, 0.940-0.992). There was no significant difference in sensitivity, specificity, and accuracy between 3D-CNN and radiologists. In addition, the performance of 3D-CNN was also evaluated in the internal test set and the external test set, respectively. The internal test set yielded an accuracy of 94.74% and AUC of 0.974 (95% CI, 0.919-0.996), and the external test set yielded an accuracy of 92.13% and AUC of 0.970 (95% CI, 0.911-0.995). CONCLUSIONS An artificial intelligence-assisted diagnostic system for CBD stones was constructed using 3D-CNN model for 3D MRCP images. The performance of 3D-CNN model was comparable to that of radiologists in diagnosing CBD stones. 3D-CNN model maintained high performance when applied to data from other hospitals.
Collapse
Affiliation(s)
- K Sun
- Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
| | - M Li
- Department of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
| | - Y Shi
- Department of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
| | - H He
- People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
| | - Y Li
- People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
| | - L Sun
- The First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, China.
| | - H Wang
- Zhejiang Herymed Technology Co., Ltd., Hangzhou, China; Hithink Flush Information Network Co., Ltd., Hangzhou, China.
| | - C Jin
- Zhejiang Herymed Technology Co., Ltd., Hangzhou, China; Hithink Flush Information Network Co., Ltd., Hangzhou, China.
| | - M Chen
- Hithink Flush Information Network Co., Ltd., Hangzhou, China.
| | - L Li
- Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
| |
Collapse
|
8
|
Fan G, Xie T, Li L, Tang L, Han X, Shi Y. Single-cell and spatial analyses revealed the co-location of cancer stem cells and SPP1+ macrophage in hypoxic region that determines the poor prognosis in hepatocellular carcinoma. NPJ Precis Oncol 2024; 8:75. [PMID: 38521868 PMCID: PMC10960828 DOI: 10.1038/s41698-024-00564-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Accepted: 03/07/2024] [Indexed: 03/25/2024] Open
Abstract
In hepatocellular carcinoma (HCC), classical cancer stem cells (CSC) markers were shared by normal stem cells, targeting which may hinder hepatic regeneration and cause liver failure. Additionally, the spatial structure of CSC still remained elusive. To address these limitations, we undertook a comprehensive study combining single-cell data (56,022 cells from 20 samples) and spatial data (38,191 spots from eight samples) to obtain CSC signature and uncover its spatial structure. Utilizing the CytoTRACE algorithm, we discretely identified CSC, which displayed upregulated proliferation pathways regulated by HIF1A. A CSC signature of 107 genes was then developed using Weighted Gene Co-expression Network Analysis (WGCNA). Notably, HCC patients with high CSC levels exhibited an accumulation of SPP1+ macrophages (Macro_SPP1) expressing metalloproteinases (MMP9, MMP12, and MMP7) regulated by HIF1A, suggesting a hypoxic tumor region connecting Macro_SPP1 and CSC. Both CSC and Macro_SPP1 correlated with worse prognosis and undesirable immunotherapy response. Spatial analysis revealed the co-location of CSC and Macro_SPP1, with CD8 T cells excluded from the tumor region. The co-location area and non-tumor area of boundary exhibited a high level of hypoxia, with the HAVRC2 checkpoint highly expressed. Within the co-location area, the SPP1 signaling pathway was most active in cell-cell communication, with SPP1-CD44 and SPP1-ITGA/ITGB identified as the main ligand-receptor pairs. This study successfully constructed a CSC signature and demonstrated the co-location of CSC and Macro_SPP1 in a hypoxic region that exacerbates the tumor microenvironment in HCC.
Collapse
Affiliation(s)
- Guangyu Fan
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China
| | - Tongji Xie
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China
| | - Lin Li
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
| | - Le Tang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China
| | - Xiaohong Han
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College; No.1, Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
| | - Yuankai Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
| |
Collapse
|
9
|
Dai L, Tan Q, Li L, Lou N, Zheng C, Yang J, Huang L, Wang S, Luo R, Fan G, Xie T, Yao J, Zhang Z, Tang L, Shi Y, Han X. High-throughput antigen microarray identifies longitudinal prognostic autoantibody for chemoimmunotherapy in advanced non-small cell lung cancer. Mol Cell Proteomics 2024:100749. [PMID: 38513890 DOI: 10.1016/j.mcpro.2024.100749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2023] [Revised: 02/03/2024] [Accepted: 03/18/2024] [Indexed: 03/23/2024] Open
Abstract
Chemoimmunotherapy has evolved as a standard treatment for advanced non-small cell lung cancer (aNSCLC). However, inevitable drug resistance has limited its efficacy, highlighting the urgent need for biomarkers of chemoimmunotherapy. A three-phase strategy to discover, verify, and validate longitudinal predictive autoantibodies (AAbs) for aNSCLC before and after chemoimmunotherapy was employed. A total of 528 plasma samples from 267 aNSCLC patients before and after anti-PD1 immunotherapy were collected, plus 30 independent formalin-fixed paraffin-embedded samples. Candidate AAbs were firstly selected using a HuProtTM high-density microarray containing 21,000 proteins in the discovery phase, followed by validation using an aNSCLC-focused microarray. Longitudinal predictive AAbs were chosen for enzyme-linked immunosorbent assay (ELISA) based on responders versus non-responders comparison and progression-free survival (PFS) survival analysis. Prognostic markers were also validated using immunohistochemistry and publicly available immunotherapy datasets. We identified and validated a panel of two AAbs (MAX and DHX29) as pre-treatment biomarkers and another panel of two AAbs (MAX and TAPBP) as on-treatment predictive markers in aNSCLC patients undergoing chemoimmunotherapy. All three AAbs exhibited a positive correlation with early responses and PFS (p < 0.05). The kinetics of MAX AAb showed an increasing trend in responders (p < 0.05) and a tendency to initially increase and then decrease in non-responders (p < 0.05). Importantly, MAX protein and mRNA levels effectively discriminated PFS (p < 0.05) in aNSCLC patients treated with immunotherapy. Our results present a longitudinal analysis of changes in prognostic AAbs in aNSCLC patients undergoing chemoimmunotherapy.
Collapse
Affiliation(s)
- Liyuan Dai
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Qiaoyun Tan
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Lin Li
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Ning Lou
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Cuiling Zheng
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Jianliang Yang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Liling Huang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Shasha Wang
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Rongrong Luo
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Guangyu Fan
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Tongji Xie
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Jiarui Yao
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Zhishang Zhang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Le Tang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Yuankai Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China.
| | - Xiaohong Han
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1, Shuaifuyuan, Dongcheng District, Beijing 100730, China.
| |
Collapse
|
10
|
Dong YJ, Guo YF, Ruan Y, Sun SY, Jiang AL, Wang JQ, Shi Y, Wu F. [Association between vitamin D level and grip strength in adults aged 50 and older in Shanghai]. Zhonghua Liu Xing Bing Xue Za Zhi 2024; 45:393-400. [PMID: 38514316 DOI: 10.3760/cma.j.cn112338-20230630-00409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/23/2024]
Abstract
Objective: To understand the association between vitamin D level and grip strength in people aged ≥50 years in Shanghai. Methods: Data were obtained from the WHO's Study on Global Ageing and Adult Health in Shanghai during 2018-2019. Logistic regression model was used to analyze the association between vitamin D level and grip strength, and a stratified analysis was conducted for different gender, age and dairy product intake groups. Restricted cubic spline was used to evaluate the dose-response association between vitamin D level and low grip strength. Results: A total of 4 391 participants were included in the study, including 2 054 men (46.8%), with an average age of (67.02±8.81) years. And 1 421 individuals (32.4%) had low grip strength; 1 533 individuals (34.9%) had vitamin D deficiency, and 401 individuals (9.1%) had vitamin D deficiency. After adjusted for confounding factors, the logistic regression results analysis showed that individuals with vitamin D deficiency had a higher risk for low grip strength (OR=1.41, 95%CI: 1.09-1.83). In men, after adjusting for confounding factors, vitamin D deficiency was positively associated with the risk for low grip strength (OR=1.67, 95%CI: 1.12-2.50), but there was no significant association between vitamin D level and grip strength in women (OR=1.30, 95%CI: 0.97-1.74). In age group 60-69 years and ≥80 years, there was significant association between vitamin D deficiency and low grip strength after adjusting for confounding factors (OR=1.57, 95%CI: 1.05-2.35; OR=2.40, 95%CI: 1.08-5.31). In people who had daily intake of dairy product <250 ml, there was positive association between vitamin D deficiency and low grip strength, but there was no significant association in people who had daily dairy product ≥250 ml after adjusting for confounding factors. The restrictive cubic spline demonstrated that risk of low grip strength might decreased with the increase of vitamin D levels, however, the difference was not significant (P>0.05). Conclusions: This study demonstrated that there is association between vitamin D level and grip strength. People with vitamin D deficiency have higher risk for low grip strength.
Collapse
Affiliation(s)
- Y J Dong
- Division of Chronic and Non-communicable Disease and Injury, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - Y F Guo
- Shanghai Institute of Preventive Medicine, Shanghai 200336, China
| | - Y Ruan
- Division of Chronic and Non-communicable Disease and Injury, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - S Y Sun
- Division of Chronic and Non-communicable Disease and Injury, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - A L Jiang
- Division of Chronic and Non-communicable Disease and Injury, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - J Q Wang
- Division of Chronic and Non-communicable Disease and Injury, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - Y Shi
- Division of Chronic and Non-communicable Disease and Injury, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - F Wu
- Office for Shanghai Medical College, Fudan University, Shanghai 200032, China
| |
Collapse
|
11
|
Ye RH, Zhang YQ, Cao DD, Shi Y, Xiao GF, Li PY, Xu YW, Wei H, Sun JT, Yang YC, Tang RH, Wang JB, He N, Ding YY, Duan S. [Incidence of diabetes and influencing factors in HIV-infected individuals after antiretroviral therapy in Dehong Dai and Jingpo Autonomous Prefecture]. Zhonghua Liu Xing Bing Xue Za Zhi 2024; 45:358-364. [PMID: 38514312 DOI: 10.3760/cma.j.cn112338-20230817-00075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/23/2024]
Abstract
Objective: To understand the incidence of diabetes and influencing factors, the trend of FPG change and risk for mortality in HIV-infected individuals after antiretroviral therapy (ART) in Dehong Dai and Jingpo Autonomous Prefecture (Dehong). Methods: The HIV/AIDS treatment database was collected from China Information System for Disease Control and Prevention. This retrospective cohort study was conducted in HIV-infected individuals with access to ART in Dehong during 2004-2020.The Cox proportional hazard regression model was used to analyze the incidence density of diabetes, the influencing factors and risk for mortality in HIV-infected individuals with access to ART, mixed linear effects model was used to analyze the trend of FPG change and predict FPG in those with different glucose metabolic status at baseline survey. Statistical analysis was performed using software SAS 9.4. Results: A total of 8 763 HIV-infected individuals were included, in whom 8 432 (96.2%) had no diabetes, 331 had diabetes. The incidence density of diabetes was 2.31/1 000 person years. Multivariate Cox proportional hazard regression analysis revealed that 30- 59 years old, BMI ≥24.0 kg/m2, Efavirenz (EFV) based initial treatment regimen and impaired fasting glucose (IFG) at baseline survey were significantly and positively associated with incidence of diabetes. Mixed effect model revealed that FPG was positively correlated with the duration of ART, age and baseline FPG. Suffering from diabetes was a risk factor for mortality in HIV-infected individuals both at baseline survey and during follow-up. Conclusions: The risk for diabetes increased in HIV-infected individuals who were 30-59 years old, baseline BMI ≥24.0 kg/m2, received EFV based initial treatment, and IFG in HIV-infected individuals after antiretroviral therapy in Dehong, 2004-2020. It is important to pay close attention to their blood glucose, and patients with high blood glucose should receive treatment as early as possible.
Collapse
Affiliation(s)
- R H Ye
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - Y Q Zhang
- Department of Epidemiology, Key Laboratory of Public Health Safety of Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - D D Cao
- Dehong Dai and Jingpo Autonomous Prefecture People's Hospital, Mangshi 678400, China
| | - Y Shi
- Mangshi People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Mangshi 678400, China
| | - G F Xiao
- Dehong Dai and Jingpo Autonomous Prefecture Hospital of Traditional Chinese Medicine, Mangshi 678400, China
| | - P Y Li
- Ruili City People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Ruili 678600, China
| | - Y W Xu
- Longchuan County People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Longchuan 678700, China
| | - H Wei
- Yingjiang County People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Yingjiang 679300, China
| | - J T Sun
- Lianghe County People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Lianghe 679200, China
| | - Y C Yang
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - R H Tang
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - J B Wang
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - N He
- Department of Epidemiology, Key Laboratory of Public Health Safety of Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - Y Y Ding
- Department of Epidemiology, Key Laboratory of Public Health Safety of Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - S Duan
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| |
Collapse
|
12
|
Liu R, Yu ZC, Xiao CX, Xiao SF, He J, Shi Y, Hua YY, Zhou JM, Zhang GY, Wang T, Jiang JY, Xiong DX, Chen Y, Xu HB, Yun H, Sun H, Pan TT, Wang R, Zhu SM, Huang D, Liu YJ, Hu YH, Ren XR, Shi MF, Song SZ, Luo JM, Liu J, Zhang J, Xu F. [Different methods in predicting mortality of pediatric intensive care units sepsis in Southwest China]. Zhonghua Er Ke Za Zhi 2024; 62:204-210. [PMID: 38378280 DOI: 10.3760/cma.j.cn112140-20231013-00282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/22/2024]
Abstract
Objective: To investigate the value of systemic inflammatory response syndrome (SIRS), pediatric sequential organ failure assessment (pSOFA) and pediatric critical illness score (PCIS) in predicting mortality of pediatric sepsis in pediatric intensive care units (PICU) from Southwest China. Methods: This was a prospective multicenter observational study. A total of 447 children with sepsis admitted to 12 PICU in Southwest China from April 2022 to March 2023 were enrolled. Based on the prognosis, the patients were divided into survival group and non-survival group. The physiological parameters of SIRS, pSOFA and PCIS were recorded and scored within 24 h after PICU admission. The general clinical data and some laboratory results were recorded. The area under the curve (AUC) of the receiver operating characteristic curve was used to compare the predictive value of SIRS, pSOFA and PCIS in mortality of pediatric sepsis. Results: Amongst 447 children with sepsis, 260 patients were male and 187 patients were female, aged 2.5 (0.8, 7.0) years, 405 patients were in the survival group and 42 patients were in the non-survival group. 418 patients (93.5%) met the criteria of SIRS, and 440 patients (98.4%) met the criteria of pSOFA≥2. There was no significant difference in the number of items meeting the SIRS criteria between the survival group and the non-survival group (3(2, 4) vs. 3(3, 4) points, Z=1.30, P=0.192). The pSOFA score of the non-survival group was significantly higher than that of the survival group (9(6, 12) vs. 4(3, 7) points, Z=6.56, P<0.001), and the PCIS score was significantly lower than that of the survival group (72(68, 81) vs. 82(76, 88) points, Z=5.90, P<0.001). The predictive value of pSOFA (AUC=0.82) and PCIS (AUC=0.78) for sepsis mortality was significantly higher than that of SIRS (AUC=0.56) (Z=6.59, 4.23, both P<0.001). There was no significant difference between pSOFA and PCIS (Z=1.35, P=0.176). Platelet count, procalcitonin, lactic acid, albumin, creatinine, total bilirubin, activated partial thromboplastin time, prothrombin time and international normalized ratio were all able to predict mortality of sepsis to a certain degree (AUC=0.64, 0.68, 0.80, 0.64, 0.68, 0.60, 0.77, 0.75, 0.76, all P<0.05). Conclusion: Compared with SIRS, both pSOFA and PCIS had better predictive value in the mortality of pediatric sepsis in PICU.
Collapse
Affiliation(s)
- R Liu
- Department of Pediatric Critical Care, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing 400014, China
| | - Z C Yu
- Department of Pediatric Critical Care, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing 400014, China
| | - C X Xiao
- Department of Pediatric Critical Care, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing 400014, China
| | - S F Xiao
- Department of Pediatric Critical Care, Kunming Children's Hospital, Kunming 650103, China
| | - J He
- Department of Pediatric Critical Care, Kunming Children's Hospital, Kunming 650103, China
| | - Y Shi
- Department of Pediatric Critical Care, the First People's Hospital of Liangshan Yi Autonomous Prefecture, Xichang 615099, China
| | - Y Y Hua
- Department of Pediatric Critical Care, the First People's Hospital of Liangshan Yi Autonomous Prefecture, Xichang 615099, China
| | - J M Zhou
- Department of Pediatric Critical Care, the First People's Hospital of Liangshan Yi Autonomous Prefecture, Xichang 615099, China
| | - G Y Zhang
- Department of Pediatric Critical Care, Chengdu Women's and Children's Central Hospital, Chengdu 610073, China
| | - T Wang
- Department of Pediatric Critical Care, Chengdu Women's and Children's Central Hospital, Chengdu 610073, China
| | - J Y Jiang
- Department of Pediatric Critical Care, Chongqing University Three Gorges Hospital, Chongqing 400030, China
| | - D X Xiong
- Department of Pediatric Critical Care, Chongqing University Three Gorges Hospital, Chongqing 400030, China
| | - Y Chen
- Department of Pediatric Critical Care, Guizhou Provincial Children's Hospital, Zunyi 563099, China
| | - H B Xu
- Department of Pediatric Critical Care, Guizhou Provincial Children's Hospital, Zunyi 563099, China
| | - H Yun
- Department of Pediatric Critical Care, Guizhou Provincial Children's Hospital, Zunyi 563099, China
| | - H Sun
- Department of Pediatric Critical Care, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China
| | - T T Pan
- Department of Pediatric Critical Care, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China
| | - R Wang
- Department of Pediatric Critical Care, Yuxi Children's Hospital, Yuxi 653199, China
| | - S M Zhu
- Department of Pediatric Critical Care, Yuxi Children's Hospital, Yuxi 653199, China
| | - D Huang
- Department of Pediatric Critical Care, Guizhou Provincial People's Hospital, Guiyang 550499, China
| | - Y J Liu
- Department of Pediatric Critical Care, Guizhou Provincial People's Hospital, Guiyang 550499, China
| | - Y H Hu
- Department of Pediatric Critical Care, Sichuan Provincial Maternity and Child Health Hospital, Chengdu 610045, China
| | - X R Ren
- Department of Pediatric Critical Care, Sichuan Provincial Maternity and Child Health Hospital, Chengdu 610045, China
| | - M F Shi
- Department of Pediatric Critical Care, the First People's Hospital of Yibin, Yibin 644099, China
| | - S Z Song
- Department of Pediatric Critical Care, the First People's Hospital of Yibin, Yibin 644099, China
| | - J M Luo
- Department of Pediatric Critical Care, the First People's Hospital of Yibin, Yibin 644099, China
| | - J Liu
- Department of Pediatric Critical Care, Nanchong Central Hospital, Nanchong 637003, China
| | - J Zhang
- Department of Pediatric Critical Care, Nanchong Central Hospital, Nanchong 637003, China
| | - F Xu
- Department of Pediatric Critical Care, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing 400014, China
| |
Collapse
|
13
|
Zou LW, Liu YF, Liu H, Chen B, Jiang JH, Shi Y, Guo DQ, Xu X, Dong ZH, Fu WG. [Surgical strategies and efficacy analysis for aortic dissection complicating intractable mesenteric artery ischemia]. Zhonghua Wai Ke Za Zhi 2024; 62:235-241. [PMID: 38291640 DOI: 10.3760/cma.j.cn112139-20230926-00141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/01/2024]
Abstract
Objective: To explore the surgical strategies and clinical efficacy for aortic dissection combined with refractory superior mesenteric artery (SMA) ischemia. Methods: This is a retrospective case series study. Clinical data of 24 patients with aortic dissection and refractory SMA ischemia admitted to the Department of Vascular Surgery, Zhongshan Hospital, Fudan University from August 2010 to August 2020 were retrospectively collected. Of the 24 patients, 21 were males and 3 were females, with an age of (50.3±9.9) years (range: 44 to 72 years).Among them, 9 cases were Stanford type A aortic dissection, and 15 cases were type B. All patients underwent CT angiography upon admission, and based on imaging characteristics, they were classified into three types. Type Ⅰ: severe stenosis/occlusion of the SMA true lumen only; Type Ⅱ: stenosis of the true lumens in the descending aorta and SMA (isolated type); Type Ⅲ: stenosis of the true lumens in the thoracoabdominal aorta and SMA (continuation type). Surgical procedures, complications, mortality, and reintervention rates were recorded. Results: Among the 24 patients, 17 (70.8%) were classified as Type Ⅰ, 4 (16.7%) as Type Ⅱ, and 3 (12.5%) as Type Ⅲ. Fourteen cases of Type Ⅰ underwent thoracic endovascular aortic repair combined with SMA stent implantation. Additionally, 3 Type Ⅰ and 1 Type Ⅱ patients underwent only SMA reconstruction (with one case of chronic TAAD treated with iliac artery-SMA bypass surgery). Moreover, 3 Type Ⅱ and 3 Type Ⅲ patients underwent descending aorta combined with SMA stent implantation. There were 5 patients (20.8%) who underwent small bowel resection, either in the same sitting or in a staged procedure. During hospitalization, 4 patients died, resulting in a mortality rate of 16.7%. Among these cases, two patients succumbed to severe intestinal ischemia resulting in multiple organ dysfunction syndrome. The follow-up duration was (46±9) months (range: 13 to 72 months). During the follow-up, 2 patients died, unrelated to intestinal ischemia. The 5-year freedom from reintervention survival rate was 86.1%, and the 5-year cumulative survival rate was 82.6%. Conclusions: Patients with aortic dissection and refractory SMA ischemia have a high perioperative mortality. However, implementing appropriate surgical strategies according to different clinical scenarios can reduce mortality and alleviate intestinal ischemia.
Collapse
Affiliation(s)
- L W Zou
- Departments of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai 200030, China
| | - Y F Liu
- Division of Vascular and Interventional Radiology, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510510, China
| | - H Liu
- Departments of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai 200030, China
| | - B Chen
- Departments of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai 200030, China
| | - J H Jiang
- Departments of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai 200030, China
| | - Y Shi
- Departments of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai 200030, China
| | - D Q Guo
- Departments of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai 200030, China
| | - X Xu
- Departments of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai 200030, China
| | - Z H Dong
- Departments of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai 200030, China
| | - W G Fu
- Departments of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai 200030, China
| |
Collapse
|
14
|
Wang S, Hao X, Dai L, Lou N, Fan G, Gao R, Yang M, Xing P, Liu Y, Wang L, Zhang Z, Yao J, Tang L, Shi Y, Han X. Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy. Lung Cancer 2024; 189:107503. [PMID: 38359741 DOI: 10.1016/j.lungcan.2024.107503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Revised: 02/03/2024] [Accepted: 02/05/2024] [Indexed: 02/17/2024]
Abstract
BACKGROUND Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) has demonstrated remarkable therapeutic effects in ALK-positive non-small cell lung cancer (NSCLC) patients. Identifying prognostic biomarkers can enhance the clinical efficacy of relapsed or refractory patients. METHODS We profiled 737 plasma proteins from 159 pre-treatment and on-treatment plasma samples of 63 ALK-positive NSCLC patients using data-independent acquisition-mass spectrometry (DIA-MS). The consensus clustering algorithm was used to identify subtypes with distinct biological features. A plasma-based prognostic model was constructed using the LASSO-Cox method. We performed the Mfuzz analysis to classify the patterns of longitudinal changes in plasma proteins during treatment. 52 baseline plasma samples from another independent ALK-TKI treatment cohort were collected to validate the potential prognostic markers using ELISA. RESULTS We identified three subtypes of ALK-positive NSCLC with distinct biological features and clinical efficacy. Patients in subgroup 1 exhibited activated humoral immunity and inflammatory responses, increased expression of positive acute-phase response proteins, and the worst prognosis. Then we constructed and verified a prognostic model that predicts the efficacy of ALK-TKI therapy using the expression levels of five plasma proteins (SERPINA4, ATRN, APOA4, TF, and MYOC) at baseline. Next, we explored the longitudinal changes in plasma protein expression during treatment and identified four distinct change patterns (Clusters 1-4). The longitudinal changes of acute-phase proteins during treatment can reflect the treatment status and tumor progression of patients. Finally, we validated the prognostic efficacy of baseline plasma CRP, SAA1, AHSG, SERPINA4, and TF in another independent NSCLC cohort undergoing ALK-TKI treatment. CONCLUSIONS This study contributes to the search for prognostic and drug-resistance biomarkers in plasma samples for ALK-TKI therapy and provides new insights into the mechanism of drug resistance and the selection of follow-up treatment.
Collapse
Affiliation(s)
- Shasha Wang
- Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China
| | - Xuezhi Hao
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China
| | - Liyuan Dai
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China
| | - Ning Lou
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China
| | - Guangyu Fan
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China
| | - Ruyun Gao
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China
| | - Mengwei Yang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China
| | - Puyuan Xing
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China
| | - Yutao Liu
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China
| | - Lin Wang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China
| | - Zhishang Zhang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China
| | - Jiarui Yao
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China
| | - Le Tang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China
| | - Yuankai Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
| | - Xiaohong Han
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
| |
Collapse
|
15
|
Wang M, Fan Y, Sun M, Wang Y, Zhao Y, Jin B, Hu Y, Han Z, Song X, Liu A, Tang K, Ding C, Liang L, Wu L, Gao J, Wang J, Cheng Y, Zhou J, He Y, Dong X, Yao Y, Yu Y, Wang H, Sun S, Huang J, Fang J, Li W, Wang L, Ren X, Zhou C, Hu Y, Zhao D, Yang R, Xu F, Huang Y, Pan Y, Cui J, Xu Y, Yang Z, Shi Y. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. Lancet Respir Med 2024; 12:217-224. [PMID: 38101437 DOI: 10.1016/s2213-2600(23)00379-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Revised: 09/28/2023] [Accepted: 10/09/2023] [Indexed: 12/17/2023]
Abstract
BACKGROUND Sunvozertinib is an oral, irreversible, and selective tyrosine kinase inhibitor that has a favourable safety profile and encouraging antitumour activity, as shown in phase 1 studies of patients with heavily pretreated non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation (exon20ins). We aimed to assess the antitumour efficacy of sunvozertinib in patients with platinum-pretreated locally advanced or metastatic NSCLC with EGFR exon20ins. METHODS WU-KONG6 is a single-group, open-label, multicentre phase 2 trial of sunvozertinib monotherapy, conducted across 37 medical centres in China. We enrolled adult patients with pathologically or cytologically confirmed locally advanced or metastatic NSCLC whose tumour tissue carried an EGFR exon20ins mutation. All patients had received at least one line of previous systemic therapy, with at least one line containing platinum-based chemotherapy. The primary endpoint was objective response rate (ORR), as assessed by the independent review committee. The ORR was defined as the percentage of patients who achieved complete or partial response, confirmed by two separate assessments with at least 4-week time interval, until disease progression or initiation of any new anti-cancer therapy. Enrolled patients received sunvozertinib 300 mg once daily until meeting discontinuation criteria per the protocol. Patients who received at least one dose of treatment and were evaluable for efficacy analysis were included in the primary analysis, and all patients who received at least one dose of treatment were included in the safety analysis. This study is registered with ChinaDrugTrials.org, CTR20211009, and ClinicalTrials.gov, NCT05712902, and efficacy and safety follow-up are ongoing. FINDINGS Between July 19, 2021, and May 6, 2022, 104 patients were enrolled. At data cutoff (Oct 17, 2022), the last enrolled patient had been followed up for about 6 months. Among 97 patients evaluable for efficacy analysis, 59 (61%) patients achieved tumour response, with a confirmed ORR of 61% (95% CI 50-71). All tumour responses were partial responses. Tumour responses were observed irrespective of age, sex, smoking history, EGFR exon20ins subtypes, brain metastasis at baseline, previous lines of therapy, and history of onco-immunotherapy. In total, 19 death events occurred over a median follow-up period of 7·6 months (IQR 6·1-9·4). Sunvozertinib was well tolerated at 300 mg once daily. The most common grade 3 or worse treatment-related adverse events were blood creatine phosphokinase increased (18 [17%] of 104), diarrhoea (eight [8%]), and anaemia (six [6%]). The most common serious treatment-related adverse events were interstitial lung disease (five [5%] of 104), anaemia (three [3%]), vomiting (two [2%]), nausea (two [2%]) and pneumonia (two [2%]). INTERPRETATION In this phase 2 study, sunvozertinib demonstrated antitumour efficacy in patients with platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins, with a manageable safety profile. A multinational randomised, phase 3 study of sunvozertinib versus platinum-doublet chemotherapy in EGFR exon20ins NSCLC is ongoing (NCT05668988). FUNDING Dizal Pharmaceutical.
Collapse
Affiliation(s)
- Mengzhao Wang
- Peking Union Medical College Hospital, Beijing, China.
| | - Yun Fan
- Zhejiang Cancer Hospital, Hangzhou, China
| | - Meili Sun
- Jinan Central Hospital, Jinan, China
| | - Yongsheng Wang
- West China Hospital of Sichuan University, Chengdu, China
| | - Yanqiu Zhao
- Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
| | - Bo Jin
- The First Hospital of China Medical University, Shenyang, China
| | - Ying Hu
- Beijing Chest Hospital, Capital Medical University, Beijing, China
| | - Zhigang Han
- The Affiliated Cancer Hospital of Xinjiang Medical University, Xinjiang, China
| | - Xia Song
- Shanxi Provincial Cancer Hospital, Taiyuan, China
| | - Anwen Liu
- The Second Affiliated Hospital of Nanchang University, Nanchang, China
| | - Kejing Tang
- The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Cuimin Ding
- The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Li Liang
- Peking University Third Hospital, Beijing, China
| | - Lin Wu
- Hunan Cancer Hospital, Changsha, China
| | - Junzhen Gao
- The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
| | | | | | - Jianying Zhou
- The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
| | - Yong He
- Army Medical Center of PLA, Chongqing, China
| | - Xiaorong Dong
- Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China
| | - Yu Yao
- The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Yan Yu
- Harbin Medical University Cancer Hospital, Harbin, China
| | - Huijie Wang
- Fudan University Shanghai Cancer Center, Shanghai, China
| | - Si Sun
- Fudan University Shanghai Cancer Center, Shanghai, China
| | - Jianan Huang
- The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Jian Fang
- Beijing Cancer Hospital, Beijing, China
| | - Wen Li
- The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
| | - Lin Wang
- Hainan General Hospital, Haikou, China
| | - Xiubao Ren
- Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
| | - Chengzhi Zhou
- The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | | | - Dahai Zhao
- The Second Hospital of Anhui Medical University, Hefei, China
| | | | - Fei Xu
- The First Affiliated Hospital of Nanchang University, Nanchang, China
| | | | | | - Jiuwei Cui
- The Bethune First Hospital of Jilin University, Changchun, China
| | - Yan Xu
- Peking Union Medical College Hospital, Beijing, China
| | | | - Yuankai Shi
- Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| |
Collapse
|
16
|
Cui H, Zhang L, Shi Y. Biomaterials-mediated ligation of immune cell surface receptors for immunoengineering. Immunooncol Technol 2024; 21:100695. [PMID: 38405432 PMCID: PMC10891334 DOI: 10.1016/j.iotech.2023.100695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/27/2024]
Abstract
A wide variety of cell surface receptors found on immune cells are essential to the body's immunological defense mechanisms. Cell surface receptors enable immune cells to sense extracellular stimuli and identify pathogens, transmitting activating or inhibitory signals that regulate the immune cell state and coordinate immunological responses. These receptors can dynamically aggregate or disperse due to the fluidity of the cell membrane, particularly during interactions between cells or between cells and pathogens. At the contact surface, cell surface receptors form microclusters, facilitating the recruitment and amplification of downstream signals. The strength of the immune signal is influenced by both the quantity and the specific types of participating receptors. Generally, receptor cross-linking, meaning multivalent ligation of receptors on one cell, leads to greater interface connectivity and more robust signaling. However, intercellular interactions are often spatially restricted by other cellular structures. Therefore, it is essential to comprehend these receptors' features for developing effective immunoengineering approaches. Biomaterials can stimulate and simulate interactions between immune cells and their targets. Biomaterials can activate immune cells to act against pathogenic organisms or cancer cells, thereby offering a valuable immunoengineering toolset for vaccination and immunotherapy. In this review, we systematically summarize biomaterial-based immunoengineering strategies that consider the biology of diverse immune cell surface receptors and the structural attributes of pathogens. By combining this knowledge, we aim to advance the development of rational and effective approaches for immune modulation and therapeutic interventions.
Collapse
Affiliation(s)
- H. Cui
- Department of Polymer Therapeutics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
| | - L. Zhang
- Department of Mechanical and Production Engineering, Aarhus University, Aarhus N, Denmark
| | - Y. Shi
- Department of Polymer Therapeutics, Institute for Experimental Molecular Imaging, Uniklinik RWTH Aachen and Helmholtz Institute for Biomedical Engineering, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
| |
Collapse
|
17
|
Tan Q, Gao R, Zhang X, Yang J, Xing P, Yang S, Wang D, Wang G, Wang S, Yao J, Zhang Z, Tang L, Yu X, Han X, Shi Y. Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients. Cancer Immunol Immunother 2024; 73:47. [PMID: 38349411 PMCID: PMC10864508 DOI: 10.1007/s00262-024-03631-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Accepted: 01/08/2024] [Indexed: 02/15/2024]
Abstract
The response rate of anti-PD1 therapy is limited, and the influence of anti-PD1 therapy on cancer patients is unclear. To address these challenges, we conducted a longitudinal analysis of plasma proteomic changes with anti-PD1 therapy in non-small cell lung cancer (NSCLC), alveolar soft part sarcoma (ASPS), and lymphoma patients. We included 339 plasma samples before and after anti-PD1 therapy from 193 patients with NSCLC, ASPS, or lymphoma. The plasma proteins were detected using data-independent acquisition-mass spectrometry and customable antibody microarrays. Differential proteomic characteristics in responders (R) and non-responders (NR) before and after anti-PD1 therapy were elucidated. A total of 1019 proteins were detected using our in-depth proteomics platform and distributed across 10-12 orders of abundance. By comparing the differential plasma proteome expression between R and NR groups, 50, 206, and 268 proteins were identified in NSCLC, ASPS, and lymphoma patients, respectively. Th17, IL-17, and JAK-STAT signal pathways were identified upregulated in NR group, while cellular senescence and transcriptional misregulation pathways were activated in R group. Longitudinal proteomics analysis revealed the IL-17 signaling pathway was downregulated after treatment. Consistently, many proteins were identified as potential combinatorial therapeutic targets (e.g., IL-17A and CD22). Five noninvasive biomarkers (FLT4, SFTPB, GNPTG, F5, and IL-17A) were further validated in an independent lymphoma cohort (n = 39), and another three noninvasive biomarkers (KIT, CCL3, and TNFSF1) were validated in NSCLC cohort (n = 76). Our results provide molecular insights into the anti-PD1 therapy in cancer patients and identify new therapeutic strategies for anti-PD1-resistant patients.
Collapse
Affiliation(s)
- Qiaoyun Tan
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, 100021, China
| | - Ruyun Gao
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, 100021, China
| | - Xiaomei Zhang
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
| | - Jianliang Yang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, 100021, China
| | - Puyuan Xing
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, 100021, China
| | - Sheng Yang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, 100021, China
| | - Dan Wang
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
| | - Guibing Wang
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
| | - Shasha Wang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, 100021, China
| | - Jiarui Yao
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, 100021, China
| | - Zhishang Zhang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, 100021, China
| | - Le Tang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, 100021, China
| | - Xiaobo Yu
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
| | - Xiaohong Han
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
| | - Yuankai Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, 100021, China.
| |
Collapse
|
18
|
Qi HM, Zhang L, Du M, Yang Y, Guo XT, Li P, Shi Y, Lu XH. [A case of fungal keratitis caused by Petriella setifera infection]. Zhonghua Yan Ke Za Zhi 2024; 60:176-179. [PMID: 38296323 DOI: 10.3760/cma.j.cn112142-20231024-00168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/07/2024]
Abstract
The patient, a 66-year-old male, suffered from redness, blurred vision, photophobia, and tearing in the right eye after being injured by a wooden board. Anti-inflammatory treatment showed poor effectiveness. A 4 mm × 4 mm infiltrate with white deposits on the surface was observed in the central cornea of the right eye. Microscopic examination of corneal scrapings, fungal culture, and in vivo confocal microscopy all indicated fungal infection. The isolated strain was identified as Scedosporium apiospermum through microscopic morphology and confirmed as Petriella setifera by gene sequencing. The patient received corneal debridement combined with routine anti-inflammatory and antifungal treatment in the outpatient clinic. During the follow-up period, the condition continued to improve. Slit lamp examination at the revisit 40 days after the initial diagnosis revealed thinning of the corneal stroma, basic healing of the epithelium, and an increase in uncorrected visual acuity from 0.3 to 0.6.
Collapse
Affiliation(s)
- H M Qi
- Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China
| | - L Zhang
- Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China
| | - M Du
- Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China
| | - Y Yang
- Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China
| | - X T Guo
- Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China
| | - P Li
- Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China
| | - Y Shi
- Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China
| | - X H Lu
- Eye Institute of Shandong First Medical University, Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, School of Ophthalmology, Shandong First Medical University, Jinan 250021, China
| |
Collapse
|
19
|
Jiang AL, Ruan Y, Guo YF, Sun SY, Dong YJ, Wang JQ, Shi Y, Wu F. [Association between dietary pattern and frailty among people aged 50 years and over in Shanghai]. Zhonghua Liu Xing Bing Xue Za Zhi 2024; 45:257-264. [PMID: 38413066 DOI: 10.3760/cma.j.cn112338-20230616-00381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/29/2024]
Abstract
Objective: To investigate dietary patterns of individuals aged ≥50 in Shanghai and analyze their association with frailty. Methods: Using data from the third wave of the Study on Global Ageing and Adult Health in Shanghai conducted between 2018 and 2019. We collected the frequency and average intake of food by the food frequency questionnaire. Factor analysis was used to extract dietary patterns, and a frailty index was constructed using the ratio of the cumulative total score of health deficits to 35 health-related variables considered. We used an ordinal multinomial logistic regression model to analyze the association between dietary patterns and frailty. Results: A total of 3 274 participants aged (67.9±9.2) years were included in the study, including 1 971 (60.2%) men and 1 303 (39.8%) women. We extracted four dietary patterns: high-protein-nuts pattern, potato-bean-vegetable-fruit pattern, poultry-meat pattern, and high-oil-salt pattern. After adjusting for confounding factors, the logistic regression analysis showed that compared with the high-oil-salt pattern, the high-protein-nuts pattern was negatively associated with the risk of higher frailty (OR=0.743, 95%CI: 0.580-0.951). We did not find an association between dietary patterns and frailty between the different gender groups. In the age group 50-64, the high-protein-nuts and potato-bean-vegetable-fruit patterns were negatively correlated with a higher degree of frailty than the high-oil-salt pattern. In the low-level physical activity group, the high-protein-nuts pattern was negatively correlated with a higher degree of frailty than the high-oil-salt pattern (OR=0.509, 95%CI: 0.361-0.720). However, we found no significant effect of the high-protein nuts pattern, potato-bean-vegetable-fruit pattern, and poultry-meat pattern on the risk of higher frailty compared to the high-oil-salt pattern in the moderate to high level of physical activity group. Conclusions: Compared to the high-oil-salt pattern, dietary patterns with a higher intake of high-protein nuts, potatoes, legumes, and fruits and vegetables might be associated with a lower risk of higher frailty in residents aged 50-64 years of age than with a high oil and salt pattern. At the same time, it may have a more significant protective effect in people with lower physical activity levels. It is suggested that a diet rich in high-protein foods, nuts, potatoes, beans, vegetables, and fruits may help reduce and delay the risk of frailty.
Collapse
Affiliation(s)
- A L Jiang
- Division of Chronic Non-communicable Disease and Injury Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - Y Ruan
- Division of Chronic Non-communicable Disease and Injury Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - Y F Guo
- Division of Chronic Non-communicable Disease and Injury Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - S Y Sun
- Division of Chronic Non-communicable Disease and Injury Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - Y J Dong
- Division of Chronic Non-communicable Disease and Injury Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - J Q Wang
- Division of Chronic Non-communicable Disease and Injury Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - Y Shi
- Division of Chronic Non-communicable Disease and Injury Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - F Wu
- Shanghai Medical College, Fudan University, Shanghai 200032, China
| |
Collapse
|
20
|
Yang L, Zhang W, Fan N, Cao P, Cheng Y, Zhu L, Luo S, Zong H, Bai Y, Zhou J, Deng Y, Ba Y, Liu T, Aili M, Yin X, Gu K, Dai G, Ying J, Shi J, Gao Y, Li W, Yu G, Xie L, Gai W, Wang Y, Meng P, Shi Y. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study. EBioMedicine 2024; 100:104966. [PMID: 38217945 PMCID: PMC10826138 DOI: 10.1016/j.ebiom.2024.104966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 12/03/2023] [Accepted: 01/02/2024] [Indexed: 01/15/2024] Open
Abstract
BACKGROUND Limited therapeutic options are available for metastatic colorectal cancer (mCRC) patients after failure of first- and second-line therapies, representing an unmet medical need for novel therapies. METHODS This is an open-label, single arm, multicenter, phase Ⅱ study aiming to perform the efficacy, safety and genomic analysis of SCT200, a noval fully humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type mCRC. SCT200 (6 mg/kg) was given weekly for the first six weeks, followed by a higher dose of 8 mg/kg every two weeks until disease progression or unacceptable toxicity. Primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR) and secondary endpoints included ORR in patients with left-sided tumor, disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and safety. FINDINGS From February 12, 2018 to December 1, 2019, a total of 110 patients aged between 26 and 77 years (median: 55; interquartile range [IQR]: 47-63) with fluorouracil, oxaliplatin, and irinotecan refractory RAS and BRAF wild-type mCRC were enrolled from 22 hospitals in China. As the data cut-off date on May 15, 2020, the IRC-assessed ORR and DCR was 31% (34/110, 95% confidence interval [CI] 22-40%) and 75% (82/110, 95% CI 65-82%), respectively. Thirty one percent (34/110) patients achieved confirmed partial response (PR). The median PFS and median OS were 5.1 months (95% CI 3.4-5.2) and 16.2 months (95% CI 11.1-not available [NA]), respectively. The most common ≥ grade 3 treatment-related adverse events (TRAEs) were hypomagnesemia (17%, 19/110) and acneiform dermatitis (11%, 12/110). No deaths occurred. Genomic analysis suggested positive association between MYC amplification and patients' response (P = 0.0058). RAS/RAF mutation and MET amplification were the most frequently detected resistance mechanisms. Patients with high circulating tumor DNA (ctDNA) at baseline or without ctDNA clearance at the 7th week after the first dose of SCT200 administration before receiving SCT200 had worse PFS and OS. INTERPRETATION SCT200 exhibited promising clinical efficacy and manageable safety profiles in RAS and BRAF wild-type mCRC patients progressed on fluorouracil, irinotecan and oxaliplatin treatment. The baseline ctDNA and ctDNA clearance status at the 7th week after the first dose of SCT200 administration before receiving SCT200 could be a potential prognostic biomarker for RAS and BRAF wild-type mCRC patients with SCT200 therapy. FUNDING This study was sponsored by Sinocelltech Ltd., Beijing, China and partly supported by the National Science and Technology Major Project for Key New Drug Development (2019ZX09732001-006, 2017ZX09304015).
Collapse
Affiliation(s)
- Lin Yang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Wen Zhang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Nanfeng Fan
- Department of Abdominal Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China
| | - Peiguo Cao
- Department of Oncology, The Third Xiangya Hospital of Central South University, Changsha, China
| | - Ying Cheng
- Department of Oncology, Cancer Hospital of Jilin Province, Changchun, China
| | - Lingjun Zhu
- Department of Oncology, Jiangsu Province Hospital, Nanjing, China
| | - Suxia Luo
- Department of Medical Oncology, Henan Provincial Cancer Hospital, Zhengzhou, China
| | - Hong Zong
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Yuxian Bai
- Department of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, China
| | - Jianfeng Zhou
- Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Yanhong Deng
- Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
| | - Yi Ba
- Department of Gastroenterology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
| | - Tianshu Liu
- Department of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, China
| | - Mayinuer Aili
- The Third Department of Oncology, Cancer Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
| | - Xianli Yin
- Department of Gastroenterology, Hunan Cancer Hospital, Changsha, China
| | - Kangsheng Gu
- Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Guanghai Dai
- Department of Medical Oncology, Chinese PLA General Hospital, Beijing, China
| | - Jieer Ying
- Department of Abdominal Oncology, Zhejiang Cancer Hospital, Hangzhou, China
| | - Jianhua Shi
- Department of Medical Oncology, Linyi Cancer Hospital, Linyi, China
| | - Yajie Gao
- Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China
| | - Wei Li
- Cancer Center, The First Hospital of Jilin University, Changchun, China
| | - Guohua Yu
- Department of Oncology, Weifang People's Hospital, Weifang, China
| | - Liangzhi Xie
- Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China
| | - Wenlin Gai
- Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China
| | - Yan Wang
- Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, China
| | - Peng Meng
- Burning Rock Biotech, Shanghai, China
| | - Yuankai Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
| |
Collapse
|
21
|
Shi Y, Han Q. Does maternal anxiety and depression increase the risk of asthma in the offspring? A systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2024; 28:1066-1076. [PMID: 38375712 DOI: 10.26355/eurrev_202402_35343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2024]
Abstract
OBJECTIVE Adverse exposures during pregnancy have been linked with respiratory disorders in the offspring. Research also shows that maternal mental disorders can influence the risk of respiratory illnesses. We hereby systematically examined if specific mental disorders during pregnancy, namely, anxiety and depression, can increase the risk of asthma in the offspring. MATERIALS AND METHODS A literature search of PubMed, CENTRAL, Scopus, Embase, and Web of Science databases from inception to 15th October 2023 was undertaken for cohort studies assessing the association between maternal anxiety/depression and the risk of asthma in the offspring. Adjusted data was quantitatively synthesized in a random-effect meta-analysis model. RESULTS Nine studies with 1,027,469 mother-child pairs were included. Studies reported data on anxiety, depression, or both anxiety and depression. Maternal anxiety (OR: 1.61 95% CI: 1.29, 2.01 I2=0%), maternal depression (OR: 1.25 95% CI: 1.07, 1.45 I2=12%), and both combined (OR: 1.28 95% CI: 1.16, 1.41 I2=93%) were associated with significantly increase the risk of asthma in childhood. Overall, the pooled analysis showed that maternal anxiety or depression significantly increased the risk of asthma in childhood by 30% (OR: 1.30 95% CI: 1.20, 1.40 I2=75%). Results remained significant on multiple subgroup analyses. CONCLUSIONS Maternal anxiety and depression can increase the risk of asthma in childhood. The observational nature of studies, differences in adjusted founders, methodological variations, and predominance of European data are important limitations. Further prospective research taking into account present limitations is needed for improved evidence.
Collapse
Affiliation(s)
- Y Shi
- Department of Respiratory Medicine, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
| | | |
Collapse
|
22
|
Sun ZH, Chen D, Chu KW, Shi Y, Hong B, Chen Y, Liu L. Comparison of clinical data between the proximal femoral bionic nail (PFBN) and hip replacement for the treatment of femoral intertrochanteric fracture. Eur Rev Med Pharmacol Sci 2024; 28:1375-1383. [PMID: 38436170 DOI: 10.26355/eurrev_202402_35458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/05/2024]
Abstract
OBJECTIVE The aim of this study was to compare the difference between proximal femoral bionic nail (PFBN) and hip replacement (HR) for femoral intertrochanteric fracture. MATERIALS AND METHODS A retrospective analysis of the differences in operative time, length of stay, postoperative Harris score, and postoperative mortality between patients with femoral intertrochanteric fracture treated by PFBN and HR admitted to Jinzhai County People's Hospital from October 2020 to September 2022 was performed. RESULTS A total of 56 patients with femoral intertrochanteric fracture, 26 with PFBN and 30 with HR, were included in the study. There were no differences in the length of surgery, pre- and post-operative hemoglobin, or post-operative Harris score at 3 months between the two groups. Compared to the HR group, the PFBN group had a lower total cost, shorter hospital stays, and lower mortality but a longer ambulation time, with a difference of 3.36 weeks. CONCLUSIONS PFBN may be a promising new treatment for femoral intertrochanteric fracture.
Collapse
Affiliation(s)
- Z-H Sun
- Department of Orthopedics, Jinzhai County People's Hospital, Liuan, China.
| | | | | | | | | | | | | |
Collapse
|
23
|
Shi Y, Luo S, Wang H, Yao Q, Shi Y, Cheng J. Three-dimensional bone remodelling of glenoid fossa in patients with skeletal Class III malocclusion after bimaxillary orthognathic surgery. Int J Oral Maxillofac Surg 2024; 53:133-140. [PMID: 37442687 DOI: 10.1016/j.ijom.2023.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Revised: 06/20/2023] [Accepted: 06/26/2023] [Indexed: 07/15/2023]
Abstract
This study aimed to characterize three-dimensional quantitative morphological changes of glenoid fossa in patients with skeletal Class III malocclusion treated with bimaxillary orthognathic surgery. Ninety-five eligible patients (50 male, 45 female; mean age 22.09 years) were enrolled retrospectively. Cone beam computed tomography obtained at 1 week preoperatively (T0), immediately after surgery (T1), and at ≥ 12 months postoperatively (T2) were registered based on cranial base using voxel-based registration in 3D Slicer. Glenoid fossa surface was divided spatially into four regions, and bone modelling in these regions was visualized with color maps. Our data revealed that the mean surface variations of glenoid fossa were small, with modest bone formation as a whole. No significant associations between anteroposterior or vertical mandibular displacement and overall glenoid fossa remodeling were found (P > 0.05). Moreover, bone deposition was frequently observed in the anterior-lateral region of glenoid fossa in patients with a larger mandibular movement during T0-T1 (P < 0.001). Paired bone formation in the anterior-lateral region of glenoid fossa and bone resorption in the anterior-lateral region of condylar head was frequently observed. Collectively, our results revealed that glenoid fossa underwent complex but modest bone remodeling after bimaxillary surgery in skeletal Class III patients.
Collapse
Affiliation(s)
- Y Shi
- Department of Oral and Maxillofacial Surgery, The Affiliated Stomatological Hospital, Nanjing Medical University, Nanjing, PR China; Jiangsu Province Engineering Research Center of Stomatological Translational Medicine, Nanjing Medical University, Jiangsu, PR China
| | - S Luo
- Department of Oral and Maxillofacial Surgery, The Affiliated Stomatological Hospital, Nanjing Medical University, Nanjing, PR China; Jiangsu Province Engineering Research Center of Stomatological Translational Medicine, Nanjing Medical University, Jiangsu, PR China; Jiangsu Key Laboratory of Oral Disease, Nanjing Medical University, Jiangsu, PR China
| | - H Wang
- Department of Oral and Maxillofacial Surgery, The Affiliated Stomatological Hospital, Nanjing Medical University, Nanjing, PR China
| | - Q Yao
- Department of Oral and Maxillofacial Surgery, The Affiliated Stomatological Hospital, Nanjing Medical University, Nanjing, PR China
| | - Y Shi
- Department of Oral and Maxillofacial Surgery, The Affiliated Stomatological Hospital, Nanjing Medical University, Nanjing, PR China
| | - J Cheng
- Department of Oral and Maxillofacial Surgery, The Affiliated Stomatological Hospital, Nanjing Medical University, Nanjing, PR China; Jiangsu Province Engineering Research Center of Stomatological Translational Medicine, Nanjing Medical University, Jiangsu, PR China.
| |
Collapse
|
24
|
Shi Y, Hu X, Li X, Gong C, Wang K, Li Y, Zhang S, Luo Y, Wang P, Jiang L, Meng X, Dong X, Wang H, Yang R, Mei Q, Liu B, Yang L, Sun Y. Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study. J Thorac Oncol 2024:S1556-0864(24)00035-2. [PMID: 38295954 DOI: 10.1016/j.jtho.2024.01.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 01/22/2024] [Accepted: 01/24/2024] [Indexed: 02/23/2024]
Abstract
INTRODUCTION Treatment options for second-generation (2nd-gen) ALK tyrosine kinase inhibitor (TKI)-resistant patients are limited. We evaluated the safety, pharmacokinetics, and efficacy of ficonalkib (SY-3505), a third-generation (3rd-gen) ALK TKI, in patients with advanced ALK-positive non-small cell lung cancer. METHODS This first-in-human, phase 1/2 study (Chinese Clinical Trial Registry identifier: ChiCTR1900025619; ClinicalTrials.gov identifier: NCT05257512) had two parts. Phase 1 included a dose-escalation phase (25-800 mg quaque die [QD]) and a dose-expansion phase (500 mg QD or 600 mg QD). Phase 2 enrolled patients treated at recommended phase 2 dose. Primary end points were safety in phase 1 and objective response rate (ORR) in phase 2. RESULTS Between April 21, 2020, and August 31, 2023, a total of 127 patients with advanced ALK-positive non-small cell lung cancer were enrolled, with 62 in phase 1. Ficonalkib was well absorbed and tolerated, with one dose-limited toxicity event occurring at 800 mg QD. Treatment-related adverse events occurred in 85.5% of patients, with 19.4% experienced greater than or equal to grade 3 events. The ORR was 38.3% (23 of 60, 95% confidence interval [CI]: 26.1%-51.8%) in phase 1, and 600 mg QD was established as recommended phase 2 dose. In phase 2, a total of 65 patients received ficonalkib at 600 mg QD. In total, 88 patients received ficonalkib at 600 mg QD in phase 1/2, and all had received prior 2nd-gen ALK TKI treatment. Furthermore, 90.9% of the patients experienced treatment-related adverse events and 14.8% experienced greater than or equal to grade 3 events. The ORR in efficacy-assessable patients who received ficonalkib at 600 mg QD was 47.5% (38 of 80, 95% CI: 36.2%-59.0%), with an intracranial ORR of 37.5% (12 of 32, 95% CI: 21.1%-56.3%) in these patients with measurable brain lesions at baseline. CONCLUSIONS Ficonalkib (SY-3505) was well tolerated, with favorable safety profiles and promising efficacy in patients resistant to prior 2nd-gen ALK TKI.
Collapse
Affiliation(s)
- Yuankai Shi
- Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, the People's Republic of China.
| | - Xingsheng Hu
- Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, the People's Republic of China
| | - Xingya Li
- Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, the People's Republic of China
| | - Caifeng Gong
- Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, the People's Republic of China
| | - Ke Wang
- Department of Respiratory Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, the People's Republic of China
| | - Yongsheng Li
- Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, the People's Republic of China
| | - Shucai Zhang
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, the People's Republic of China
| | - Yongzhong Luo
- Thoracic Medicine Department 1, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, the People's Republic of China
| | - Pingli Wang
- Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, the People's Republic of China
| | - Liyan Jiang
- Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, the People's Republic of China
| | - Xiangjiao Meng
- Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, the People's Republic of China
| | - Xiaorong Dong
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, the People's Republic of China
| | - Huijuan Wang
- Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, the People's Republic of China
| | - Runxiang Yang
- Department of Medical Oncology, Yunnan Cancer Hospital, Kunming Medical University, Kunming, Yunnan, the People's Republic of China
| | - Qi Mei
- Cancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi, the People's Republic of China
| | - Baogang Liu
- Department of Respiratory Medicine, The Third Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, the People's Republic of China
| | - Limin Yang
- Shouyao Holdings (Beijing) Co.,Ltd., Beijing, the People's Republic of China
| | - Yinghui Sun
- Shouyao Holdings (Beijing) Co.,Ltd., Beijing, the People's Republic of China
| |
Collapse
|
25
|
Shi Y, Chen J, Yang R, Wu H, Wang Z, Yang W, Cui J, Zhang Y, Liu C, Cheng Y, Liu Y, Shan J, Wang D, Yang L, Hu C, Zhao J, Cao R, Tan B, Xu K, Si M, Li H, Mao R, Li L, Kang X, Wang L. Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE). J Thorac Oncol 2024:S1556-0864(24)00033-9. [PMID: 38280448 DOI: 10.1016/j.jtho.2024.01.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Revised: 01/16/2024] [Accepted: 01/19/2024] [Indexed: 01/29/2024]
Abstract
INTRODUCTION Iruplinalkib (WX-0593) is a new-generation, potent ALK tyrosine kinase inhibitor (TKI) that has been found to have systemic and central nervous system (CNS) efficacy in ALK-positive NSCLC. We compared the efficacy and safety of iruplinalkib with crizotinib in patients with ALK TKI-naive, locally advanced or metastatic ALK-positive NSCLC. METHODS In this open-label, randomized, multicenter, phase 3 study, patients with ALK-positive NSCLC were randomly assigned to receive iruplinalkib 180 mg once daily (7-d run-in at 60 mg once daily) or crizotinib 250 mg twice daily. The primary end point was progression-free survival (PFS) assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points included PFS by investigator, objective response rate (ORR), time to response, duration of response, intracranial ORR and time to CNS progression by IRC and investigator, overall survival, and safety. An interim analysis was planned after approximately 70% (134 events) of all 192 expected PFS events assessed by IRC were observed. Efficacy was analyzed in the intention-to-treat population. Safety was assessed in the safety population, which included all randomized patients who received at least one dose of the study drugs. This study is registered with Center for Drug Evaluation of China National Medical Products Administration (CTR20191231) and Clinicaltrials.gov (NCT04632758). RESULTS From September 4, 2019, to December 2, 2020, a total of 292 patients were randomized and treated; 143 with iruplinalkib and 149 with crizotinib. At this interim analysis (145 events), the median follow-up time was 26.7 months (range: 3.7-37.7) in the iruplinalkib group and 25.9 months (range: 0.5-35.9) in the crizotinib group. The PFS assessed by IRC was significantly longer among patients in the iruplinalkib group (median PFS, 27.7 mo [95% confidence interval (CI): 26.3-not estimable] versus 14.6 mo [95% CI: 11.1-16.5] in the crizotinib group; hazard ratio, 0.34 [98.02% CI: 0.23-0.52], p < 0.0001). The ORR assessed by IRC was 93.0% (95% CI: 87.5-96.6) in the iruplinalkib group and 89.3% (95% CI: 83.1-93.7) in the crizotinib group. The intracranial ORR was 90.9% (10 of 11, 95% CI: 58.7-99.8) in the iruplinalkib group and 60.0% (nine of 15, 95% CI: 32.3-83.7) in the crizotinib group for patients with measurable baseline CNS metastases. Incidence of grade 3 or 4 treatment-related adverse events was 51.7% in the iruplinalkib group and 49.7% in the crizotinib group. CONCLUSIONS Iruplinalkib was found to have significantly improved PFS and improved intracranial antitumor activity versus crizotinib. Iruplinalkib may be a new treatment option for patients with advanced ALK-positive and ALK TKI-naive NSCLC. FUNDING This study was funded by Qilu Pharmaceutical Co., Ltd., Jinan, People's Republic of China, and partly supported by the National Science and Technology Major Project for Key New Drug Development (2017ZX09304015).
Collapse
Affiliation(s)
- Yuankai Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, People's Republic of China.
| | - Jianhua Chen
- Thoracic Medicine Department I, Hunan Cancer Hospital, Changsha, People's Republic of China
| | - Runxiang Yang
- The Second Department of Medical Oncology, Yunnan Cancer Hospital, Kunming, People's Republic of China
| | - Hongbo Wu
- Respiratory Intervention Department, Henan Cancer Hospital, Zhengzhou, People's Republic of China
| | - Zhehai Wang
- Respiratory Medical Oncology Ward II, Shandong Cancer Hospital & Institute, Jinan, People's Republic of China
| | - Weihua Yang
- Department of Respiratory, Shanxi Provincial Cancer Hospital, Taiyuan, People's Republic of China
| | - Jiuwei Cui
- Oncology Department, The First Hospital of Jilin University, Changchun, People's Republic of China
| | - Yiping Zhang
- Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China
| | - Chunling Liu
- Pulmonary Medicine Ward II, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, People's Republic of China
| | - Ying Cheng
- Thoracic Oncology Department, Jilin Cancer Hospital, Changchun, People's Republic of China
| | - Yunpeng Liu
- Department of Internal Medical Oncology, The First Hospital of China Medical University, Shenyang, People's Republic of China
| | - Jinlu Shan
- Oncology Department, Army Medical Center of PLA, Chongqing, People's Republic of China
| | - Donglin Wang
- Department of Internal Medical Oncology, Chongqing University Cancer Hospital, Chongqing, People's Republic of China
| | - Lei Yang
- Department of Respiratory Oncology, Gansu Province Cancer Hospital, Lanzhou, People's Republic of China
| | - Changlu Hu
- Ward 4 of Department of Oncology, Anhui Provincial Cancer Hospital, Hefei, People's Republic of China
| | - Jian Zhao
- Thoracic Surgery Department 1, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, People's Republic of China
| | - Ranhua Cao
- Department of Internal Medical Oncology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People's Republic of China
| | - Bangxian Tan
- Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, People's Republic of China
| | - Ke Xu
- Department of Respiratory, Anhui Provincial Cancer Hospital, Hefei, People's Republic of China
| | - Meimei Si
- Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, People's Republic of China
| | - Hui Li
- Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, People's Republic of China
| | - Ruifeng Mao
- Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, People's Republic of China
| | - Lingyan Li
- Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, People's Republic of China
| | - Xiaoyan Kang
- Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, People's Republic of China
| | - Lin Wang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, People's Republic of China
| |
Collapse
|
26
|
Qin Y, Song Y, Wang D, Bai O, Feng J, Sun X, Qiu L, Yang J, Yang Y, Wang Z, Hu J, Wang H, Su H, Jin Z, Qian W, Jin C, Zhang M, Yu D, Liu L, Chen G, Li Y, Sun T, Jin J, Bao H, Du X, Zhou H, Fu G, Shi Y. Long-term outcomes with HLX01 (HanliKang ®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study. BMC Cancer 2024; 24:124. [PMID: 38267866 PMCID: PMC10809427 DOI: 10.1186/s12885-024-11876-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 01/13/2024] [Indexed: 01/26/2024] Open
Abstract
HLX01 (HanliKang®) is a rituximab biosimilar that showed bioequivalence to reference rituximab in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) in the phase 3 HLX01-NHL03 study. Here, we report the 5-year follow-up results from the open-label extension part. Patients were randomised to either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or HLX01 plus CHOP (H-CHOP) every 21 days for up to six cycles. The primary efficacy endpoint was overall survival (OS), and secondary efficacy endpoint was progression-free survival (PFS). Of the 407 patients enrolled in HLX01-NHL03, 316 patients (H-CHOP = 157; R-CHOP = 159) were included in the 5-year follow-up for a median duration of 65.1 (range, 2.2-76.5) months. 96.5% of the patients had an International Prognostic Index (IPI) of 1 or 2, and 17.7% had bone marrow involvement. The 5-year OS rates were 81.0% (95% CI: 74.9-87.5%) and 75.4% (95% CI: 68.9-82.6%)( HR: 0.75, 95% CI 0.47-1.20; p = 0.23) while 5-year PFS rates were 77.7% (95% CI: 71.4-84.6%) and 73.0% (95% CI: 66.3-80.3%) (HR: 0.84, 95% CI 0.54-1.30; p = 0.43) in the H-CHOP and R-CHOP groups, respectively. Treatment outcomes did not differ between groups regardless of IPI score and were consistent with the primary analysis. H-CHOP and R-CHOP provided no significant difference in 5-year OS or PFS in previously untreated patients with low or low-intermediate risk DLBCL.
Collapse
Affiliation(s)
- Yan Qin
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, 100021, Beijing, China
| | - Yongping Song
- Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Dong Wang
- Department of Oncology, Army Characteristic Medical Center, Chongqing, China
| | - Ou Bai
- Department of Hematology, Cancer Center, the First Hospital of Jilin University, Changchun, China
| | - Jifeng Feng
- Department of Oncology, Jiangsu Cancer Hospital, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Institute of Cancer Research, Nanjing, China
| | - Xiuhua Sun
- Department of Medical Oncology, the Second Affiliated Hospital of Dalian Medical University, Dalian, China
| | - Lihua Qiu
- Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin, China
| | - Jianmin Yang
- Department of Hematology, Changhai Hospital, Naval Medical University, Shanghai, China
| | - Yu Yang
- Department of Lymphoma & Head and Neck Tumors, Fujian Medical University Cancer Hospital, Fuzhou, China
| | - Zhao Wang
- Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Jianda Hu
- Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China
| | - Huaqing Wang
- Department of Medical Oncology, Tianjin Union Medical Centre of Nankai University, Tianin, China
| | - Hang Su
- Department of Lymphoma, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, China
| | - Zhengming Jin
- Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China
| | - Wenbin Qian
- Department of Hematology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
| | - Chuan Jin
- Department of Oncology, Guangzhou Medical University, Guangzhou, China
| | - Mingzhi Zhang
- Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Ding Yu
- Department of Oncology Medicine, Hubei Cancer Hospital, Wuhan, China
| | - Li Liu
- Department of Hematology, the Second Affiliated Hospital of Air Force Medical University (Tangdu Hospital), Xian, China
| | - Guoan Chen
- Department of Hematology, the First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Yarong Li
- Hematology and Oncology Department, the Second Hospital of Jilin University, Changchun, China
| | - Tao Sun
- Department of Breast Medicine, Liaoning Cancer Hospital, Shenyang, China
| | - Jie Jin
- Department of Hematology, the First Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, China
| | - Huizheng Bao
- Department of Lymphology and Hematology, Jilin Provincial Cancer Hospital, Changchun, China
| | - Xin Du
- Department of Hematology, Guangdong Provincial People's Hospital, Guangzhou, China
| | - Hui Zhou
- Department of Lymphoma & Hematology, Hunan Cancer Hospital, Changsha, China
| | - Gan Fu
- Department of Hematology, Xiangya Hospital, Central South University, Changsha, China
| | - Yuankai Shi
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, 100021, Beijing, China.
| |
Collapse
|
27
|
Shi Y, Lu Y, Zhang RD, Zhang YY, Lin W, Yu JJ, Wu Y, Fan J, Qi PJ, Huang PL, Cai LX, Huang Q, Zhang P, Sun YM, Liu Y, Zheng HY. [Clinical characteristics and prognosis of 28 cases of infant acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi 2024; 62:49-54. [PMID: 38154977 DOI: 10.3760/cma.j.cn112140-20230720-00020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 12/30/2023]
Abstract
Objective: To analyze the clinical characteristics and prognosis of patients with infant acute lymphoblastic leukemia (IALL). Methods: A retrospective cohort study.Clinical data, treatment and prognosis of 28 cases of IALL who have been treated at Beijing Children's Hospital, Capital Medical University and Baoding Children's Hospital from October 2013 to May 2023 were analyzed retrospectively. Based on the results of fluorescence in situ hybridization (FISH), all patients were divided into KMT2A gene rearrangement (KMT2A-R) positive group and KMT2A-R negative group. The prognosis of two groups were compared. Kaplan-Meier method and Log-Rank test were used to analyze the survival of the patients. Results: Among 28 cases of IALL, there were 10 males and 18 females, with the onset age of 10.9 (9.4,11.8) months. In terms of immune classification, 25 cases were B-ALL (89%), while the remaining 3 cases were T-ALL (11%). Most infant B-ALL showed pro-B lymphocyte phenotype (16/25,64%). A total of 22 cases (79%) obtained chromosome karyotype results, of which 7 were normal karyotypes, no complex karyotypes and 15 were abnormal karyotypes were found. Among abnormal karyotypes, there were 4 cases of t (9; 11), 2 cases of t (4; 11), 2 cases of t (11; 19), 1 case of t (1; 11) and 6 cases of other abnormal karyotypes. A total of 19 cases (68%) were positive for KMT2A-R detected by FISH. The KMT2A fusion gene was detected by real-time PCR in 16 cases (57%). A total of 24 patients completed standardized induction chemotherapy and were able to undergo efficacy evaluation, 23 cases (96%) achieved complete remission through induction chemotherapy, 4 cases (17%) died of relapse. The 5-year event free survival rate (EFS) was (46±13)%, and the 5-year overall survival rate (OS) was (73±10)%.The survival time was 31.3 (3.3, 62.5) months. There was no significant statistical difference in 5-year EFS ((46±14)% vs. (61±18)%) and 5-year OS ((64±13)% vs. (86±13)%) between the KMT2A-R positive group (15 cases) and the KMT2A-R negative group (9 cases) (χ2=1.88, 1.47, P=0.170, 0.224). Conclusions: Most IALL patients were accompanied by KMT2A-R. They had poor tolerance to traditional chemotherapy, the relapse rate during treatment was high and the prognosis was poor.
Collapse
Affiliation(s)
- Y Shi
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - Y Lu
- Hematology Oncology Center, Baoding Children's Hospital,Baoding Key Laboratory of Precision Medicine for Pediatric Hematology Oncology, Hematology Oncology Center of National Center for Children's Health in Baoding, Baoding 071027, China
| | - R D Zhang
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - Y Y Zhang
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - W Lin
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - J J Yu
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - Y Wu
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - J Fan
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - P J Qi
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - P L Huang
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| | - L X Cai
- Hematology Oncology Center, Baoding Children's Hospital,Baoding Key Laboratory of Precision Medicine for Pediatric Hematology Oncology, Hematology Oncology Center of National Center for Children's Health in Baoding, Baoding 071027, China
| | - Q Huang
- Hematology Oncology Center, Baoding Children's Hospital,Baoding Key Laboratory of Precision Medicine for Pediatric Hematology Oncology, Hematology Oncology Center of National Center for Children's Health in Baoding, Baoding 071027, China
| | - P Zhang
- Hematology Oncology Center, Baoding Children's Hospital,Baoding Key Laboratory of Precision Medicine for Pediatric Hematology Oncology, Hematology Oncology Center of National Center for Children's Health in Baoding, Baoding 071027, China
| | - Y M Sun
- Hematology Oncology Center, Baoding Children's Hospital,Baoding Key Laboratory of Precision Medicine for Pediatric Hematology Oncology, Hematology Oncology Center of National Center for Children's Health in Baoding, Baoding 071027, China
| | - Y Liu
- Hematology Oncology Center, Baoding Children's Hospital,Baoding Key Laboratory of Precision Medicine for Pediatric Hematology Oncology, Hematology Oncology Center of National Center for Children's Health in Baoding, Baoding 071027, China
| | - H Y Zheng
- Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China
| |
Collapse
|
28
|
Zhong Q, Chen H, Chen D, Qin Y, He X, Yang Y, Yang J, Liu P, Zhou S, Yang S, Zhou Y, Tang L, Chen C, Shi Y. Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study. Ann Hematol 2024; 103:211-226. [PMID: 37861735 DOI: 10.1007/s00277-023-05491-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Accepted: 09/30/2023] [Indexed: 10/21/2023]
Abstract
BACKGROUND This study aimed to develop and validate a novel risk stratification model and a web-based survival rate calculator to improve discriminative and predictive accuracy for diffuse large B-cell lymphoma (DLBCL) in the rituximab era. METHODS We retrospectively collected pre-treatment data from 873 primary DLBCL patients who received R-CHOP-based immunochemotherapy regimens at the Cancer Hospital, Chinese Academy of Medical Sciences, from January 1, 2005, to December 31, 2018. An independent cohort of 175 DLBCL patients from Fujian Cancer Hospital was used for external validation. FINDINGS Age, ECOG PS, number of extranodal sites, Ann Arbor stage, bulky disease, and LDH levels were screened to develop the nomogram and web-based survival rate calculator. The C-index of the nomogram in the training, internal validation, and external validation cohorts was 0.761, 0.758, and 0.768, respectively. The risk stratification model generated based on the nomogram effectively stratified patients into three distinct risk groups. K-M survival curves demonstrated that the novel risk stratification model exhibited a superior level of predictive accuracy compared to IPI, R-IPI, and NCCN-IPI both in training and two validation cohorts. Additionally, the area under the curve (AUC) value of the novel model (0.763) for predicting 5-year overall survival rates was higher than those of IPI (0.749), R-IPI (0.725), and NCCN-IPI (0.727) in the training cohort. Similar results were observed in both internal and external validation cohort. CONCLUSIONS In conclusion, we have successfully developed and validated a novel risk stratification model and a web-based survival rate calculator that demonstrated superior discriminative and predictive accuracy compared to IPI, R-IPI, and NCCN-IPI in the rituximab era.
Collapse
Affiliation(s)
- Qiaofeng Zhong
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China
- Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fujian Provincial Key Laboratory of Translational Cancer Medicine, 420 Fuma Road, Fuzhou, 350014, China
- Interdisciplinary Institute for Medical Engineering, Fuzhou University, Fuzhou, China
| | - Haizhu Chen
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China
| | - Daoguang Chen
- Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, 420 Fuma Road, Fuzhou, 350014, China
| | - Yan Qin
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China
| | - Xiaohui He
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China
| | - Yu Yang
- Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, 420 Fuma Road, Fuzhou, 350014, China
| | - Jianliang Yang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China
| | - Peng Liu
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China
| | - Shengyu Zhou
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China
| | - Sheng Yang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China
| | - Yu Zhou
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China
| | - Le Tang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China
| | - Chuanben Chen
- Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, 420 Fuma Road, Fuzhou, 350014, China.
| | - Yuankai Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
| |
Collapse
|
29
|
Shi Y, Yao JJ, Yao YH, Liu ZB, Gao F, Li XY, Feng SQ. [A case of recurrent acute promyelocytic leukemia with p.R394G resistance]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:1049-1050. [PMID: 38503533 PMCID: PMC10834878 DOI: 10.3760/cma.j.issn.0253-2727.2023.12.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Received: 07/22/2023] [Indexed: 03/21/2024]
Affiliation(s)
- Y Shi
- Department of Hematology, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, China Tangshan Vocation & Technical College, Tangshan 063000, China
| | - J J Yao
- Department of Hematology, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, China
| | - Y H Yao
- Department of Hematology, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, China
| | - Z B Liu
- Department of Hematology, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, China
| | - F Gao
- Department of Hematology, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, China
| | - X Y Li
- Department of Hematology, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, China
| | - S Q Feng
- Department of Hematology, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, China
| |
Collapse
|
30
|
Shi Y, Gao L, Tian Y, Bai C, Chen J, Wang J, Li X, Zhang C, Sun Y, Su H, Liu Z. Penpulimab combined with anlotinib in patients with R/M HNSCC after failure of platinum-based chemotherapy: a single-arm, multicenter, phase Ⅱ study. ESMO Open 2023; 8:102194. [PMID: 38100934 PMCID: PMC10774955 DOI: 10.1016/j.esmoop.2023.102194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Revised: 10/31/2023] [Accepted: 11/01/2023] [Indexed: 12/17/2023] Open
Abstract
BACKGROUND Treatment regimens for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after failure of platinum-based chemotherapy have been illustrated with limited efficacy. PATIENTS AND METHODS Here, we report a single-arm, multicenter, phase Ⅱ study of R/M HNSCC patients treated with a programmed cell death-1 antibody penpulimab (200 mg) and anlotinib (12 mg) after failing at least one line of platinum-based chemotherapy. RESULTS Of 38 patients in total, 13 (34.21%) patients achieved partial response and 16 (42.11%) patients achieved stable disease. After a median follow-up of 7.06 months (range: 4.14-15.70 months), the independent review committee-assessed objective response rate was 34.21%, the disease control rate was 76.32%. The median progression-free survival was 8.35 months (95% confidence interval 5.95-13.11 months). Twelve patients died and the median overall survival (OS) was not reached. The 12-month OS rate was 59.76%. Grade 3/4 treatment-related adverse events occurred in 47.37% of the patients. CONCLUSION Penpulimab combined with anlotinib demonstrated promising efficacy and manageable safety in R/M HNSCC patients after failure of platinum-based chemotherapy.
Collapse
Affiliation(s)
- Y Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing.
| | - L Gao
- Third Ward, Department of Radiotherapy, Gansu Provincial Cancer Hospital, Lanzhou, Gansu, China
| | - Y Tian
- Department of Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou
| | - C Bai
- Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing
| | - J Chen
- Thoracic Medicine Department, Hunan Cancer Hospital, Changsha
| | - J Wang
- Department of Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou
| | - X Li
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou
| | - C Zhang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing
| | - Y Sun
- Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing
| | - H Su
- Department of Oncology, Tangdu Hospital, Air Force Medical University, Xi'an
| | - Z Liu
- Department of Head and Neck Oncology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China
| |
Collapse
|
31
|
Abdulhamid MI, Aboona BE, Adam J, Adams JR, Agakishiev G, Aggarwal I, Aggarwal MM, Ahammed Z, Aitbaev A, Alekseev I, Anderson DM, Aparin A, Aslam S, Atchison J, Averichev GS, Bairathi V, Baker W, Cap JGB, Barish K, Bhagat P, Bhasin A, Bhatta S, Bordyuzhin IG, Brandenburg JD, Brandin AV, Cai XZ, Caines H, Sánchez MCDLB, Cebra D, Ceska J, Chakaberia I, Chan BK, Chang Z, Chatterjee A, Chen D, Chen J, Chen JH, Chen Z, Cheng J, Cheng Y, Choudhury S, Christie W, Chu X, Crawford HJ, Dale-Gau G, Das A, Daugherity M, Dedovich TG, Deppner IM, Derevschikov AA, Dhamija A, Di Carlo L, Dixit P, Dong X, Drachenberg JL, Duckworth E, Dunlop JC, Engelage J, Eppley G, Esumi S, Evdokimov O, Ewigleben A, Eyser O, Fatemi R, Fazio S, Feng CJ, Feng Y, Finch E, Fisyak Y, Flor FA, Fu C, Gao T, Geurts F, Ghimire N, Gibson A, Gopal K, Gou X, Grosnick D, Gupta A, Hamed A, Han Y, Harasty MD, Harris JW, Harrison-Smith H, He W, He XH, He Y, Hu C, Hu Q, Hu Y, Huang H, Huang HZ, Huang SL, Huang T, Huang X, Huang Y, Huang Y, Humanic TJ, Isenhower D, Isshiki M, Jacobs WW, Jalotra A, Jena C, Ji Y, Jia J, Jin C, Ju X, Judd EG, Kabana S, Kabir ML, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Keane D, Kechechyan A, Kelsey M, Kimelman B, Kiselev A, Knospe AG, Ko HS, Kochenda L, Korobitsin AA, Kravtsov P, Kumar L, Kumar S, Elayavalli RK, Lacey R, Landgraf JM, Lebedev A, Lednicky R, Lee JH, Leung YH, Lewis N, Li C, Li W, Li X, Li Y, Li Y, Li Z, Liang X, Liang Y, Lin T, Liu C, Liu F, Liu G, Liu H, Liu H, Liu L, Liu T, Liu X, Liu Y, Liu Z, Ljubicic T, Llope WJ, Lomicky O, Longacre RS, Loyd EM, Lu T, Lukow NS, Luo XF, Luong VB, Ma L, Ma R, Ma YG, Magdy N, Mallick D, Margetis S, Matis HS, Mazer JA, McNamara G, Mi K, Minaev NG, Mohanty B, Mondal MM, Mooney I, Morozov DA, Mudrokh A, Nagy MI, Nain AS, Nam JD, Nasim M, Neff D, Nelson JM, Nemes DB, Nie M, Nigmatkulov G, Niida T, Nishitani R, Nogach LV, Nonaka T, Odyniec G, Ogawa A, Oh S, Okorokov VA, Okubo K, Page BS, Pak R, Pan J, Pandav A, Pandey AK, Panebratsev Y, Pani T, Parfenov P, Paul A, Perkins C, Pokhrel BR, Posik M, Protzman T, Pruthi NK, Putschke J, Qin Z, Qiu H, Quintero A, Racz C, Radhakrishnan SK, Raha N, Ray RL, Ritter HG, Robertson CW, Rogachevsky OV, Aguilar MAR, Roy D, Ruan L, Sahoo AK, Sahoo NR, Sako H, Salur S, Samigullin E, Sato S, Schmidke WB, Schmitz N, Seger J, Seto R, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao T, Sharma M, Sharma N, Sharma R, Sharma SR, Sheikh AI, Shen D, Shen DY, Shen K, Shi SS, Shi Y, Shou QY, Si F, Singh J, Singha S, Sinha P, Skoby MJ, Söhngen Y, Song Y, Srivastava B, Stanislaus TDS, Stewart DJ, Strikhanov M, Stringfellow B, Su Y, Sun C, Sun X, Sun Y, Sun Y, Surrow B, Svirida DN, Sweger ZW, Tamis A, Tang AH, Tang Z, Taranenko A, Tarnowsky T, Thomas JH, Tlusty D, Todoroki T, Tokarev MV, Tomkiel CA, Trentalange S, Tribble RE, Tribedy P, Tsai OD, Tsang CY, Tu Z, Tyler J, Ullrich T, Underwood DG, Upsal I, Van Buren G, Vasiliev AN, Verkest V, Videbæk F, Vokal S, Voloshin SA, Wang F, Wang G, Wang JS, Wang J, Wang X, Wang Y, Wang Y, Wang Y, Wang Z, Webb JC, Weidenkaff PC, Westfall GD, Wieman H, Wilks G, Wissink SW, Wu J, Wu J, Wu X, Wu X, Wu Y, Xi B, Xiao ZG, Xie G, Xie W, Xu H, Xu N, Xu QH, Xu Y, Xu Y, Xu Z, Xu Z, Yan G, Yan Z, Yang C, Yang Q, Yang S, Yang Y, Ye Z, Ye Z, Yi L, Yip K, Yu Y, Zha W, Zhang C, Zhang D, Zhang J, Zhang S, Zhang W, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang ZJ, Zhang Z, Zhang Z, Zhao F, Zhao J, Zhao M, Zhou C, Zhou J, Zhou S, Zhou Y, Zhu X, Zurek M, Zyzak M. Hyperon Polarization along the Beam Direction Relative to the Second and Third Harmonic Event Planes in Isobar Collisions at sqrt[s_{NN}]=200 GeV. Phys Rev Lett 2023; 131:202301. [PMID: 38039468 DOI: 10.1103/physrevlett.131.202301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Revised: 07/07/2023] [Accepted: 10/03/2023] [Indexed: 12/03/2023]
Abstract
The polarization of Λ and Λ[over ¯] hyperons along the beam direction has been measured relative to the second and third harmonic event planes in isobar Ru+Ru and Zr+Zr collisions at sqrt[s_{NN}]=200 GeV. This is the first experimental evidence of the hyperon polarization by the triangular flow originating from the initial density fluctuations. The amplitudes of the sine modulation for the second and third harmonic results are comparable in magnitude, increase from central to peripheral collisions, and show a mild p_{T} dependence. The azimuthal angle dependence of the polarization follows the vorticity pattern expected due to elliptic and triangular anisotropic flow, and qualitatively disagrees with most hydrodynamic model calculations based on thermal vorticity and shear induced contributions. The model results based on one of existing implementations of the shear contribution lead to a correct azimuthal angle dependence, but predict centrality and p_{T} dependence that still disagree with experimental measurements. Thus, our results provide stringent constraints on the thermal vorticity and shear-induced contributions to hyperon polarization. Comparison to previous measurements at RHIC and the LHC for the second-order harmonic results shows little dependence on the collision system size and collision energy.
Collapse
Affiliation(s)
| | - B E Aboona
- Texas A&M University, College Station, Texas 77843
| | - J Adam
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - J R Adams
- The Ohio State University, Columbus, Ohio 43210
| | - G Agakishiev
- Joint Institute for Nuclear Research, Dubna 141 980
| | - I Aggarwal
- Panjab University, Chandigarh 160014, India
| | | | - Z Ahammed
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - A Aitbaev
- Joint Institute for Nuclear Research, Dubna 141 980
| | - I Alekseev
- Alikhanov Institute for Theoretical and Experimental Physics NRC "Kurchatov Institute," Moscow 117218
- National Research Nuclear University MEPhI, Moscow 115409
| | - D M Anderson
- Texas A&M University, College Station, Texas 77843
| | - A Aparin
- Joint Institute for Nuclear Research, Dubna 141 980
| | - S Aslam
- Indian Institute Technology, Patna, Bihar 801106, India
| | - J Atchison
- Abilene Christian University, Abilene, Texas 79699
| | | | - V Bairathi
- Instituto de Alta Investigación, Universidad de Tarapacá, Arica 1000000, Chile
| | - W Baker
- University of California, Riverside, California 92521
| | | | - K Barish
- University of California, Riverside, California 92521
| | - P Bhagat
- University of Jammu, Jammu 180001, India
| | - A Bhasin
- University of Jammu, Jammu 180001, India
| | - S Bhatta
- State University of New York, Stony Brook, New York 11794
| | - I G Bordyuzhin
- Alikhanov Institute for Theoretical and Experimental Physics NRC "Kurchatov Institute," Moscow 117218
| | | | - A V Brandin
- National Research Nuclear University MEPhI, Moscow 115409
| | - X Z Cai
- Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800
| | - H Caines
- Yale University, New Haven, Connecticut 06520
| | | | - D Cebra
- University of California, Davis, California 95616
| | - J Ceska
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - I Chakaberia
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - B K Chan
- University of California, Los Angeles, California 90095
| | - Z Chang
- Indiana University, Bloomington, Indiana 47408
| | - A Chatterjee
- National Institute of Technology Durgapur, Durgapur-713209, India
| | - D Chen
- University of California, Riverside, California 92521
| | - J Chen
- Shandong University, Qingdao, Shandong 266237
| | - J H Chen
- Fudan University, Shanghai, 200433
| | - Z Chen
- Shandong University, Qingdao, Shandong 266237
| | - J Cheng
- Tsinghua University, Beijing 100084
| | - Y Cheng
- University of California, Los Angeles, California 90095
| | | | - W Christie
- Brookhaven National Laboratory, Upton, New York 11973
| | - X Chu
- Brookhaven National Laboratory, Upton, New York 11973
| | - H J Crawford
- University of California, Berkeley, California 94720
| | - G Dale-Gau
- University of Illinois at Chicago, Chicago, Illinois 60607
| | - A Das
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - M Daugherity
- Abilene Christian University, Abilene, Texas 79699
| | - T G Dedovich
- Joint Institute for Nuclear Research, Dubna 141 980
| | - I M Deppner
- University of Heidelberg, Heidelberg 69120, Germany
| | - A A Derevschikov
- NRC "Kurchatov Institute," Institute of High Energy Physics, Protvino 142281
| | - A Dhamija
- Panjab University, Chandigarh 160014, India
| | - L Di Carlo
- Wayne State University, Detroit, Michigan 48201
| | - P Dixit
- Indian Institute of Science Education and Research (IISER), Berhampur 760010, India
| | - X Dong
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | | | | | - J C Dunlop
- Brookhaven National Laboratory, Upton, New York 11973
| | - J Engelage
- University of California, Berkeley, California 94720
| | - G Eppley
- Rice University, Houston, Texas 77251
| | - S Esumi
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - O Evdokimov
- University of Illinois at Chicago, Chicago, Illinois 60607
| | - A Ewigleben
- Lehigh University, Bethlehem, Pennsylvania 18015
| | - O Eyser
- Brookhaven National Laboratory, Upton, New York 11973
| | - R Fatemi
- University of Kentucky, Lexington, Kentucky 40506-0055
| | - S Fazio
- University of Calabria & INFN-Cosenza, Rende 87036, Italy
| | - C J Feng
- National Cheng Kung University, Tainan 70101
| | - Y Feng
- Purdue University, West Lafayette, Indiana 47907
| | - E Finch
- Southern Connecticut State University, New Haven, Connecticut 06515
| | - Y Fisyak
- Brookhaven National Laboratory, Upton, New York 11973
| | - F A Flor
- Yale University, New Haven, Connecticut 06520
| | - C Fu
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - T Gao
- Shandong University, Qingdao, Shandong 266237
| | - F Geurts
- Rice University, Houston, Texas 77251
| | - N Ghimire
- Temple University, Philadelphia, Pennsylvania 19122
| | - A Gibson
- Valparaiso University, Valparaiso, Indiana 46383
| | - K Gopal
- Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati 517507, India
| | - X Gou
- Shandong University, Qingdao, Shandong 266237
| | - D Grosnick
- Valparaiso University, Valparaiso, Indiana 46383
| | - A Gupta
- University of Jammu, Jammu 180001, India
| | - A Hamed
- American University in Cairo, New Cairo 11835, Egypt
| | - Y Han
- Rice University, Houston, Texas 77251
| | - M D Harasty
- University of California, Davis, California 95616
| | - J W Harris
- Yale University, New Haven, Connecticut 06520
| | | | - W He
- Fudan University, Shanghai, 200433
| | - X H He
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - Y He
- Shandong University, Qingdao, Shandong 266237
| | - C Hu
- University of Chinese Academy of Sciences, Beijing 101408
| | - Q Hu
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - Y Hu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - H Huang
- National Cheng Kung University, Tainan 70101
| | - H Z Huang
- University of California, Los Angeles, California 90095
| | - S L Huang
- State University of New York, Stony Brook, New York 11794
| | - T Huang
- University of Illinois at Chicago, Chicago, Illinois 60607
| | - X Huang
- Tsinghua University, Beijing 100084
| | - Y Huang
- Tsinghua University, Beijing 100084
| | - Y Huang
- Central China Normal University, Wuhan, Hubei 430079
| | - T J Humanic
- The Ohio State University, Columbus, Ohio 43210
| | - D Isenhower
- Abilene Christian University, Abilene, Texas 79699
| | - M Isshiki
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - W W Jacobs
- Indiana University, Bloomington, Indiana 47408
| | - A Jalotra
- University of Jammu, Jammu 180001, India
| | - C Jena
- Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati 517507, India
| | - Y Ji
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - J Jia
- Brookhaven National Laboratory, Upton, New York 11973
- State University of New York, Stony Brook, New York 11794
| | - C Jin
- Rice University, Houston, Texas 77251
| | - X Ju
- University of Science and Technology of China, Hefei, Anhui 230026
| | - E G Judd
- University of California, Berkeley, California 94720
| | - S Kabana
- Instituto de Alta Investigación, Universidad de Tarapacá, Arica 1000000, Chile
| | - M L Kabir
- University of California, Riverside, California 92521
| | - D Kalinkin
- University of Kentucky, Lexington, Kentucky 40506-0055
| | - K Kang
- Tsinghua University, Beijing 100084
| | - D Kapukchyan
- University of California, Riverside, California 92521
| | - K Kauder
- Brookhaven National Laboratory, Upton, New York 11973
| | - D Keane
- Kent State University, Kent, Ohio 44242
| | - A Kechechyan
- Joint Institute for Nuclear Research, Dubna 141 980
| | - M Kelsey
- Wayne State University, Detroit, Michigan 48201
| | - B Kimelman
- University of California, Davis, California 95616
| | - A Kiselev
- Brookhaven National Laboratory, Upton, New York 11973
| | - A G Knospe
- Lehigh University, Bethlehem, Pennsylvania 18015
| | - H S Ko
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - L Kochenda
- National Research Nuclear University MEPhI, Moscow 115409
| | | | - P Kravtsov
- National Research Nuclear University MEPhI, Moscow 115409
| | - L Kumar
- Panjab University, Chandigarh 160014, India
| | - S Kumar
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | | | - R Lacey
- State University of New York, Stony Brook, New York 11794
| | - J M Landgraf
- Brookhaven National Laboratory, Upton, New York 11973
| | - A Lebedev
- Brookhaven National Laboratory, Upton, New York 11973
| | - R Lednicky
- Joint Institute for Nuclear Research, Dubna 141 980
| | - J H Lee
- Brookhaven National Laboratory, Upton, New York 11973
| | - Y H Leung
- University of Heidelberg, Heidelberg 69120, Germany
| | - N Lewis
- Brookhaven National Laboratory, Upton, New York 11973
| | - C Li
- Shandong University, Qingdao, Shandong 266237
| | - W Li
- Rice University, Houston, Texas 77251
| | - X Li
- University of Science and Technology of China, Hefei, Anhui 230026
| | - Y Li
- University of Science and Technology of China, Hefei, Anhui 230026
| | - Y Li
- Tsinghua University, Beijing 100084
| | - Z Li
- University of Science and Technology of China, Hefei, Anhui 230026
| | - X Liang
- University of California, Riverside, California 92521
| | - Y Liang
- Kent State University, Kent, Ohio 44242
| | - T Lin
- Shandong University, Qingdao, Shandong 266237
| | - C Liu
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - F Liu
- Central China Normal University, Wuhan, Hubei 430079
| | - G Liu
- South China Normal University, Guangzhou, Guangdong 510631
| | - H Liu
- Indiana University, Bloomington, Indiana 47408
| | - H Liu
- Central China Normal University, Wuhan, Hubei 430079
| | - L Liu
- Central China Normal University, Wuhan, Hubei 430079
| | - T Liu
- Yale University, New Haven, Connecticut 06520
| | - X Liu
- The Ohio State University, Columbus, Ohio 43210
| | - Y Liu
- Texas A&M University, College Station, Texas 77843
| | - Z Liu
- Central China Normal University, Wuhan, Hubei 430079
| | - T Ljubicic
- Brookhaven National Laboratory, Upton, New York 11973
| | - W J Llope
- Wayne State University, Detroit, Michigan 48201
| | - O Lomicky
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - R S Longacre
- Brookhaven National Laboratory, Upton, New York 11973
| | - E M Loyd
- University of California, Riverside, California 92521
| | - T Lu
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - N S Lukow
- Temple University, Philadelphia, Pennsylvania 19122
| | - X F Luo
- Central China Normal University, Wuhan, Hubei 430079
| | - V B Luong
- Joint Institute for Nuclear Research, Dubna 141 980
| | - L Ma
- Fudan University, Shanghai, 200433
| | - R Ma
- Brookhaven National Laboratory, Upton, New York 11973
| | - Y G Ma
- Fudan University, Shanghai, 200433
| | - N Magdy
- State University of New York, Stony Brook, New York 11794
| | - D Mallick
- National Institute of Science Education and Research, HBNI, Jatni 752050, India
| | | | - H S Matis
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - J A Mazer
- Rutgers University, Piscataway, New Jersey 08854
| | - G McNamara
- Wayne State University, Detroit, Michigan 48201
| | - K Mi
- Central China Normal University, Wuhan, Hubei 430079
| | - N G Minaev
- NRC "Kurchatov Institute," Institute of High Energy Physics, Protvino 142281
| | - B Mohanty
- National Institute of Science Education and Research, HBNI, Jatni 752050, India
| | - M M Mondal
- National Institute of Science Education and Research, HBNI, Jatni 752050, India
| | - I Mooney
- Yale University, New Haven, Connecticut 06520
| | - D A Morozov
- NRC "Kurchatov Institute," Institute of High Energy Physics, Protvino 142281
| | - A Mudrokh
- Joint Institute for Nuclear Research, Dubna 141 980
| | - M I Nagy
- ELTE Eötvös Loránd University, Budapest, Hungary H-1117
| | - A S Nain
- Panjab University, Chandigarh 160014, India
| | - J D Nam
- Temple University, Philadelphia, Pennsylvania 19122
| | - M Nasim
- Indian Institute of Science Education and Research (IISER), Berhampur 760010, India
| | - D Neff
- University of California, Los Angeles, California 90095
| | - J M Nelson
- University of California, Berkeley, California 94720
| | - D B Nemes
- Yale University, New Haven, Connecticut 06520
| | - M Nie
- Shandong University, Qingdao, Shandong 266237
| | - G Nigmatkulov
- University of Illinois at Chicago, Chicago, Illinois 60607
| | - T Niida
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - R Nishitani
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - L V Nogach
- NRC "Kurchatov Institute," Institute of High Energy Physics, Protvino 142281
| | - T Nonaka
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - G Odyniec
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - A Ogawa
- Brookhaven National Laboratory, Upton, New York 11973
| | - S Oh
- Sejong University, Seoul 05006, South Korea
| | - V A Okorokov
- National Research Nuclear University MEPhI, Moscow 115409
| | - K Okubo
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - B S Page
- Brookhaven National Laboratory, Upton, New York 11973
| | - R Pak
- Brookhaven National Laboratory, Upton, New York 11973
| | - J Pan
- Texas A&M University, College Station, Texas 77843
| | - A Pandav
- National Institute of Science Education and Research, HBNI, Jatni 752050, India
| | - A K Pandey
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | | | - T Pani
- Rutgers University, Piscataway, New Jersey 08854
| | - P Parfenov
- National Research Nuclear University MEPhI, Moscow 115409
| | - A Paul
- University of California, Riverside, California 92521
| | - C Perkins
- University of California, Berkeley, California 94720
| | - B R Pokhrel
- Temple University, Philadelphia, Pennsylvania 19122
| | - M Posik
- Temple University, Philadelphia, Pennsylvania 19122
| | - T Protzman
- Lehigh University, Bethlehem, Pennsylvania 18015
| | - N K Pruthi
- Panjab University, Chandigarh 160014, India
| | - J Putschke
- Wayne State University, Detroit, Michigan 48201
| | - Z Qin
- Tsinghua University, Beijing 100084
| | - H Qiu
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - A Quintero
- Temple University, Philadelphia, Pennsylvania 19122
| | - C Racz
- University of California, Riverside, California 92521
| | | | - N Raha
- Wayne State University, Detroit, Michigan 48201
| | - R L Ray
- University of Texas, Austin, Texas 78712
| | - H G Ritter
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | | | | | | | - D Roy
- Rutgers University, Piscataway, New Jersey 08854
| | - L Ruan
- Brookhaven National Laboratory, Upton, New York 11973
| | - A K Sahoo
- Indian Institute of Science Education and Research (IISER), Berhampur 760010, India
| | - N R Sahoo
- Texas A&M University, College Station, Texas 77843
| | - H Sako
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - S Salur
- Rutgers University, Piscataway, New Jersey 08854
| | - E Samigullin
- Alikhanov Institute for Theoretical and Experimental Physics NRC "Kurchatov Institute," Moscow 117218
| | - S Sato
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - W B Schmidke
- Brookhaven National Laboratory, Upton, New York 11973
| | - N Schmitz
- Max-Planck-Institut für Physik, Munich 80805, Germany
| | - J Seger
- Creighton University, Omaha, Nebraska 68178
| | - R Seto
- University of California, Riverside, California 92521
| | - P Seyboth
- Max-Planck-Institut für Physik, Munich 80805, Germany
| | - N Shah
- Indian Institute Technology, Patna, Bihar 801106, India
| | - E Shahaliev
- Joint Institute for Nuclear Research, Dubna 141 980
| | | | - T Shao
- Fudan University, Shanghai, 200433
| | - M Sharma
- University of Jammu, Jammu 180001, India
| | - N Sharma
- Indian Institute of Science Education and Research (IISER), Berhampur 760010, India
| | - R Sharma
- Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati 517507, India
| | - S R Sharma
- Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati 517507, India
| | | | - D Shen
- Shandong University, Qingdao, Shandong 266237
| | - D Y Shen
- Fudan University, Shanghai, 200433
| | - K Shen
- University of Science and Technology of China, Hefei, Anhui 230026
| | - S S Shi
- Central China Normal University, Wuhan, Hubei 430079
| | - Y Shi
- Shandong University, Qingdao, Shandong 266237
| | - Q Y Shou
- Fudan University, Shanghai, 200433
| | - F Si
- University of Science and Technology of China, Hefei, Anhui 230026
| | - J Singh
- Panjab University, Chandigarh 160014, India
| | - S Singha
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - P Sinha
- Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati 517507, India
| | - M J Skoby
- Ball State University, Muncie, Indiana 47306
- Purdue University, West Lafayette, Indiana 47907
| | - Y Söhngen
- University of Heidelberg, Heidelberg 69120, Germany
| | - Y Song
- Yale University, New Haven, Connecticut 06520
| | - B Srivastava
- Purdue University, West Lafayette, Indiana 47907
| | | | - D J Stewart
- Wayne State University, Detroit, Michigan 48201
| | - M Strikhanov
- National Research Nuclear University MEPhI, Moscow 115409
| | | | - Y Su
- University of Science and Technology of China, Hefei, Anhui 230026
| | - C Sun
- State University of New York, Stony Brook, New York 11794
| | - X Sun
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - Y Sun
- University of Science and Technology of China, Hefei, Anhui 230026
| | - Y Sun
- Huzhou University, Huzhou, Zhejiang 313000
| | - B Surrow
- Temple University, Philadelphia, Pennsylvania 19122
| | - D N Svirida
- Alikhanov Institute for Theoretical and Experimental Physics NRC "Kurchatov Institute," Moscow 117218
| | - Z W Sweger
- University of California, Davis, California 95616
| | - A Tamis
- Yale University, New Haven, Connecticut 06520
| | - A H Tang
- Brookhaven National Laboratory, Upton, New York 11973
| | - Z Tang
- University of Science and Technology of China, Hefei, Anhui 230026
| | - A Taranenko
- National Research Nuclear University MEPhI, Moscow 115409
| | - T Tarnowsky
- Michigan State University, East Lansing, Michigan 48824
| | - J H Thomas
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - D Tlusty
- Creighton University, Omaha, Nebraska 68178
| | - T Todoroki
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - M V Tokarev
- Joint Institute for Nuclear Research, Dubna 141 980
| | - C A Tomkiel
- Lehigh University, Bethlehem, Pennsylvania 18015
| | - S Trentalange
- University of California, Los Angeles, California 90095
| | - R E Tribble
- Texas A&M University, College Station, Texas 77843
| | - P Tribedy
- Brookhaven National Laboratory, Upton, New York 11973
| | - O D Tsai
- Brookhaven National Laboratory, Upton, New York 11973
- University of California, Los Angeles, California 90095
| | - C Y Tsang
- Brookhaven National Laboratory, Upton, New York 11973
- Kent State University, Kent, Ohio 44242
| | - Z Tu
- Brookhaven National Laboratory, Upton, New York 11973
| | - J Tyler
- Texas A&M University, College Station, Texas 77843
| | - T Ullrich
- Brookhaven National Laboratory, Upton, New York 11973
| | - D G Underwood
- Argonne National Laboratory, Argonne, Illinois 60439
- Valparaiso University, Valparaiso, Indiana 46383
| | - I Upsal
- University of Science and Technology of China, Hefei, Anhui 230026
| | - G Van Buren
- Brookhaven National Laboratory, Upton, New York 11973
| | - A N Vasiliev
- National Research Nuclear University MEPhI, Moscow 115409
- NRC "Kurchatov Institute," Institute of High Energy Physics, Protvino 142281
| | - V Verkest
- Wayne State University, Detroit, Michigan 48201
| | - F Videbæk
- Brookhaven National Laboratory, Upton, New York 11973
| | - S Vokal
- Joint Institute for Nuclear Research, Dubna 141 980
| | | | - F Wang
- Purdue University, West Lafayette, Indiana 47907
| | - G Wang
- University of California, Los Angeles, California 90095
| | - J S Wang
- Huzhou University, Huzhou, Zhejiang 313000
| | - J Wang
- Shandong University, Qingdao, Shandong 266237
| | - X Wang
- Shandong University, Qingdao, Shandong 266237
| | - Y Wang
- University of Science and Technology of China, Hefei, Anhui 230026
| | - Y Wang
- Central China Normal University, Wuhan, Hubei 430079
| | - Y Wang
- Tsinghua University, Beijing 100084
| | - Z Wang
- Shandong University, Qingdao, Shandong 266237
| | - J C Webb
- Brookhaven National Laboratory, Upton, New York 11973
| | | | - G D Westfall
- Michigan State University, East Lansing, Michigan 48824
| | - H Wieman
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - G Wilks
- University of Illinois at Chicago, Chicago, Illinois 60607
| | - S W Wissink
- Indiana University, Bloomington, Indiana 47408
| | - J Wu
- Central China Normal University, Wuhan, Hubei 430079
| | - J Wu
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - X Wu
- University of California, Los Angeles, California 90095
| | - X Wu
- University of Science and Technology of China, Hefei, Anhui 230026
| | - Y Wu
- University of California, Riverside, California 92521
| | - B Xi
- Fudan University, Shanghai, 200433
| | - Z G Xiao
- Tsinghua University, Beijing 100084
| | - G Xie
- University of Chinese Academy of Sciences, Beijing 101408
| | - W Xie
- Purdue University, West Lafayette, Indiana 47907
| | - H Xu
- Huzhou University, Huzhou, Zhejiang 313000
| | - N Xu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - Q H Xu
- Shandong University, Qingdao, Shandong 266237
| | - Y Xu
- Shandong University, Qingdao, Shandong 266237
| | - Y Xu
- Central China Normal University, Wuhan, Hubei 430079
| | - Z Xu
- Brookhaven National Laboratory, Upton, New York 11973
| | - Z Xu
- University of California, Los Angeles, California 90095
| | - G Yan
- Shandong University, Qingdao, Shandong 266237
| | - Z Yan
- State University of New York, Stony Brook, New York 11794
| | - C Yang
- Shandong University, Qingdao, Shandong 266237
| | - Q Yang
- Shandong University, Qingdao, Shandong 266237
| | - S Yang
- South China Normal University, Guangzhou, Guangdong 510631
| | - Y Yang
- National Cheng Kung University, Tainan 70101
| | - Z Ye
- Rice University, Houston, Texas 77251
| | - Z Ye
- University of Illinois at Chicago, Chicago, Illinois 60607
| | - L Yi
- Shandong University, Qingdao, Shandong 266237
| | - K Yip
- Brookhaven National Laboratory, Upton, New York 11973
| | - Y Yu
- Shandong University, Qingdao, Shandong 266237
| | - W Zha
- University of Science and Technology of China, Hefei, Anhui 230026
| | - C Zhang
- State University of New York, Stony Brook, New York 11794
| | - D Zhang
- Central China Normal University, Wuhan, Hubei 430079
| | - J Zhang
- Shandong University, Qingdao, Shandong 266237
| | - S Zhang
- University of Science and Technology of China, Hefei, Anhui 230026
| | - W Zhang
- South China Normal University, Guangzhou, Guangdong 510631
| | - X Zhang
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - Y Zhang
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - Y Zhang
- University of Science and Technology of China, Hefei, Anhui 230026
| | - Y Zhang
- Shandong University, Qingdao, Shandong 266237
| | - Y Zhang
- Central China Normal University, Wuhan, Hubei 430079
| | - Z J Zhang
- National Cheng Kung University, Tainan 70101
| | - Z Zhang
- Brookhaven National Laboratory, Upton, New York 11973
| | - Z Zhang
- University of Illinois at Chicago, Chicago, Illinois 60607
| | - F Zhao
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - J Zhao
- Fudan University, Shanghai, 200433
| | - M Zhao
- Brookhaven National Laboratory, Upton, New York 11973
| | - C Zhou
- Fudan University, Shanghai, 200433
| | - J Zhou
- University of Science and Technology of China, Hefei, Anhui 230026
| | - S Zhou
- Central China Normal University, Wuhan, Hubei 430079
| | - Y Zhou
- Central China Normal University, Wuhan, Hubei 430079
| | - X Zhu
- Tsinghua University, Beijing 100084
| | - M Zurek
- Argonne National Laboratory, Argonne, Illinois 60439
- Brookhaven National Laboratory, Upton, New York 11973
| | - M Zyzak
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| |
Collapse
|
32
|
Zhang RY, Zhang XS, Lu C, Wang ZR, Shi Y, Wang YG, Zhang P, Chen Y. TLR4-MyD88-NF-κB signaling imbalances Th17 and Treg cells in thymoma with myasthenia gravis. Eur Rev Med Pharmacol Sci 2023; 27:10342-10364. [PMID: 37975358 DOI: 10.26355/eurrev_202311_34309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 11/19/2023]
Abstract
OBJECTIVE Thymus is an immune organ in which pathological changes may cause autoimmune diseases, including myasthenia gravis (MG). Recent studies have focused on Toll-like receptor 4 (TLR4) signaling as the cause of such changes. In our previous study, an imbalance of T helper 17 (Th17) cells and T regulatory (Treg) cells was found in MG thymoma. These results suggest the involvement of TLR4 in the pathogenesis of thymoma MG via an alteration of the Th17/Treg balance. Here, we aimed to assess whether the TLR4-MyD88-NF-κB pathway is upregulated in MG thymoma and its relationship with Th17/Treg cells. PATIENTS AND METHODS We collect thymoma samples from 54 patients with or without MG, detecting the expression level of TLR4, MyD88, and NF-κB in thymoma tissues. Next, we established an in vitro experiment of coculturing thymoma cells with CD4+ T cells and detected the differentiation of Th17 cells and Treg cells and their marker protein, retinoid-related orphan receptor gamma t (RORγt) and forkhead transcription factor 3 (Foxp3). RESULTS We found TLR4, MyD88, and NF-κB expressed more in MG thymoma compared with simple thymoma. After the transwell coculturing, we observed an imbalance of Th17/Treg cells after TLR4 stimulation. CONCLUSIONS TLR4 is stimulated in thymoma, causing an increase of Th17 cells and a decrease of Treg cells, namely an imbalance of Th17/Treg cells, resulting in MG.
Collapse
Affiliation(s)
- R-Y Zhang
- Department of Cardiothoracic Surgery, Tianjin Medical University General Hospital, Heping District, Tianjin, China.
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Fan G, Xie T, Tan Q, Lou N, Wang S, Han X, Shi Y. An immunosuppressive subtype of senescent tumor cells predicted worse immunotherapy response in lung adenocarcinoma. iScience 2023; 26:107894. [PMID: 37766998 PMCID: PMC10520875 DOI: 10.1016/j.isci.2023.107894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 08/14/2023] [Accepted: 09/07/2023] [Indexed: 09/29/2023] Open
Abstract
Senescent tumor cells (STCs) can induce immunosuppression, promoting tumor progression and therapy resistance. However, the specific characteristics of immunosuppressive STC have not been thoroughly investigated. This study aimed to characterize and elucidate the immunosuppressive phenotype of STC in lung adenocarcinoma by employing single-cell and bulk transcriptomics, as well as serum proteomics profiling. We identified senescence-related genes specific to tumors and identified Cluster10 of STC as the immunomodulatory subtype. Cluster10 exhibited a distinct secretome dominated by cytokines such as CXCL1, CXCL2, and CXCL8 and showed activation of transcription factors associated with cytokine secretion, including NFKB1, RELA, and STAT3. Notably, Cluster10 demonstrated the highest degree of intercellular communication among all cell types, with interactions as LGALS9-TIM3 and MIF-CD74. Furthermore, Cluster10 showed significant associations with poor prognosis and diminished response to immunotherapy. Analysis of serum proteomics data from our in-house cohort identified CXCL8 as a potential marker for predicting immunotherapeutic outcomes.
Collapse
Affiliation(s)
- Guangyu Fan
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Tongji Xie
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Qiaoyun Tan
- Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, N0.109,Machang Road, Jianghan District, Wuhan 430024, China
| | - Ning Lou
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Shasha Wang
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| | - Xiaohong Han
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1, Shuaifuyuan, Dongcheng District, Beijing 100730, China
| | - Yuankai Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China
| |
Collapse
|
34
|
Huang L, Lou N, Xie T, Tang L, Han X, Shi Y. Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing. Cancer Immunol Immunother 2023; 72:3259-3277. [PMID: 37458771 DOI: 10.1007/s00262-023-03485-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Accepted: 06/20/2023] [Indexed: 09/09/2023]
Abstract
BACKGROUND Antigen-presenting cells (APC)/T/NK cells are key immune cells that play crucial roles in fighting against malignancies including lung adenocarcinoma (LUAD). In this study, we aimed to identify an APC/T/NK cells-related gene signature (ATNKGS) and potential immune cell-related genes (IRGs) to realize risk stratification, prognosis, and immunotherapeutic response prediction for LUAD patients. METHODS Based on the univariate Cox regression and the LASSO Cox regression results of 196 APC/T/NK cells-related genes collected from three pathways in the KEGG database, we determined the final genes and established the ATNKGS-related risk model. The single-cell RNA sequencing data were applied for key IRGs identification and investigate their value in immunotherapeutic response prediction. Several GEO datasets and an external immunotherapy cohort from Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, were applied for validation. RESULTS In this study, nine independent public datasets including 1108 patients were enrolled. An ATNKGS containing 16 genes for predicting overall survival of LUAD patients was constructed with robust prognostic capability. The ATNKGS high risk group was related to significantly worse OS outcomes than those in the low-risk group, which were verified in TCGA and four GEO datatsets. A nomogram combining the ATNKGS risk score with clinical TNM stage achieved the optimal prediction performance. The single-cell RNA sequencing analysis revealed CTSL as an IRG of macrophage and monocyte. Moreover, though CTSL was an indicator for poor prognosis of LUAD patients, CTSL high expression group was associated with higher ESTIMATEScore, immune checkpoints expression, and lower TIDE score. Several immunotherapeutic cohorts have confirmed the response-predicting significance of CTSL in patients receiving immune checkpoint inhibitor (ICI) treatment. CONCLUSIONS Our study provided an insight into the significant role of APC/T/NK cells-related genes in survival risk stratification and CTSL in response prediction of immunotherapy in patients with LUAD.
Collapse
Affiliation(s)
- Liling Huang
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
| | - Ning Lou
- Department of Clinical Laboratory, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
| | - Tongji Xie
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
| | - Le Tang
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China
| | - Xiaohong Han
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
| | - Yuankai Shi
- Department of Medical Oncology, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
| |
Collapse
|
35
|
Shi Y, Frost P, Hoang B, Yang Y, Fukunaga R, Gera J, Lichtenstein A. Editorial Expression of Concern: MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells. Oncogene 2023; 42:3088. [PMID: 37626215 DOI: 10.1038/s41388-023-02818-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/27/2023]
Affiliation(s)
- Y Shi
- Department of Medicine, Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center of the UCLA Medical Center, Los Angeles, CA, USA
- Laboratory of Biochemistry, Department of Biochemistry, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - P Frost
- Department of Medicine, Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center of the UCLA Medical Center, Los Angeles, CA, USA
- Laboratory of Biochemistry, Department of Biochemistry, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - B Hoang
- Department of Medicine, Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center of the UCLA Medical Center, Los Angeles, CA, USA
- Laboratory of Biochemistry, Department of Biochemistry, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - Y Yang
- Department of Medicine, Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center of the UCLA Medical Center, Los Angeles, CA, USA
- Laboratory of Biochemistry, Department of Biochemistry, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - R Fukunaga
- Department of Medicine, Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center of the UCLA Medical Center, Los Angeles, CA, USA
- Laboratory of Biochemistry, Department of Biochemistry, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - J Gera
- Department of Medicine, Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center of the UCLA Medical Center, Los Angeles, CA, USA
- Laboratory of Biochemistry, Department of Biochemistry, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan
| | - A Lichtenstein
- Department of Medicine, Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center of the UCLA Medical Center, Los Angeles, CA, USA.
- Laboratory of Biochemistry, Department of Biochemistry, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan.
| |
Collapse
|
36
|
Chen H, Tao Y, Zhou Y, Liu P, Yang J, He X, Zhou S, Qin Y, Song Y, Gui L, Zhang C, Yang S, Shi Y. The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients. Asia Pac J Clin Oncol 2023; 19:e202-e214. [PMID: 35821612 DOI: 10.1111/ajco.13831] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2021] [Revised: 06/22/2022] [Accepted: 06/27/2022] [Indexed: 12/22/2022]
Abstract
AIM This study aimed to analyze the clinical features, treatment, survival, and prognostic factors of Chinese patients with peripheral T-cell lymphoma (PTCL) excluding natural killer/T-cell lymphoma (NKTCL). METHODS Data on patients with newly diagnosed PTCLs between January 1, 2006 and December 31, 2017 at our hospital were retrospectively reviewed. Patients with NKTCL were excluded. RESULTS A total of 240 patients were included. PTCL, not otherwise specified (PTCL-NOS), was the most frequent subtype (42.5%), followed by angioimmunoblastic T-cell lymphoma (AITL) (21.3%), anaplastic lymphoma kinase (ALK)-negative anaplastic large-cell lymphoma (ALK-ALCL) (16.7%), ALK-positive ALCL (ALK+ALCL) (10.8%) and others (8.8%). With a median follow-up of 81.1 months, the 5-year progression-free survival (PFS) and overall survival (OS) rates for all patients were 30.4% (95% CI 25.0%-37.0%) and 48.8% (95% CI 42.6%-55.7%), respectively. On multivariate analysis, no consolidative autologous stem cell transplantation (ASCT) and not achieving complete response after first-line chemotherapy retained independently prognostic value for inferior PFS and OS. Besides, bone marrow involvement and serum albumin level were independent factors for PFS, and Eastern Cooperative Oncology Group performance status ≥2 was significantly predictive of inferior OS. Compared with PTCL-NOS, significantly superior PFS and OS were observed for ALK+ALCL and ALK-ALCL. CONCLUSION The survival outcomes with current treatment for most PTCL subtypes are still unsatisfactory. Prospective randomized studies are needed to establish the value of consolidative ASCT in PTCL, and novel therapeutic approaches should be explored.
Collapse
Affiliation(s)
- Haizhu Chen
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Yunxia Tao
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Yu Zhou
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Peng Liu
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Jianliang Yang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Xiaohui He
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Shengyu Zhou
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Yan Qin
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Yongwen Song
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Lin Gui
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Changgong Zhang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Sheng Yang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Yuankai Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| |
Collapse
|
37
|
Shi Y, Abidan A, Li D, Zibigu R, Wang M, Zheng X, Kang X, Wang H, Li J, Zhang C. [Effect of Echinococcus multilocularis infection on Tim3 expression in spleen natural killer cells of mice]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2023; 35:366-373. [PMID: 37926471 DOI: 10.16250/j.32.1374.2023064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/07/2023]
Abstract
OBJECTIVE To investigate the effect of Echinococcus multilocularis infection on Tim3 expression and its co-expression with immune checkpoint molecules 2B4 and LAG3 in spleen natural killer (NK) cells of mice. METHODS C57BL/6 mice, each weighing (20 ± 2) g, were randomly divided into a high-dose infection group (15 mice), a low-dose infection group (13 mice), and a control group (11 mice). Mice in the high- and low-dose infection groups were inoculated with 2 000 and 50 Echinococcus multilocularis protoscolices via the hepatic portal vein, while animals in the control group was injected with an equivalent amount of physiological saline via the hepatic portal vein. Mouse spleen cells were harvested 12 and 24 weeks post-infection, and Tim3 expression and its co-expression with 2B4 and LAG3 in NK cells were detected using flow cytometry. RESULTS There were significant differences in the proportions of Tim3 expression (F = 13.559, P < 0.001) and Tim3 and 2B4 co-expression (F = 12.465, P < 0.001) in mouse spleen NK cells among groups 12 weeks post-infection with E. multilocularis, and the proportion of Tim3 expression was significantly higher in mouse spleen NK cells in the low-dose infection group [(23.84 ± 2.28)%] than in the high-dose infection group [(15.72 ± 3.67)%] and the control group [(16.14 ± 3.83)%] (both P values < 0.01), while the proportion of Tim3 and 2B4 co-expression was significantly higher in mouse spleen NK cells in the low-dose infection group [(22.20 ± 2.13)%] than in the high-dose infection group [(14.17 ± 3.81)%] and the control group [(15.20 ± 3.77)%] (both P values < 0.01). There were significant differences in the proportions of Tim3 expression (F = 5.243, P < 0.05) and Tim3 and 2B4 co-expression (F = 4.659, P < 0.05) in mouse spleen NK cells among groups 24 weeks post-infection with E. multilocularis infection, and the proportions of Tim3 expression and Tim3 and 2B4 co-expression were significantly lower in mouse spleen NK cells in the high-dose infection group [(20.55 ± 7.04)% and (20.98 ± 7.12)%] than in the control group [(31.38 ± 3.19)% and (31.25 ± 3.06)%] (both P values < 0.05), and there were no significantly difference between the proportions of Tim3 expression and Tim3 and 2B4 co-expression in splenic NK cells in the low-dose infection group [(26.80 ± 6.47)% and (26.48 ± 6.48)%] and the control group (both P > 0.05). There were no significant differences in the proportions of Tim3 and LAG3 co-expression in mouse spleen NK cells among groups 12 (F = 2.283, P > 0.05) and 24 weeks post-infection (F = 0.375, P > 0.05). In the low-dose infection group, there were no significant differences in the proportions of Tim3 expression or Tim3 and 2B4 co-expression in mouse spleen NK cells 12 (t = -1.137, P > 0.05) or 24 weeks post-infection (t = -1.658, P > 0.05), and the proportion of Tim3 and LAG3 co-expression increased in mouse spleen NK cells 24 weeks post-infection relative to 12 weeks post-infection (t = -5.261, P < 0.01). In the highdose infection group, there was no significant difference in the proportion of Tim3 expression in mouse spleen NK cells 12 and 24 weeks post-infection (t = -1.546, P > 0.05); however, the proportions of Tim3 co-expression with 2B4 and LAG3 increased in mouse splenic NK cells 24 weeks post-infection relative to 12 weeks post-infection (t = -2.425 and -4.745, both P values < 0.05). CONCLUSIONS The Tim3 expression and Tim3 co-expression with LAG3 and 2B4 on spleen NK cells is affected by doses of E. multilocularis infection and disease stages, and present different phenotypes during the course of alveolar echinococcosis. NK cells tend to form an immunosuppressive phenotype with the progression of E. multilocularis infection, which facilitates immune escape and chronic parasitism of E. multilocularis.
Collapse
Affiliation(s)
- Y Shi
- College of Basic Medical Sciences, Xinjiang Medical University, Urumqi, Xinjiang 830054, China
- Institute of Clinical Medicine, The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Uygur Autonomous Region Key Laboratory of Echinococcosis, Urumqi, Xinjiang 830054, China
- Xinjiang Uygur Autonomous Region Key Laboratory of Molecular Biology for Endemic Diseases, China
| | - A Abidan
- College of Basic Medical Sciences, Xinjiang Medical University, Urumqi, Xinjiang 830054, China
- Institute of Clinical Medicine, The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Uygur Autonomous Region Key Laboratory of Echinococcosis, Urumqi, Xinjiang 830054, China
| | - D Li
- College of Basic Medical Sciences, Xinjiang Medical University, Urumqi, Xinjiang 830054, China
- Institute of Clinical Medicine, The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Uygur Autonomous Region Key Laboratory of Echinococcosis, Urumqi, Xinjiang 830054, China
| | - R Zibigu
- College of Basic Medical Sciences, Xinjiang Medical University, Urumqi, Xinjiang 830054, China
- Institute of Clinical Medicine, The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Uygur Autonomous Region Key Laboratory of Echinococcosis, Urumqi, Xinjiang 830054, China
| | - M Wang
- College of Basic Medical Sciences, Xinjiang Medical University, Urumqi, Xinjiang 830054, China
- Institute of Clinical Medicine, The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Uygur Autonomous Region Key Laboratory of Echinococcosis, Urumqi, Xinjiang 830054, China
| | - X Zheng
- College of Basic Medical Sciences, Xinjiang Medical University, Urumqi, Xinjiang 830054, China
- Institute of Clinical Medicine, The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Uygur Autonomous Region Key Laboratory of Echinococcosis, Urumqi, Xinjiang 830054, China
| | - X Kang
- College of Basic Medical Sciences, Xinjiang Medical University, Urumqi, Xinjiang 830054, China
- Institute of Clinical Medicine, The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Uygur Autonomous Region Key Laboratory of Echinococcosis, Urumqi, Xinjiang 830054, China
| | - H Wang
- College of Basic Medical Sciences, Xinjiang Medical University, Urumqi, Xinjiang 830054, China
- Institute of Clinical Medicine, The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Uygur Autonomous Region Key Laboratory of Echinococcosis, Urumqi, Xinjiang 830054, China
| | - J Li
- College of Basic Medical Sciences, Xinjiang Medical University, Urumqi, Xinjiang 830054, China
- Institute of Clinical Medicine, The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Uygur Autonomous Region Key Laboratory of Echinococcosis, Urumqi, Xinjiang 830054, China
| | - C Zhang
- College of Basic Medical Sciences, Xinjiang Medical University, Urumqi, Xinjiang 830054, China
- Institute of Clinical Medicine, The First Affiliated Hospital of Xinjiang Medical University, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Uygur Autonomous Region Key Laboratory of Echinococcosis, Urumqi, Xinjiang 830054, China
| |
Collapse
|
38
|
Chen D, Li L, Wang M, Hu X, Jiang J, Li W, Yang L, Fan M, Shi Y, Lv F, Liu Y. Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer. Front Immunol 2023; 14:1086479. [PMID: 37795095 PMCID: PMC10547148 DOI: 10.3389/fimmu.2023.1086479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 08/09/2023] [Indexed: 10/06/2023] Open
Abstract
Objective This study sought to assess the efficacy and safety of immunotherapy combined with single-agent chemotherapy as a second- or later-line setting for metastatic non-small cell lung cancer (NSCLC) and to provide clinical evidence for this treatment regimen. The predictive value of extracellular vesicle (EV) membrane proteins was explored in patients who underwent this treatment. Methods Clinical data from patients diagnosed with metastatic NSCLC who received immunotherapy plus single-agent chemotherapy as a second- or later-line setting were retrospectively collected between March 2019 and January 2022. A total of 30 patients met the inclusion criteria, and all were pathologically confirmed to have NSCLC. Short-term efficacy, progression-free survival (PFS), EV markers for response prediction, and adverse events were assessed. Results Efficacy data were available for all 30 patients and included a partial response in 5 patients, stable disease in 18 patients, and disease progression in 7 patients. The objective response rate was 16.7%, the disease control rate was 76.7%, and the median PFS was 3.2 months. Univariate analysis showed that PFS was not associated with sex, age, smoking status, treatment lines, prior use of immunotherapy, or prior use of antiangiogenic drugs. The EV membrane proteins MET proto-oncogene, receptor tyrosine kinase (c-MET), epidermal growth factor receptor (EGFR), and vascular endothelial growth factor receptor 2 (VEGFR2) at baseline were associated with poor prognosis and correlated with the efficacy of immunotherapy plus chemotherapy. According to the receiver operating characteristics and Kaplan-Meier curve analyses, patients with high c-MET, EGFR, and VEGFR2 expression at baseline had significantly shorter PFS than those with low expression. In addition, VEGFR2 expression was increased after combined immunotherapy in responders, which was decreased in non-responders. The most common grade 2 or higher adverse events were neutropenia, gastrointestinal reactions, and thyroid dysfunction, all of which were tolerated. Conclusions Immunotherapy plus single-agent chemotherapy as a second- or later-line treatment is safe, effective, and tolerable for metastatic NSCLC. EV markers can be used as predictive markers of efficacy in patients with metastatic NSCLC treated with immunotherapy plus chemotherapy to help monitor treatment efficacy and guide treatment decisions.
Collapse
Affiliation(s)
- Dongna Chen
- Department of Medical Oncology, Beijing Chao Yang District San Huan Cancer Hospital, Beijing, China
| | - Lin Li
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Mingzhao Wang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Xingsheng Hu
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Jun Jiang
- Department of Diagnostic Image, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Weihua Li
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Lin Yang
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Meng Fan
- Research and Development Department, EVbio Technology Co., Ltd., Beijing, China
| | - Yuankai Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Fang Lv
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yutao Liu
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
39
|
Lou N, Wang G, Wang Y, Xu M, Zhou Y, Tan Q, Zhong Q, Zhang L, Zhang X, Liu S, Luo R, Wang S, Tang L, Yao J, Zhang Z, Shi Y, Yu X, Han X. Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma. Mol Cell Proteomics 2023; 22:100625. [PMID: 37500057 PMCID: PMC10470290 DOI: 10.1016/j.mcpro.2023.100625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2023] [Revised: 06/24/2023] [Accepted: 07/24/2023] [Indexed: 07/29/2023] Open
Abstract
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, although disease stratification using in-depth plasma proteomics has not been performed to date. By measuring more than 1000 proteins in the plasma of 147 DLBCL patients using data-independent acquisition mass spectrometry and antibody array, DLBCL patients were classified into four proteomic subtypes (PS-I-IV). Patients with the PS-IV subtype and worst prognosis had increased levels of proteins involved in inflammation, including a high expression of metalloproteinase inhibitor-1 (TIMP-1) that was associated with poor survival across two validation cohorts (n = 180). Notably, the combination of TIMP-1 with the international prognostic index (IPI) identified 64.00% to 88.24% of relapsed and 65.00% to 80.49% of deceased patients in the discovery and two validation cohorts, which represents a 24.00% to 41.67% and 20.00% to 31.70% improvement compared to the IPI score alone, respectively. Taken together, we demonstrate that DLBCL heterogeneity is reflected in the plasma proteome and that TIMP-1, together with the IPI, could improve the prognostic stratification of patients.
Collapse
Affiliation(s)
- Ning Lou
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Guibin Wang
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, China
| | - Yanrong Wang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Meng Xu
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, China
| | - Yu Zhou
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Qiaoyun Tan
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Qiaofeng Zhong
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Lei Zhang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Xiaomei Zhang
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, China
| | - Shuxia Liu
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Rongrong Luo
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Shasha Wang
- Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Le Tang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Jiarui Yao
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Zhishang Zhang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
| | - Yuankai Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
| | - Xiaobo Yu
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, China.
| | - Xiaohong Han
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
| |
Collapse
|
40
|
Shi Y, Yang Y, Hoang B, Bardeleben C, Holmes B, Gera J, Lichtenstein A. Retraction Note: Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress. Oncogene 2023; 42:3016. [PMID: 37653116 PMCID: PMC10562938 DOI: 10.1038/s41388-023-02820-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
Affiliation(s)
- Y Shi
- Division of Hematology-Oncology, UCLA-Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center, VA West LA Hospital/Hematology-Oncology, W111H, West LA VA Hospital, Los Angeles, CA, USA
| | - Y Yang
- Division of Hematology-Oncology, UCLA-Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center, VA West LA Hospital/Hematology-Oncology, W111H, West LA VA Hospital, Los Angeles, CA, USA
| | - B Hoang
- Division of Hematology-Oncology, UCLA-Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center, VA West LA Hospital/Hematology-Oncology, W111H, West LA VA Hospital, Los Angeles, CA, USA
| | - C Bardeleben
- Division of Hematology-Oncology, UCLA-Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center, VA West LA Hospital/Hematology-Oncology, W111H, West LA VA Hospital, Los Angeles, CA, USA
| | - B Holmes
- Division of Hematology-Oncology, UCLA-Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center, VA West LA Hospital/Hematology-Oncology, W111H, West LA VA Hospital, Los Angeles, CA, USA
| | - J Gera
- Division of Hematology-Oncology, UCLA-Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center, VA West LA Hospital/Hematology-Oncology, W111H, West LA VA Hospital, Los Angeles, CA, USA
| | - A Lichtenstein
- Division of Hematology-Oncology, UCLA-Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center, VA West LA Hospital/Hematology-Oncology, W111H, West LA VA Hospital, Los Angeles, CA, USA.
| |
Collapse
|
41
|
Feng Y, Tao Y, Chen H, Zhou Y, Tang L, Liu C, Hu X, Shi Y. Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: A systematic review and meta-analysis. Thorac Cancer 2023; 14:2536-2547. [PMID: 37551891 PMCID: PMC10481143 DOI: 10.1111/1759-7714.15063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2023] [Revised: 07/24/2023] [Accepted: 07/25/2023] [Indexed: 08/09/2023] Open
Abstract
BACKGROUND The aim of the study was to explore the efficacy and safety of immune checkpoint inhibitor (ICI) rechallenge in patients with non-small cell lung cancer (NSCLC). METHODS Studies that enrolled NSCLC patients treated with two lines of ICIs were included using four databases. The initial line (1L-) and subsequent lines (2L-) of ICIs were defined as 1L-ICI and 2L-ICI, respectively. RESULTS A total of 17 studies involving 2100 patients were included. The pooled objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and median overall survival (mOS) for 2L-ICIs were 10%, 50%, 3.0 months, and 13.1 months, respectively. The 2L-ICI discontinuation rates caused by toxicities ranged from 0% to 23.5%. Original data were extracted from six studies, covering 89 patients. Patients in whom 1L-ICIs were discontinued following clinical decision (the mPFS of 2L-ICIs was not reach) achieved a more prolonged mPFS of 2L-ICIs than those due to toxicity (5.2 months) and progressive disease (2.1 months) (p < 0.0001). Patients' 1L-PFS for more than 2-years had preferable 2L-ORR (35.0% vs. 9.8%, p = 0.03), 2L-DCR (85.0% vs. 49.0%, p = 0.007), and 2L-mPFS (12.4 vs. 3.0 months, p < 0.0001) than those less than 1-year. Patients administered the same drugs achieved a significantly prolonged mPFS compared with the remaining patients (5.4 vs. 2.3 months, p = 0.0004), and those who did not accept antitumor treatments during the intervals of two lines of ICIs achieved a prolonged mPFS compared to those patients who did accept treatments (7.6 vs. 1.9 months, p < 0.0001). CONCLUSIONS ICI rechallenge is a useful therapeutic strategy for NSCLC patients, especially suitable for those who achieve long-term tumor remission for more than 2-years under 1L-ICIs.
Collapse
Affiliation(s)
- Yu Feng
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijingChina
- Department of Medical OncologyBeijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua UniversityBeijingChina
| | - Yunxia Tao
- Department of OncologyThe Affiliated Hospital of Xuzhou Medical UniversityXuzhouChina
| | - Haizhu Chen
- Breast Tumor Center, Department of Medical Oncology, Phase I Clinical Trial Center, Sun Yat‐sen Memorial HospitalSun Yat‐sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene RegulationGuangzhouChina
| | - Yu Zhou
- Thoracic Medicine Department II, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of MedicineCentral South UniversityChangshaChina
| | - Le Tang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijingChina
| | - Chenwei Liu
- Department of PharmacyThe Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'anChina
| | - Xingsheng Hu
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijingChina
| | - Yuankai Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijingChina
| |
Collapse
|
42
|
Shi Y, Cui J, Zhou H, Zhang X, Zou L, Cao J, Gao Y, Jin C, Li X, Liu H, Peng Z, Xie L, Zhang H, Zhang W, Zhang H, Zhong L, Zhou F, Guo G, He W. Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003). Cancer Immunol Immunother 2023; 72:2991-3002. [PMID: 37289256 DOI: 10.1007/s00262-023-03467-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Accepted: 05/13/2023] [Indexed: 06/09/2023]
Abstract
BACKGROUND This study aimed to assess the efficacy and safety of geptanolimab (GB226), a fully humanized, recombinant anti-programmed cell death-1 monoclonal antibody, in Chinese patients with refractory or relapsed (r/r) primary mediastinal large B-cell lymphoma (PMBCL). METHODS This was a multicenter, open-label, single-arm phase II study (Gxplore-003), conducted at 43 hospitals in China (NCT03639181). Patients received geptanolimab intravenously at a dose of 3 mg/kg every 2 weeks until documented confirmed disease progression, intolerable toxicity, or any other cessation criteria was met. The primary endpoint was objective response rate (ORR) in the full analysis set assessed by the independent review committee (IRC) according to the Lugano Classification 2014. RESULTS This study was prematurely terminated due to the slow rate of patient accrual. Between Oct 15th, 2018 and Oct 7th, 2020, 25 patients were enrolled and treated. By the data cutoff date on Dec 23rd, 2020, the IRC-assessed ORR was 68.0% (17/25; 95% confidence interval [CI] 46.5-85.1%), with the complete response rate of 24%. The disease control rate was 88% (22/25; 95%CI 68.8-97.5%). Median duration of response was not reached (NR) (95%CI, 5.62 months to NR), with 79.5% of patients having response durations of more than 12 months. Median progression-free survival was NR (95%CI, 6.83 months to NR). Treatment-related adverse events (TRAEs) were reported in 20 of 25 (80.0%) patients, and grade 3 or higher TRAEs occurred in 11 of 25 (44%) patients. No treatment-related deaths occurred. The immune-related adverse events (irAEs) of any grade were observed in 6 (24.0%) patients, and no grade 4 or grade 5 irAEs were reported. CONCLUSION Geptanolimab (GB226) demonstrated promising efficacy and a manageable safety profile in Chinese patients with r/r PMBCL.
Collapse
Affiliation(s)
- Yuankai Shi
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
| | - Jie Cui
- Department of Hematology, Gansu Provincial Cancer Hospital, Lanzhou, China
| | - Hui Zhou
- Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, China
| | - Xiaohong Zhang
- Department of Hematology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
| | - Liqun Zou
- Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China
| | - Junning Cao
- Department of Hematology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - Yuhuan Gao
- Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Chuan Jin
- Department of Medical Oncology, The Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, China
| | - Xiaoling Li
- Department of Medical Oncology, Liaoning Cancer Hospital and Institute, Shenyang, China
| | - Hui Liu
- Department of Hematology, Beijing Hospital, Beijing, China
| | - Zhigang Peng
- Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - Liping Xie
- Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
| | - Huilai Zhang
- Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
| | - Weihua Zhang
- Department of Hematology, The First Affiliated Hospital of Shanxi Medical University, Taiyuan, China
| | - Hongyu Zhang
- Department of Oncology, The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai, China
| | - Liye Zhong
- Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
| | - Fang Zhou
- Department of Hematology, The 960th Hospital of the PLA Joint Logistics Support Force, Tai'an, China
| | - Genny Guo
- Department of Medical Science, Genor Biopharma Co., Ltd., Shanghai, China
| | - Wenduo He
- Department of Medical Science, Genor Biopharma Co., Ltd., Shanghai, China
| |
Collapse
|
43
|
Helzer KT, Sharifi MN, Sperger JM, Shi Y, Annala M, Bootsma ML, Reese SR, Taylor A, Kaufmann KR, Krause HK, Schehr JL, Sethakorn N, Kosoff D, Kyriakopoulos C, Burkard ME, Rydzewski NR, Yu M, Harari PM, Bassetti M, Blitzer G, Floberg J, Sjöström M, Quigley DA, Dehm SM, Armstrong AJ, Beltran H, McKay RR, Feng FY, O'Regan R, Wisinski KB, Emamekhoo H, Wyatt AW, Lang JM, Zhao SG. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels. Ann Oncol 2023; 34:813-825. [PMID: 37330052 PMCID: PMC10527168 DOI: 10.1016/j.annonc.2023.06.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 05/30/2023] [Accepted: 06/06/2023] [Indexed: 06/19/2023] Open
Abstract
BACKGROUND The isolation of cell-free DNA (cfDNA) from the bloodstream can be used to detect and analyze somatic alterations in circulating tumor DNA (ctDNA), and multiple cfDNA-targeted sequencing panels are now commercially available for Food and Drug Administration (FDA)-approved biomarker indications to guide treatment. More recently, cfDNA fragmentation patterns have emerged as a tool to infer epigenomic and transcriptomic information. However, most of these analyses used whole-genome sequencing, which is insufficient to identify FDA-approved biomarker indications in a cost-effective manner. PATIENTS AND METHODS We used machine learning models of fragmentation patterns at the first coding exon in standard targeted cancer gene cfDNA sequencing panels to distinguish between cancer and non-cancer patients, as well as the specific tumor type and subtype. We assessed this approach in two independent cohorts: a published cohort from GRAIL (breast, lung, and prostate cancers, non-cancer, n = 198) and an institutional cohort from the University of Wisconsin (UW; breast, lung, prostate, bladder cancers, n = 320). Each cohort was split 70%/30% into training and validation sets. RESULTS In the UW cohort, training cross-validated accuracy was 82.1%, and accuracy in the independent validation cohort was 86.6% despite a median ctDNA fraction of only 0.06. In the GRAIL cohort, to assess how this approach performs in very low ctDNA fractions, training and independent validation were split based on ctDNA fraction. Training cross-validated accuracy was 80.6%, and accuracy in the independent validation cohort was 76.3%. In the validation cohort where the ctDNA fractions were all <0.05 and as low as 0.0003, the cancer versus non-cancer area under the curve was 0.99. CONCLUSIONS To our knowledge, this is the first study to demonstrate that sequencing from targeted cfDNA panels can be utilized to analyze fragmentation patterns to classify cancer types, dramatically expanding the potential capabilities of existing clinically used panels at minimal additional cost.
Collapse
Affiliation(s)
- K T Helzer
- Department of Human Oncology, University of Wisconsin, Madison
| | - M N Sharifi
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - J M Sperger
- Department of Medicine, University of Wisconsin, Madison, USA
| | - Y Shi
- Department of Human Oncology, University of Wisconsin, Madison
| | - M Annala
- Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
| | - M L Bootsma
- Department of Human Oncology, University of Wisconsin, Madison
| | - S R Reese
- Department of Human Oncology, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - A Taylor
- Department of Medicine, University of Wisconsin, Madison, USA
| | - K R Kaufmann
- Department of Medicine, University of Wisconsin, Madison, USA
| | - H K Krause
- Department of Medicine, University of Wisconsin, Madison, USA
| | - J L Schehr
- Carbone Cancer Center, University of Wisconsin, Madison
| | - N Sethakorn
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - D Kosoff
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - C Kyriakopoulos
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - M E Burkard
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - N R Rydzewski
- Department of Human Oncology, University of Wisconsin, Madison
| | - M Yu
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison
| | - P M Harari
- Department of Human Oncology, University of Wisconsin, Madison; Carbone Cancer Center, University of Wisconsin, Madison
| | - M Bassetti
- Department of Human Oncology, University of Wisconsin, Madison; Carbone Cancer Center, University of Wisconsin, Madison
| | - G Blitzer
- Department of Human Oncology, University of Wisconsin, Madison; Carbone Cancer Center, University of Wisconsin, Madison
| | - J Floberg
- Department of Human Oncology, University of Wisconsin, Madison; Carbone Cancer Center, University of Wisconsin, Madison
| | - M Sjöström
- Department of Radiation Oncology, University of California San Francisco, San Francisco; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco
| | - D A Quigley
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco; Departments of Epidemiology and Biostatistics; Urology, University of California San Francisco, San Francisco
| | - S M Dehm
- Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis
| | - A J Armstrong
- Duke Cancer Institute Center for Prostate and Urologic Cancers, Department of Medicine, Duke University, Durham
| | - H Beltran
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston
| | - R R McKay
- Moores Cancer Center, University of California San Diego, La Jolla
| | - F Y Feng
- Department of Radiation Oncology, University of California San Francisco, San Francisco; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco
| | - R O'Regan
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA; Department of Medicine, University of Rochester, Rochester, USA
| | - K B Wisinski
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - H Emamekhoo
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - A W Wyatt
- Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada; Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada
| | - J M Lang
- Carbone Cancer Center, University of Wisconsin, Madison; Department of Medicine, University of Wisconsin, Madison, USA
| | - S G Zhao
- Department of Human Oncology, University of Wisconsin, Madison; Carbone Cancer Center, University of Wisconsin, Madison; William S. Middleton Memorial Veterans' Hospital, Madison, USA.
| |
Collapse
|
44
|
Adam J, Adamczyk L, Adams JR, Adkins JK, Agakishiev G, Aggarwal MM, Ahammed Z, Alekseev I, Anderson DM, Aparin A, Aschenauer EC, Ashraf MU, Atetalla FG, Attri A, Averichev GS, Bairathi V, Barish K, Behera A, Bellwied R, Bhasin A, Bielcik J, Bielcikova J, Bland LC, Bordyuzhin IG, Brandenburg JD, Brandin AV, Butterworth J, Caines H, Calderón de la Barca Sánchez M, Cebra D, Chakaberia I, Chaloupka P, Chan BK, Chang FH, Chang Z, Chankova-Bunzarova N, Chatterjee A, Chen D, Chen J, Chen JH, Chen X, Chen Z, Cheng J, Cherney M, Chevalier M, Choudhury S, Christie W, Chu X, Crawford HJ, Csanád M, Daugherity M, Dedovich TG, Deppner IM, Derevschikov AA, Didenko L, Dong X, Drachenberg JL, Dunlop JC, Edmonds T, Elsey N, Engelage J, Eppley G, Esumi S, Evdokimov O, Ewigleben A, Eyser O, Fatemi R, Fazio S, Federic P, Fedorisin J, Feng CJ, Feng Y, Filip P, Finch E, Fisyak Y, Francisco A, Fulek L, Gagliardi CA, Galatyuk T, Geurts F, Ghimire N, Gibson A, Gopal K, Gou X, Grosnick D, Guryn W, Hamad AI, Hamed A, Harabasz S, Harris JW, He S, He W, He XH, He Y, Heppelmann S, Heppelmann S, Herrmann N, Hoffman E, Holub L, Hong Y, Horvat S, Hu Y, Huang HZ, Huang SL, Huang T, Huang X, Humanic TJ, Huo P, Igo G, Isenhower D, Jacobs WW, Jena C, Jentsch A, Ji Y, Jia J, Jiang K, Jowzaee S, Ju X, Judd EG, Kabana S, Kabir ML, Kagamaster S, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Ke HW, Keane D, Kechechyan A, Kelsey M, Khyzhniak YV, Kikoła DP, Kim C, Kimelman B, Kincses D, Kinghorn TA, Kisel I, Kiselev A, Kocan M, Kochenda L, Kosarzewski LK, Kramarik L, Kravtsov P, Krueger K, Kulathunga Mudiyanselage N, Kumar L, Kumar S, Kunnawalkam Elayavalli R, Kwasizur JH, Lacey R, Lan S, Landgraf JM, Lauret J, Lebedev A, Lednicky R, Lee JH, Leung YH, Li C, Li C, Li W, Li W, Li X, Li Y, Liang Y, Licenik R, Lin T, Lin Y, Lisa MA, Liu F, Liu H, Liu P, Liu P, Liu T, Liu X, Liu Y, Liu Z, Ljubicic T, Llope WJ, Longacre RS, Lukow NS, Luo S, Luo X, Ma GL, Ma L, Ma R, Ma YG, Magdy N, Majka R, Mallick D, Margetis S, Markert C, Matis HS, Mazer JA, Minaev NG, Mioduszewski S, Mohanty B, Mooney I, Moravcova Z, Morozov DA, Nagy M, Nam JD, Nasim M, Nayak K, Neff D, Nelson JM, Nemes DB, Nie M, Nigmatkulov G, Niida T, Nogach LV, Nonaka T, Nunes AS, Odyniec G, Ogawa A, Oh S, Okorokov VA, Page BS, Pak R, Pandav A, Panebratsev Y, Pawlik B, Pawlowska D, Pei H, Perkins C, Pinsky L, Pintér RL, Pluta J, Pokhrel BR, Porter J, Posik M, Pruthi NK, Przybycien M, Putschke J, Qiu H, Quintero A, Radhakrishnan SK, Ramachandran S, Ray RL, Reed R, Ritter HG, Rogachevskiy OV, Romero JL, Ruan L, Rusnak J, Sahoo NR, Sako H, Salur S, Sandweiss J, Sato S, Schmidke WB, Schmitz N, Schweid BR, Seck F, Seger J, Sergeeva M, Seto R, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Sheikh AI, Shen WQ, Shi SS, Shi Y, Shou QY, Sichtermann EP, Sikora R, Simko M, Singh J, Singha S, Smirnov N, Solyst W, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Stefaniak M, Stewart DJ, Strikhanov M, Stringfellow B, Suaide AAP, Sumbera M, Summa B, Sun XM, Sun X, Sun Y, Sun Y, Surrow B, Svirida DN, Szymanski P, Tang AH, Tang Z, Taranenko A, Tarnowsky T, Thomas JH, Timmins AR, Tlusty D, Tokarev M, Tomkiel CA, Trentalange S, Tribble RE, Tribedy P, Tripathy SK, Tsai OD, Tu Z, Ullrich T, Underwood DG, Upsal I, Van Buren G, Vanek J, Vasiliev AN, Vassiliev I, Videbæk F, Vokal S, Voloshin SA, Wang F, Wang G, Wang JS, Wang P, Wang Y, Wang Y, Wang Z, Webb JC, Weidenkaff PC, Wen L, Westfall GD, Wieman H, Wissink SW, Witt R, Wu Y, Xiao ZG, Xie G, Xie W, Xu H, Xu N, Xu QH, Xu YF, Xu Y, Xu Z, Xu Z, Yang C, Yang Q, Yang S, Yang Y, Yang Z, Ye Z, Ye Z, Yi L, Yip K, Yu Y, Zbroszczyk H, Zha W, Zhang C, Zhang D, Zhang S, Zhang S, Zhang XP, Zhang Y, Zhang Y, Zhang ZJ, Zhang Z, Zhang Z, Zhao J, Zhong C, Zhou C, Zhu X, Zhu Z, Zurek M, Zyzak M. Erratum: Global Polarization of Ξ and Ω Hyperons in Au+Au Collisions at sqrt[s_{NN}]=200 GeV [Phys. Rev. Lett. 126, 162301 (2021)]. Phys Rev Lett 2023; 131:089901. [PMID: 37683178 DOI: 10.1103/physrevlett.131.089901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Indexed: 09/10/2023]
Abstract
This corrects the article DOI: 10.1103/PhysRevLett.126.162301.
Collapse
|
45
|
Li HL, Fang J, Wu CX, Gao LF, Tan YT, Gu K, Shi Y, Xiang YB. [Pre- and post-diagnosis body mass index in association with colorectal cancer death in a prospective cohort study]. Zhonghua Zhong Liu Za Zhi 2023; 45:657-665. [PMID: 37580270 DOI: 10.3760/cma.j.cn112152-20220824-00576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 08/16/2023]
Abstract
Objective: To evaluate the association between pre-and post-diagnosis body mass index (BMI) and risk of colorectal cancer (CRC) death. Methods: The cohort consisted of 3, 057 CRC patients from Shanghai who were diagnosed from Jan. 1, 2009 to Dec. 31, 2011 and aged from 20 to 74 years. The pre- and post-diagnosis BMI and clinical and lifestyle factors were collected at baseline. Death information was collected using record linkage with the Shanghai Cancer Registry and telephone confirmation during follow-up by the end of 2019. The Cox proportional regression model was used to estimate HR with 95% CI. Results: Analysis by multivariable Cox model showed no association between pre-diagnosis BMI and death risk in both male and female patients. Male patients with a post-diagnosis underweight BMI had an elevated risk of death compared to those in normal weight (HR=1.69, 95% CI: 1.21-2.37), especially in early stage cases. Overweight patients (HR=0.74, 95% CI: 0.61-0.89) and patients with obesity class Ⅰ (HR=0.63, 95% CI: 0.45-0.89)had better survival with decreased risks of death, especially in advanced stage cases. The decreased death risk in patients with obesity class Ⅱ was not significant (HR=0.57, 95% CI: 0.24-1.39). The P(trend) value for decreased risk of death with increased BMI in female patients was statistically significant (P<0.001), and the overweight and obesity class Ⅰ categories had better survival in advanced stage(HR(overweight)=0.62, 95% CI: 0.42-0.93; HR(obesity class Ⅰ)=0.39, 95% CI: 0.16-0.98). Both male and female patients with post-diagnosis BMI loss >2.0 kg/m(2) had an increased death risk when compared with those with stable BMI (change≤1.0 kg/m(2)) between pre- and post-diagnosis. BMI gain after diagnosis did not change death risk. Conclusions: Post-diagnosis BMI in the overweight or obesity class Ⅰ groups might be conducive to prolonging male CRC patients' survival, while underweight might result in poor prognosis. Keeping weight and avoiding excessive weight loss should be suggested for all CRC patients after diagnosis.
Collapse
Affiliation(s)
- H L Li
- State Key Laboratory of Oncogenes and Related Genes and Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China
| | - J Fang
- State Key Laboratory of Oncogenes and Related Genes and Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China
| | - C X Wu
- Department of Cancer Control and Prevention, Division of Noncommunicable Diseases and Injury, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - L F Gao
- State Key Laboratory of Oncogenes and Related Genes and Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China
| | - Y T Tan
- State Key Laboratory of Oncogenes and Related Genes and Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China
| | - K Gu
- Department of Cancer Control and Prevention, Division of Noncommunicable Diseases and Injury, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - Y Shi
- Division of Noncommunicable Diseases and Injury, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
| | - Y B Xiang
- State Key Laboratory of Oncogenes and Related Genes and Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China
| |
Collapse
|
46
|
Qiu HR, Qiao C, Yang H, Guo R, Shi Y, Zhao XL, Li JY, Zhu Y. [ST13-PDGFRβ positive acute myeloid leukaemia: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:676-679. [PMID: 37803843 PMCID: PMC10520237 DOI: 10.3760/cma.j.issn.0253-2727.2023.08.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Received: 10/12/2022] [Indexed: 10/08/2023]
Affiliation(s)
- H R Qiu
- Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
| | - C Qiao
- Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
| | - H Yang
- Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
| | - R Guo
- Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
| | - Y Shi
- Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
| | - X L Zhao
- Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
| | - J Y Li
- Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
| | - Y Zhu
- Department of Hematology, Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
| |
Collapse
|
47
|
He XQ, Yang X, Shi Y, Duan JZ, Dong KX, Xu YX, Xu YQ, Su YY. [Clinical effects of retrograde anterolateral thigh flaps in repairing anterior knee joint wounds under the concept of precise flap surgery]. Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi 2023; 39:648-654. [PMID: 37805694 DOI: 10.3760/cma.j.cn501225-20221020-00461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 10/09/2023]
Abstract
Objective: To introduce the methods of retrograde anterolateral thigh flaps in repairing anterior knee joint wounds under the concept of precise flap surgery and to explore the clinical effects. Methods: A retrospective observational study was conducted. From August 2014 to March 2022, 7 patients with anterior knee joint wounds were treated with retrograde anterolateral thigh flap under the guidance of the concept of precise flap surgery in the 920th Hospital of Joint Logistic Support Force of PLA. Among them, 6 were males and 1 was female, aged 36 to 66 years. The sizes of wounds were 7 cm×5 cm to 15 cm×11 cm after debridement. All the patients were performed with computed tomography angiography (CTA), the donor and recipient sites were evaluated according to the precise flap surgery method, and the optimal pedicle, perforator, and pivot of flaps were chosen. The flap sizes were 10 cm×6 cm to 20 cm×9 cm, and all the donor sites of flaps were sutured directly. The consistency of the intraoperative exploration with preoperative CTA was observed. The flap survival and occurrence of complications were observed after surgery. The color, appearance, texture, and occurrence of complications were followed up. At the last follow-up, the blood supply of flaps was evaluated using the blood circulation evaluation indicators of Chinese Medical Association Hand Surgery Branch's trial criteria for digital replantation function evaluation, and the function of knee joint was evaluated using knee joint scoring system of hospital for special surgery. Results: The flap condition of the intraoperative exploration was completely consistent with that of preoperative CTA. The flaps survived completely after surgery in 6 patients, while necrosis at the edge of the flap occurred in 1 patient, which healed after dressing change. All the flaps were hyperperfused after surgery, and the color of the flaps gradually became normal after 1 week. Follow-up of 7 to 44 months showed that the color, appearance, and texture were well in all the patients, while local osteomyelitis at the proximal tibia occurred in 1 patient. At the last follow-up, all the 7 patients had excellent blood circulation; the function score of knee joint was 69 to 91, which was evaluated as excellent in 3 cases, good in 3 cases, and fair in 1 case. Conclusions: The retrograde anterolateral thigh flap has large variations, and the application of precise flap surgery method can accurately understand the variations before surgery, guide the design and cutting of the flaps, thus achieving precise repair of anterior knee joint wounds, with good repair outcome.
Collapse
Affiliation(s)
- X Q He
- Department of Orthopedic Surgery, the 920th Hospital of Joint Logistic Support Force of PLA, Kunming 650032, China
| | - X Yang
- Department of Orthopedic Surgery, the 920th Hospital of Joint Logistic Support Force of PLA, Kunming 650032, China
| | - Y Shi
- Department of Orthopedic Surgery, the 920th Hospital of Joint Logistic Support Force of PLA, Kunming 650032, China
| | - J Z Duan
- Department of Emergency Surgery, the Second People's Hospital of Yunnan Province, Kunming 650021, China
| | - K X Dong
- Department of Orthopedic Surgery, the First People's Hospital of Yunnan Province, Kunming 650034, China
| | - Y X Xu
- Department of Orthopedic Surgery, the 920th Hospital of Joint Logistic Support Force of PLA, Kunming 650032, China
| | - Y Q Xu
- Department of Orthopedic Surgery, the 920th Hospital of Joint Logistic Support Force of PLA, Kunming 650032, China
| | - Y Y Su
- Department of Orthopedic Surgery, the 920th Hospital of Joint Logistic Support Force of PLA, Kunming 650032, China
| |
Collapse
|
48
|
Yang JH, Xue MJ, Zhang XL, Wei ZC, Shao LL, Shi Y, Hou M. [Efficacy of decitabine in patients with glucocorticoid-resistant primary immune thrombocytopenia: factors influencing treatment responses]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:567-571. [PMID: 37749037 PMCID: PMC10509621 DOI: 10.3760/cma.j.issn.0253-2727.2023.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Indexed: 09/27/2023]
Abstract
Objective: This study aimed to evaluate the efficacy of decitabine (DAC) and identify factors influencing treatment responses in patients with primary immune thrombocytopenia (ITP) who had failed glucocorticoid therapy. Methods: Clinical data of 61 patients with glucocorticoid-resistant ITP who received DAC therapy (5 mg·m(-2)·d(-1)×3 d via intravenous infusion) for at least three cycles with 3-4-week intervals at the Department of Hematology, Qilu Hospital of Shandong University, from November 2015 to June 2021 were analyzed retrospectively. Results: The 61 patients comprised 20 males and 41 females, with a median age of 45 years (range: 15-81 years). Among them, 43 patients were glucocorticoid-dependent (glucocorticoid-dependent group), while 18 patients were glucocorticoid-resistant (glucocorticoid-resistant group). Following DAC treatment, 12 patients (19.67% ) achieved complete response (CR), and 16 patients (26.23% ) exhibited response (R), resulting in an overall response (OR) rate of 45.90% (28/61). Comparison between the OR group (n=28) and the non-response (NR) group (n=33) revealed significant differences in responses to glucocorticoids (dependent or resistant) and platelet counts before treatment (χ(2)=8.789, P=0.003; z=-2.416, P=0.016). The glucocorticoid-dependent group showed higher platelet counts than the glucocorticoid-resistant group after the second and third cycles of DAC treatment (P=0.032, 0.024). Moreover, the OR rates after the first, second, and third cycles of DAC treatment in the glucocorticoid-dependent group were all higher than those in the glucocorticoid-resistant group (P=0.042, P=0.012, P=0.029). A significant correlation was observed between glucocorticoid dependence and responses to DAC treatment (OR=9.213, 95% CI 1.937-43.820, P=0.005) . Conclusion: DAC demonstrates definitive efficacy with mild adverse effects in a subset of patients with glucocorticoid-resistant primary ITP. Glucocorticoid dependence and higher platelet counts before treatment are associated with a favorable response to DAC therapy.
Collapse
Affiliation(s)
- J H Yang
- Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China
| | - M J Xue
- Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China
| | - X L Zhang
- Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China
| | - Z C Wei
- Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China
| | - L L Shao
- Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China
| | - Y Shi
- Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China
| | - M Hou
- Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China
| |
Collapse
|
49
|
Abdulhamid MI, Aboona BE, Adam J, Adams JR, Agakishiev G, Aggarwal I, Aggarwal MM, Ahammed Z, Aitbaev A, Alekseev I, Anderson DM, Aparin A, Aslam S, Atchison J, Averichev GS, Bairathi V, Baker W, Ball Cap JG, Barish K, Bhagat P, Bhasin A, Bhatta S, Bordyuzhin IG, Brandenburg JD, Brandin AV, Cai XZ, Caines H, Calderón de la Barca Sánchez M, Cebra D, Ceska J, Chakaberia I, Chan BK, Chang Z, Chatterjee A, Chen D, Chen J, Chen JH, Chen Z, Cheng J, Cheng Y, Choudhury S, Christie W, Chu X, Crawford HJ, Dale-Gau G, Das A, Daugherity M, Dedovich TG, Deppner IM, Derevschikov AA, Dhamija A, Di Carlo L, Didenko L, Dixit P, Dong X, Drachenberg JL, Duckworth E, Dunlop JC, Engelage J, Eppley G, Esumi S, Evdokimov O, Ewigleben A, Eyser O, Fatemi R, Fazio S, Feng CJ, Feng Y, Finch E, Fisyak Y, Flor FA, Fu C, Geurts F, Ghimire N, Gibson A, Gopal K, Gou X, Grosnick D, Gupta A, Hamed A, Han Y, Harasty MD, Harris JW, Harrison-Smith H, He W, He XH, He Y, Hu C, Hu Q, Hu Y, Huang H, Huang HZ, Huang SL, Huang T, Huang X, Huang Y, Huang Y, Humanic TJ, Isenhower D, Isshiki M, Jacobs WW, Jalotra A, Jena C, Ji Y, Jia J, Jin C, Ju X, Judd EG, Kabana S, Kabir ML, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Ke HW, Keane D, Kechechyan A, Kelsey M, Kimelman B, Kiselev A, Knospe AG, Ko HS, Kochenda L, Korobitsin AA, Kravtsov P, Kumar L, Kumar S, Kunnawalkam Elayavalli R, Lacey R, Landgraf JM, Lebedev A, Lednicky R, Lee JH, Leung YH, Lewis N, Li C, Li W, Li X, Li Y, Li Y, Li Z, Liang X, Liang Y, Lin T, Liu C, Liu F, Liu G, Liu H, Liu H, Liu L, Liu T, Liu X, Liu Y, Liu Z, Ljubicic T, Llope WJ, Lomicky O, Longacre RS, Loyd EM, Lu T, Lukow NS, Luo XF, Luong VB, Ma L, Ma R, Ma YG, Magdy N, Mallick D, Margetis S, Matis HS, Mazer JA, McNamara G, Mi K, Minaev NG, Mohanty B, Mondal MM, Mooney I, Morozov DA, Mudrokh A, Nagy MI, Nain AS, Nam JD, Nasim M, Neff D, Nelson JM, Nemes DB, Nie M, Nigmatkulov G, Niida T, Nishitani R, Nogach LV, Nonaka T, Odyniec G, Ogawa A, Oh S, Okorokov VA, Okubo K, Page BS, Pak R, Pan J, Pandav A, Pandey AK, Panebratsev Y, Pani T, Parfenov P, Paul A, Perkins C, Pokhrel BR, Posik M, Protzman T, Pruthi NK, Putschke J, Qin Z, Qiu H, Quintero A, Racz C, Radhakrishnan SK, Raha N, Ray RL, Ritter HG, Robertson CW, Rogachevsky OV, Rosales Aguilar MA, Roy D, Ruan L, Sahoo AK, Sahoo NR, Sako H, Salur S, Samigullin E, Sato S, Schmidke WB, Schmitz N, Seger J, Seto R, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao T, Sharma M, Sharma N, Sharma R, Sharma SR, Sheikh AI, Shen DY, Shen K, Shi SS, Shi Y, Shou QY, Si F, Singh J, Singha S, Sinha P, Skoby MJ, Söhngen Y, Song Y, Srivastava B, Stanislaus TDS, Stewart DJ, Strikhanov M, Stringfellow B, Su Y, Sun C, Sun X, Sun Y, Sun Y, Surrow B, Svirida DN, Sweger ZW, Tamis A, Tang AH, Tang Z, Taranenko A, Tarnowsky T, Thomas JH, Tlusty D, Todoroki T, Tokarev MV, Tomkiel CA, Trentalange S, Tribble RE, Tribedy P, Tsai OD, Tsang CY, Tu Z, Ullrich T, Underwood DG, Upsal I, Van Buren G, Vasiliev AN, Verkest V, Videbæk F, Vokal S, Voloshin SA, Wang F, Wang G, Wang JS, Wang X, Wang Y, Wang Y, Wang Y, Wang Z, Webb JC, Weidenkaff PC, Westfall GD, Wieman H, Wilks G, Wissink SW, Wu J, Wu J, Wu X, Wu Y, Xi B, Xiao ZG, Xie G, Xie W, Xu H, Xu N, Xu QH, Xu Y, Xu Y, Xu Z, Xu Z, Yan G, Yan Z, Yang C, Yang Q, Yang S, Yang Y, Ye Z, Ye Z, Yi L, Yip K, Yu Y, Zha W, Zhang C, Zhang D, Zhang J, Zhang S, Zhang W, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang ZJ, Zhang Z, Zhang Z, Zhao F, Zhao J, Zhao M, Zhou C, Zhou J, Zhou S, Zhou Y, Zhu X, Zurek M, Zyzak M. Measurements of the Elliptic and Triangular Azimuthal Anisotropies in Central ^{3}He+Au, d+Au and p+Au Collisions at sqrt[s_{NN}]=200 GeV. Phys Rev Lett 2023; 130:242301. [PMID: 37390421 DOI: 10.1103/physrevlett.130.242301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 02/27/2023] [Accepted: 05/15/2023] [Indexed: 07/02/2023]
Abstract
The elliptic (v_{2}) and triangular (v_{3}) azimuthal anisotropy coefficients in central ^{3}He+Au, d+Au, and p+Au collisions at sqrt[s_{NN}]=200 GeV are measured as a function of transverse momentum (p_{T}) at midrapidity (|η|<0.9), via the azimuthal angular correlation between two particles both at |η|<0.9. While the v_{2}(p_{T}) values depend on the colliding systems, the v_{3}(p_{T}) values are system independent within the uncertainties, suggesting an influence on eccentricity from subnucleonic fluctuations in these small-sized systems. These results also provide stringent constraints for the hydrodynamic modeling of these systems.
Collapse
Affiliation(s)
- M I Abdulhamid
- American University of Cairo, New Cairo 11835, New Cairo, Egypt
| | - B E Aboona
- Texas A&M University, College Station, Texas 77843
| | - J Adam
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - J R Adams
- The Ohio State University, Columbus, Ohio 43210
| | - G Agakishiev
- Joint Institute for Nuclear Research, Dubna 141 980
| | - I Aggarwal
- Panjab University, Chandigarh 160014, India
| | | | - Z Ahammed
- Variable Energy Cyclotron Centre, Kolkata 700064, India
| | - A Aitbaev
- Joint Institute for Nuclear Research, Dubna 141 980
| | - I Alekseev
- Alikhanov Institute for Theoretical and Experimental Physics NRC "Kurchatov Institute", Moscow 117218
- National Research Nuclear University MEPhI, Moscow 115409
| | - D M Anderson
- Texas A&M University, College Station, Texas 77843
| | - A Aparin
- Joint Institute for Nuclear Research, Dubna 141 980
| | - S Aslam
- Indian Institute Technology, Patna, Bihar 801106, India
| | - J Atchison
- Abilene Christian University, Abilene, Texas 79699
| | | | - V Bairathi
- Instituto de Alta Investigación, Universidad de Tarapacá, Arica 1000000, Chile
| | - W Baker
- University of California, Riverside, California 92521
| | | | - K Barish
- University of California, Riverside, California 92521
| | - P Bhagat
- University of Jammu, Jammu 180001, India
| | - A Bhasin
- University of Jammu, Jammu 180001, India
| | - S Bhatta
- State University of New York, Stony Brook, New York 11794
| | - I G Bordyuzhin
- Alikhanov Institute for Theoretical and Experimental Physics NRC "Kurchatov Institute", Moscow 117218
| | | | - A V Brandin
- National Research Nuclear University MEPhI, Moscow 115409
| | - X Z Cai
- Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800
| | - H Caines
- Yale University, New Haven, Connecticut 06520
| | | | - D Cebra
- University of California, Davis, California 95616
| | - J Ceska
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - I Chakaberia
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - B K Chan
- University of California, Los Angeles, California 90095
| | - Z Chang
- Indiana University, Bloomington, Indiana 47408
| | - A Chatterjee
- National Institute of Technology Durgapur, Durgapur - 713209, India
| | - D Chen
- University of California, Riverside, California 92521
| | - J Chen
- Shandong University, Qingdao, Shandong 266237
| | - J H Chen
- Fudan University, Shanghai, 200433
| | - Z Chen
- Shandong University, Qingdao, Shandong 266237
| | - J Cheng
- Tsinghua University, Beijing 100084
| | - Y Cheng
- University of California, Los Angeles, California 90095
| | | | - W Christie
- Brookhaven National Laboratory, Upton, New York 11973
| | - X Chu
- Brookhaven National Laboratory, Upton, New York 11973
| | - H J Crawford
- University of California, Berkeley, California 94720
| | - G Dale-Gau
- University of Illinois at Chicago, Chicago, Illinois 60607
| | - A Das
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - M Daugherity
- Abilene Christian University, Abilene, Texas 79699
| | - T G Dedovich
- Joint Institute for Nuclear Research, Dubna 141 980
| | - I M Deppner
- University of Heidelberg, Heidelberg 69120, Germany
| | - A A Derevschikov
- NRC "Kurchatov Institute", Institute of High Energy Physics, Protvino 142281
| | - A Dhamija
- Panjab University, Chandigarh 160014, India
| | - L Di Carlo
- Wayne State University, Detroit, Michigan 48201
| | - L Didenko
- Brookhaven National Laboratory, Upton, New York 11973
| | - P Dixit
- Indian Institute of Science Education and Research (IISER), Berhampur 760010, India
| | - X Dong
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | | | | | - J C Dunlop
- Brookhaven National Laboratory, Upton, New York 11973
| | - J Engelage
- University of California, Berkeley, California 94720
| | - G Eppley
- Rice University, Houston, Texas 77251
| | - S Esumi
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - O Evdokimov
- University of Illinois at Chicago, Chicago, Illinois 60607
| | - A Ewigleben
- Lehigh University, Bethlehem, Pennsylvania 18015
| | - O Eyser
- Brookhaven National Laboratory, Upton, New York 11973
| | - R Fatemi
- University of Kentucky, Lexington, Kentucky 40506-0055
| | - S Fazio
- University of Calabria & INFN-Cosenza, Rende 87036, Italy
| | - C J Feng
- National Cheng Kung University, Tainan 70101
| | - Y Feng
- Purdue University, West Lafayette, Indiana 47907
| | - E Finch
- Southern Connecticut State University, New Haven, Connecticut 06515
| | - Y Fisyak
- Brookhaven National Laboratory, Upton, New York 11973
| | - F A Flor
- Yale University, New Haven, Connecticut 06520
| | - C Fu
- Central China Normal University, Wuhan, Hubei 430079
| | - F Geurts
- Rice University, Houston, Texas 77251
| | - N Ghimire
- Temple University, Philadelphia, Pennsylvania 19122
| | - A Gibson
- Valparaiso University, Valparaiso, Indiana 46383
| | - K Gopal
- Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati 517507, India
| | - X Gou
- Shandong University, Qingdao, Shandong 266237
| | - D Grosnick
- Valparaiso University, Valparaiso, Indiana 46383
| | - A Gupta
- University of Jammu, Jammu 180001, India
| | - A Hamed
- American University of Cairo, New Cairo 11835, New Cairo, Egypt
| | - Y Han
- Rice University, Houston, Texas 77251
| | - M D Harasty
- University of California, Davis, California 95616
| | - J W Harris
- Yale University, New Haven, Connecticut 06520
| | | | - W He
- Fudan University, Shanghai, 200433
| | - X H He
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - Y He
- Shandong University, Qingdao, Shandong 266237
| | - C Hu
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - Q Hu
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - Y Hu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - H Huang
- National Cheng Kung University, Tainan 70101
| | - H Z Huang
- University of California, Los Angeles, California 90095
| | - S L Huang
- State University of New York, Stony Brook, New York 11794
| | - T Huang
- University of Illinois at Chicago, Chicago, Illinois 60607
| | - X Huang
- Tsinghua University, Beijing 100084
| | - Y Huang
- Tsinghua University, Beijing 100084
| | - Y Huang
- Central China Normal University, Wuhan, Hubei 430079
| | - T J Humanic
- The Ohio State University, Columbus, Ohio 43210
| | - D Isenhower
- Abilene Christian University, Abilene, Texas 79699
| | - M Isshiki
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - W W Jacobs
- Indiana University, Bloomington, Indiana 47408
| | - A Jalotra
- University of Jammu, Jammu 180001, India
| | - C Jena
- Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati 517507, India
| | - Y Ji
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - J Jia
- Brookhaven National Laboratory, Upton, New York 11973
- State University of New York, Stony Brook, New York 11794
| | - C Jin
- Rice University, Houston, Texas 77251
| | - X Ju
- University of Science and Technology of China, Hefei, Anhui 230026
| | - E G Judd
- University of California, Berkeley, California 94720
| | - S Kabana
- Instituto de Alta Investigación, Universidad de Tarapacá, Arica 1000000, Chile
| | - M L Kabir
- University of California, Riverside, California 92521
| | - D Kalinkin
- University of Kentucky, Lexington, Kentucky 40506-0055
| | - K Kang
- Tsinghua University, Beijing 100084
| | - D Kapukchyan
- University of California, Riverside, California 92521
| | - K Kauder
- Brookhaven National Laboratory, Upton, New York 11973
| | - H W Ke
- Brookhaven National Laboratory, Upton, New York 11973
| | - D Keane
- Kent State University, Kent, Ohio 44242
| | - A Kechechyan
- Joint Institute for Nuclear Research, Dubna 141 980
| | - M Kelsey
- Wayne State University, Detroit, Michigan 48201
| | - B Kimelman
- University of California, Davis, California 95616
| | - A Kiselev
- Brookhaven National Laboratory, Upton, New York 11973
| | - A G Knospe
- Lehigh University, Bethlehem, Pennsylvania 18015
| | - H S Ko
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - L Kochenda
- National Research Nuclear University MEPhI, Moscow 115409
| | | | - P Kravtsov
- National Research Nuclear University MEPhI, Moscow 115409
| | - L Kumar
- Panjab University, Chandigarh 160014, India
| | - S Kumar
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | | | - R Lacey
- State University of New York, Stony Brook, New York 11794
| | - J M Landgraf
- Brookhaven National Laboratory, Upton, New York 11973
| | - A Lebedev
- Brookhaven National Laboratory, Upton, New York 11973
| | - R Lednicky
- Joint Institute for Nuclear Research, Dubna 141 980
| | - J H Lee
- Brookhaven National Laboratory, Upton, New York 11973
| | - Y H Leung
- University of Heidelberg, Heidelberg 69120, Germany
| | - N Lewis
- Brookhaven National Laboratory, Upton, New York 11973
| | - C Li
- Shandong University, Qingdao, Shandong 266237
| | - W Li
- Rice University, Houston, Texas 77251
| | - X Li
- University of Science and Technology of China, Hefei, Anhui 230026
| | - Y Li
- University of Science and Technology of China, Hefei, Anhui 230026
| | - Y Li
- Tsinghua University, Beijing 100084
| | - Z Li
- University of Science and Technology of China, Hefei, Anhui 230026
| | - X Liang
- University of California, Riverside, California 92521
| | - Y Liang
- Kent State University, Kent, Ohio 44242
| | - T Lin
- Shandong University, Qingdao, Shandong 266237
| | - C Liu
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - F Liu
- Central China Normal University, Wuhan, Hubei 430079
| | - G Liu
- South China Normal University, Guangzhou, Guangdong 510631
| | - H Liu
- Indiana University, Bloomington, Indiana 47408
| | - H Liu
- Central China Normal University, Wuhan, Hubei 430079
| | - L Liu
- Central China Normal University, Wuhan, Hubei 430079
| | - T Liu
- Yale University, New Haven, Connecticut 06520
| | - X Liu
- The Ohio State University, Columbus, Ohio 43210
| | - Y Liu
- Texas A&M University, College Station, Texas 77843
| | - Z Liu
- Central China Normal University, Wuhan, Hubei 430079
| | - T Ljubicic
- Brookhaven National Laboratory, Upton, New York 11973
| | - W J Llope
- Wayne State University, Detroit, Michigan 48201
| | - O Lomicky
- Czech Technical University in Prague, FNSPE, Prague 115 19, Czech Republic
| | - R S Longacre
- Brookhaven National Laboratory, Upton, New York 11973
| | - E M Loyd
- University of California, Riverside, California 92521
| | - T Lu
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - N S Lukow
- Temple University, Philadelphia, Pennsylvania 19122
| | - X F Luo
- Central China Normal University, Wuhan, Hubei 430079
| | - V B Luong
- Joint Institute for Nuclear Research, Dubna 141 980
| | - L Ma
- Fudan University, Shanghai, 200433
| | - R Ma
- Brookhaven National Laboratory, Upton, New York 11973
| | - Y G Ma
- Fudan University, Shanghai, 200433
| | - N Magdy
- State University of New York, Stony Brook, New York 11794
| | - D Mallick
- National Institute of Science Education and Research, HBNI, Jatni 752050, India
| | | | - H S Matis
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - J A Mazer
- Rutgers University, Piscataway, New Jersey 08854
| | - G McNamara
- Wayne State University, Detroit, Michigan 48201
| | - K Mi
- Central China Normal University, Wuhan, Hubei 430079
| | - N G Minaev
- NRC "Kurchatov Institute", Institute of High Energy Physics, Protvino 142281
| | - B Mohanty
- National Institute of Science Education and Research, HBNI, Jatni 752050, India
| | - M M Mondal
- National Institute of Science Education and Research, HBNI, Jatni 752050, India
| | - I Mooney
- Yale University, New Haven, Connecticut 06520
| | - D A Morozov
- NRC "Kurchatov Institute", Institute of High Energy Physics, Protvino 142281
| | - A Mudrokh
- Joint Institute for Nuclear Research, Dubna 141 980
| | - M I Nagy
- ELTE Eötvös Loránd University, Budapest, Hungary H-1117
| | - A S Nain
- Panjab University, Chandigarh 160014, India
| | - J D Nam
- Temple University, Philadelphia, Pennsylvania 19122
| | - Md Nasim
- Indian Institute of Science Education and Research (IISER), Berhampur 760010, India
| | - D Neff
- University of California, Los Angeles, California 90095
| | - J M Nelson
- University of California, Berkeley, California 94720
| | - D B Nemes
- Yale University, New Haven, Connecticut 06520
| | - M Nie
- Shandong University, Qingdao, Shandong 266237
| | - G Nigmatkulov
- National Research Nuclear University MEPhI, Moscow 115409
| | - T Niida
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - R Nishitani
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - L V Nogach
- NRC "Kurchatov Institute", Institute of High Energy Physics, Protvino 142281
| | - T Nonaka
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - G Odyniec
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - A Ogawa
- Brookhaven National Laboratory, Upton, New York 11973
| | - S Oh
- Sejong University, Seoul, 05006, South Korea
| | - V A Okorokov
- National Research Nuclear University MEPhI, Moscow 115409
| | - K Okubo
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - B S Page
- Brookhaven National Laboratory, Upton, New York 11973
| | - R Pak
- Brookhaven National Laboratory, Upton, New York 11973
| | - J Pan
- Texas A&M University, College Station, Texas 77843
| | - A Pandav
- National Institute of Science Education and Research, HBNI, Jatni 752050, India
| | - A K Pandey
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | | | - T Pani
- Rutgers University, Piscataway, New Jersey 08854
| | - P Parfenov
- National Research Nuclear University MEPhI, Moscow 115409
| | - A Paul
- University of California, Riverside, California 92521
| | - C Perkins
- University of California, Berkeley, California 94720
| | - B R Pokhrel
- Temple University, Philadelphia, Pennsylvania 19122
| | - M Posik
- Temple University, Philadelphia, Pennsylvania 19122
| | - T Protzman
- Lehigh University, Bethlehem, Pennsylvania 18015
| | - N K Pruthi
- Panjab University, Chandigarh 160014, India
| | - J Putschke
- Wayne State University, Detroit, Michigan 48201
| | - Z Qin
- Tsinghua University, Beijing 100084
| | - H Qiu
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - A Quintero
- Temple University, Philadelphia, Pennsylvania 19122
| | - C Racz
- University of California, Riverside, California 92521
| | | | - N Raha
- Wayne State University, Detroit, Michigan 48201
| | - R L Ray
- University of Texas, Austin, Texas 78712
| | - H G Ritter
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | | | | | | | - D Roy
- Rutgers University, Piscataway, New Jersey 08854
| | - L Ruan
- Brookhaven National Laboratory, Upton, New York 11973
| | - A K Sahoo
- Indian Institute of Science Education and Research (IISER), Berhampur 760010, India
| | - N R Sahoo
- Shandong University, Qingdao, Shandong 266237
| | - H Sako
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - S Salur
- Rutgers University, Piscataway, New Jersey 08854
| | - E Samigullin
- Alikhanov Institute for Theoretical and Experimental Physics NRC "Kurchatov Institute", Moscow 117218
| | - S Sato
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - W B Schmidke
- Brookhaven National Laboratory, Upton, New York 11973
| | - N Schmitz
- Max-Planck-Institut für Physik, Munich 80805, Germany
| | - J Seger
- Creighton University, Omaha, Nebraska 68178
| | - R Seto
- University of California, Riverside, California 92521
| | - P Seyboth
- Max-Planck-Institut für Physik, Munich 80805, Germany
| | - N Shah
- Indian Institute Technology, Patna, Bihar 801106, India
| | - E Shahaliev
- Joint Institute for Nuclear Research, Dubna 141 980
| | | | - T Shao
- Fudan University, Shanghai, 200433
| | - M Sharma
- University of Jammu, Jammu 180001, India
| | - N Sharma
- Indian Institute of Science Education and Research (IISER), Berhampur 760010, India
| | - R Sharma
- Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati 517507, India
| | - S R Sharma
- Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati 517507, India
| | | | - D Y Shen
- Fudan University, Shanghai, 200433
| | - K Shen
- University of Science and Technology of China, Hefei, Anhui 230026
| | - S S Shi
- Central China Normal University, Wuhan, Hubei 430079
| | - Y Shi
- Shandong University, Qingdao, Shandong 266237
| | - Q Y Shou
- Fudan University, Shanghai, 200433
| | - F Si
- University of Science and Technology of China, Hefei, Anhui 230026
| | - J Singh
- Panjab University, Chandigarh 160014, India
| | - S Singha
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - P Sinha
- Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati 517507, India
| | - M J Skoby
- Ball State University, Muncie, Indiana, 47306
- Purdue University, West Lafayette, Indiana 47907
| | - Y Söhngen
- University of Heidelberg, Heidelberg 69120, Germany
| | - Y Song
- Yale University, New Haven, Connecticut 06520
| | - B Srivastava
- Purdue University, West Lafayette, Indiana 47907
| | | | - D J Stewart
- Wayne State University, Detroit, Michigan 48201
| | - M Strikhanov
- National Research Nuclear University MEPhI, Moscow 115409
| | | | - Y Su
- University of Science and Technology of China, Hefei, Anhui 230026
| | - C Sun
- State University of New York, Stony Brook, New York 11794
| | - X Sun
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - Y Sun
- University of Science and Technology of China, Hefei, Anhui 230026
| | - Y Sun
- Huzhou University, Huzhou, Zhejiang 313000
| | - B Surrow
- Temple University, Philadelphia, Pennsylvania 19122
| | - D N Svirida
- Alikhanov Institute for Theoretical and Experimental Physics NRC "Kurchatov Institute", Moscow 117218
| | - Z W Sweger
- University of California, Davis, California 95616
| | - A Tamis
- Yale University, New Haven, Connecticut 06520
| | - A H Tang
- Brookhaven National Laboratory, Upton, New York 11973
| | - Z Tang
- University of Science and Technology of China, Hefei, Anhui 230026
| | - A Taranenko
- National Research Nuclear University MEPhI, Moscow 115409
| | - T Tarnowsky
- Michigan State University, East Lansing, Michigan 48824
| | - J H Thomas
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - D Tlusty
- Creighton University, Omaha, Nebraska 68178
| | - T Todoroki
- University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - M V Tokarev
- Joint Institute for Nuclear Research, Dubna 141 980
| | - C A Tomkiel
- Lehigh University, Bethlehem, Pennsylvania 18015
| | - S Trentalange
- University of California, Los Angeles, California 90095
| | - R E Tribble
- Texas A&M University, College Station, Texas 77843
| | - P Tribedy
- Brookhaven National Laboratory, Upton, New York 11973
| | - O D Tsai
- Brookhaven National Laboratory, Upton, New York 11973
- University of California, Los Angeles, California 90095
| | - C Y Tsang
- Brookhaven National Laboratory, Upton, New York 11973
- Kent State University, Kent, Ohio 44242
| | - Z Tu
- Brookhaven National Laboratory, Upton, New York 11973
| | - T Ullrich
- Brookhaven National Laboratory, Upton, New York 11973
| | - D G Underwood
- Argonne National Laboratory, Argonne, Illinois 60439
- Valparaiso University, Valparaiso, Indiana 46383
| | - I Upsal
- Rice University, Houston, Texas 77251
| | - G Van Buren
- Brookhaven National Laboratory, Upton, New York 11973
| | - A N Vasiliev
- National Research Nuclear University MEPhI, Moscow 115409
- NRC "Kurchatov Institute", Institute of High Energy Physics, Protvino 142281
| | - V Verkest
- Wayne State University, Detroit, Michigan 48201
| | - F Videbæk
- Brookhaven National Laboratory, Upton, New York 11973
| | - S Vokal
- Joint Institute for Nuclear Research, Dubna 141 980
| | | | - F Wang
- Purdue University, West Lafayette, Indiana 47907
| | - G Wang
- University of California, Los Angeles, California 90095
| | - J S Wang
- Huzhou University, Huzhou, Zhejiang 313000
| | - X Wang
- Shandong University, Qingdao, Shandong 266237
| | - Y Wang
- University of Science and Technology of China, Hefei, Anhui 230026
| | - Y Wang
- Central China Normal University, Wuhan, Hubei 430079
| | - Y Wang
- Tsinghua University, Beijing 100084
| | - Z Wang
- Shandong University, Qingdao, Shandong 266237
| | - J C Webb
- Brookhaven National Laboratory, Upton, New York 11973
| | | | - G D Westfall
- Michigan State University, East Lansing, Michigan 48824
| | - H Wieman
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - G Wilks
- University of Illinois at Chicago, Chicago, Illinois 60607
| | - S W Wissink
- Indiana University, Bloomington, Indiana 47408
| | - J Wu
- Central China Normal University, Wuhan, Hubei 430079
| | - J Wu
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - X Wu
- University of California, Los Angeles, California 90095
| | - Y Wu
- University of California, Riverside, California 92521
| | - B Xi
- Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800
| | - Z G Xiao
- Tsinghua University, Beijing 100084
| | - G Xie
- University of Chinese Academy of Sciences, Beijing, 101408
| | - W Xie
- Purdue University, West Lafayette, Indiana 47907
| | - H Xu
- Huzhou University, Huzhou, Zhejiang 313000
| | - N Xu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - Q H Xu
- Shandong University, Qingdao, Shandong 266237
| | - Y Xu
- Shandong University, Qingdao, Shandong 266237
| | - Y Xu
- Central China Normal University, Wuhan, Hubei 430079
| | - Z Xu
- Brookhaven National Laboratory, Upton, New York 11973
| | - Z Xu
- University of California, Los Angeles, California 90095
| | - G Yan
- Shandong University, Qingdao, Shandong 266237
| | - Z Yan
- State University of New York, Stony Brook, New York 11794
| | - C Yang
- Shandong University, Qingdao, Shandong 266237
| | - Q Yang
- Shandong University, Qingdao, Shandong 266237
| | - S Yang
- South China Normal University, Guangzhou, Guangdong 510631
| | - Y Yang
- National Cheng Kung University, Tainan 70101
| | - Z Ye
- Rice University, Houston, Texas 77251
| | - Z Ye
- University of Illinois at Chicago, Chicago, Illinois 60607
| | - L Yi
- Shandong University, Qingdao, Shandong 266237
| | - K Yip
- Brookhaven National Laboratory, Upton, New York 11973
| | - Y Yu
- Shandong University, Qingdao, Shandong 266237
| | - W Zha
- University of Science and Technology of China, Hefei, Anhui 230026
| | - C Zhang
- State University of New York, Stony Brook, New York 11794
| | - D Zhang
- Central China Normal University, Wuhan, Hubei 430079
| | - J Zhang
- Shandong University, Qingdao, Shandong 266237
| | - S Zhang
- University of Science and Technology of China, Hefei, Anhui 230026
| | - W Zhang
- South China Normal University, Guangzhou, Guangdong 510631
| | - X Zhang
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - Y Zhang
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - Y Zhang
- University of Science and Technology of China, Hefei, Anhui 230026
| | - Y Zhang
- Central China Normal University, Wuhan, Hubei 430079
| | - Z J Zhang
- National Cheng Kung University, Tainan 70101
| | - Z Zhang
- Brookhaven National Laboratory, Upton, New York 11973
| | - Z Zhang
- University of Illinois at Chicago, Chicago, Illinois 60607
| | - F Zhao
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu 730000
| | - J Zhao
- Fudan University, Shanghai, 200433
| | - M Zhao
- Brookhaven National Laboratory, Upton, New York 11973
| | - C Zhou
- Fudan University, Shanghai, 200433
| | - J Zhou
- University of Science and Technology of China, Hefei, Anhui 230026
| | - S Zhou
- Central China Normal University, Wuhan, Hubei 430079
| | - Y Zhou
- Central China Normal University, Wuhan, Hubei 430079
| | - X Zhu
- Tsinghua University, Beijing 100084
| | - M Zurek
- Argonne National Laboratory, Argonne, Illinois 60439
- Brookhaven National Laboratory, Upton, New York 11973
| | - M Zyzak
- Frankfurt Institute for Advanced Studies FIAS, Frankfurt 60438, Germany
| |
Collapse
|
50
|
Han X, Bi X, Zhao H, Shi Y, Wen Q, Lü J, Sun J, Fu X, Liu D. [Bioinformatics analysis and prokaryotic expression of Strongyloides stercoralis serine protease inhibitor 1]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2023; 35:244-250. [PMID: 37455094 DOI: 10.16250/j.32.1374.2022285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Indexed: 07/18/2023]
Abstract
OBJECTIVE To predict the structure and antigenic epitope of the Strongyloides stercoralis serine protease inhibitor 1 (Ss-SRPN-1) protein using bioinformatics tools, and to construct prokaryotic expression plasmids for expression of recombinant Ss-SRPN-1 protein, so as to provide the basis for unraveling the function of the Ss-SRPN-1 protein. METHODS The amino acid sequence of the Ss-SRPN-1 protein was downloaded from the NCBI database, and the physicochemical properties, structure and antigenic epitopes of the Ss-SRPN-1 protein were predicted using bioinformatics tools, including ExPASy, SWISS-MODEL and Protean. Primers were designed according to the nucleotide sequences of Ss-SRPN-1, and the Ss-SRPN-1 gene was amplified, cloned and sequenced with genomic DNA extracted from the infective third-stage larvae of S. stercoralis as a template. The Ss-SRPN-1 protein sequence was cloned into the pET28a (+) expression vector and transformed into Escherichia coli BL21 (DE) cells for induction of the recombinant Ss-SRPN-1 protein expression. The recombinant Ss-SRPN-1 protein was then purified and identified using Western blotting and mass spectrometry. RESULTS Bioinformatics analysis showed that the Ss-SRPN-1 protein, which was composed of 372 amino acids and had a molecular formula of C1948H3046N488O575S16, was a stable hydrophilic protein, and the subcellular localization of the protein was predicted to be extracellular. The Ss-SRPN-1 protein was predicted to contain 11 dominant B-cell antigenic epitopes and 20 T-cell antigenic epitopes. The Ss-SRPN-1 gene with a length of 1 119 bp was successfully amplified, and the recombinant plasmid pET28a (+)/Ss-SRPN-1 was constructed and transformed into E. coli BL21(DE) cells. The expressed recombinant Ss-SRPN-1 protein had a molecular weight of approximately 43 kDa, and was characterized as a Ss-SRPN-1 protein. CONCLUSIONS The recombinant Ss-SRPN-1 protein has been expressed successfully, and this recombinant protein may be a potential vaccine candidate against strongyloidiasis.
Collapse
Affiliation(s)
- X Han
- Department of Parasitology, Guangxi Medical University, Key Laboratory of Basic Research on Regional Diseases in Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, China
| | - X Bi
- Department of Parasitology, Guangxi Medical University, Key Laboratory of Basic Research on Regional Diseases in Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, China
| | - H Zhao
- Department of Laboratory Medicine, Guangxi Zhuang Autonomous Region People's Hospital, Nanning, Guangxi 530021, China
| | - Y Shi
- Department of Parasitology, Guangxi Medical University, Key Laboratory of Basic Research on Regional Diseases in Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, China
| | - Q Wen
- Department of Parasitology, Guangxi Medical University, Key Laboratory of Basic Research on Regional Diseases in Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, China
| | - J Lü
- Department of Parasitology, Guangxi Medical University, Key Laboratory of Basic Research on Regional Diseases in Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, China
| | - J Sun
- Department of Parasitology, Guangxi Medical University, Key Laboratory of Basic Research on Regional Diseases in Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, China
| | - X Fu
- Department of Parasitology, Guangxi Medical University, Key Laboratory of Basic Research on Regional Diseases in Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, China
| | - D Liu
- Department of Parasitology, Guangxi Medical University, Key Laboratory of Basic Research on Regional Diseases in Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, China
| |
Collapse
|